



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: U.S. Patent No. 6,673,838
Inventors: HADFIELD, Anthony F. et al.
Issue Date: January 6, 2007
For: SUCCINATE SALT OF O-DESMETHYL-VENLAFAXINE
Assignee: Wyeth
Date: April 25, 2008

Mail Stop Hatch-Waxman PTE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

APPLICATION FOR EXTENSION OF PATENT
TERM UNDER 35 U.S.C. §156

Commissioner for Patents:

Applicant, Wyeth, a corporation organized and existing under the laws of Delaware, and having a principal place of business at 5 Giralda Farms, Madison, NJ 07490, represents that it is the owner of the entire interest in and to U.S. Patent No. 6,673,838, granted to Anthony Francis Hadfield, Syed M. Shah, Michael W. Winkley, Karen W. Sutherland, James A. Provost, Aeri Park, Rex A. Shiplett, Brenton W. Russell, and Beat T. Weber for "Succinate Salt of O-desmethyl-venlafaxine," as reflected in the various assignment documents recorded by the U.S. Patent and Trademark Office on August 27, 2001 at Reel 012126, Frame 0893, on August 27, 2001 at Reel 012127, Frame 0102, on April 12, 2002 at Reel 012828, Frame 0928, on July 30, 2002 at Reel 013121, Frame 0837, on July 30, 2002 at Reel 013121, Frame 0855, on July 31, 2002 at Reel 013127, Frame 0287, on July 31, 2002 at Reel 013127, Frame 0306, on August 1, 2002 at Reel 013130, Frame 0479, and on August 21, 2002 at Reel 013229, Frame 0864. Attached at **Exhibit A** is a Power of Attorney document appointing the undersigned patent attorney as legal representative of Applicant.

U.S. Patent No. 6,673,838
Transmittal Application for Extension of Patent


☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-1349.

Respectfully submitted,

HOGAN & HARTSON LLP

Dated: April 25, 2008

HOGAN & HARTSON LLP
555 Thirteenth Street, N.W.
Washington, D.C. 20004
Telephone: 202-637-5703
Facsimile: 202-637-5910
e-mail: cjcrowson@hhlaw.com
Customer No. 24633

By: 
Celine Jimenez Crowson
Registration No. 40,357


Kevin G. Shaw
Registration No. 43,110

Wyeth Pharmaceuticals is a wholly owned division of Wyeth and has a principal place of business at 5 Giralda Farms, Madison, NJ 07490. Wyeth Pharmaceuticals is the owner of a New Drug Application ("NDA") for PRISTIQ™, NDA number NDA 21-966. Attached at **Exhibit A** is a Power of Attorney document appointing the undersigned patent attorney as legal representative of Applicant and as agent of Wyeth and its division Wyeth Pharmaceuticals for purposes of requesting and/or obtaining any patent term extensions with respect to NDA number 21-966.

Applicant, acting through its duly authorized attorney, hereby submits this application for extension of patent term under 35 U.S.C. §156, based upon the approval by the Food and Drug Administration for commercial marketing or use of PRISTIQ™, since the active ingredient of PRISTIQ™ is desvenlafaxine succinate, which falls within the ambit of the claims of U.S. Patent No. 6,673,838. The information contained in this Application and its Exhibits is provided in accordance with the rules promulgated by the U.S. Patent and Trademark Office at 37 CFR §§1.710-1.785 and presented in the manner set forth at 37 CFR §1.740.

1. A Complete Identification Of The Approved Product As By Appropriate Chemical And Generic Name, Physical Structure Or Characteristics

The approved product, PRISTIQ™, contains desvenlafaxine succinate as its active ingredient. The chemical name of desvenlafaxine (also known as O-desmethyl venlafaxine) is RS-4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol and has the empirical formula $C_{16}H_{25}NO_2$. Desvenlafaxine succinate is a succinate salt of desvenlafaxine, and has the empirical formula $C_{16}H_{25}NO_2 \cdot C_4H_6O_4$ ($C_{16}H_{25}NO_2 \cdot C_4H_6O_4 \cdot H_2O$ for the monohydrate). Desvenlafaxine succinate monohydrate has a molecular weight of 399.48, and the following structural formula:



Desvenlafaxine succinate is prepared as a white to off-white powder that is soluble in water (pH dependent), with an octanol:aqueous system (at pH 7.0) partition coefficient of 0.21. The approved product is formulated as an extended release tablet for once daily oral administration, and is available in tablet strengths of 50 mg and 100 mg. Each PRISTIQ™ tablet contains either 76 mg or 152 mg of desvenlafaxine succinate monohydrate, which is equivalent to 50 mg or 100 mg, respectively, of desvenlafaxine.

2. A Complete Identification Of The Federal Statute Including The Applicable Provisions Of Law Under Which The Regulatory Review Occurred

The approved product, PRISTIQ™, was subject to regulatory review under Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §355).

3. An Identification Of The Date On Which The Product Received Permission For Commercial Marketing Or Use Under The Provision Of Law Under Which The Applicable Regulatory Review Period Occurred

The approved product, PRISTIQ™, received permission for commercial marketing or use under Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §355) on February 29, 2008. A copy of a letter from the Food and Drug Administration (“FDA”) indicating the date of approval is attached hereto at **Exhibit B**.

4. In The Case Of A Drug Product, An Identification Of Each Active Ingredient In The Product And As To Each Active Ingredient, A Statement That It Has Not Been Previously Approved For Commercial Marketing Or Use Under The Federal Food, Drug, and Cosmetic Act, The Public Health Service Act, Or The Virus-Serum-Toxin Act, Or A Statement Of When The Active Ingredient Was Approved For Commercial Marketing Or Use (Either Alone Or In Combination With Other Active Ingredients), The Use For Which It Was Approved, And The Provision Of Law Under Which It Was Approved

The active ingredient in PRISTIQ™ is desvenlafaxine succinate, which has not been previously approved for commercial marketing or use under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, or the Virus-Serum-Toxin Act.

5. A Statement That The Application Is Being Submitted Within The Sixty Day Period Permitted For Submission Pursuant to 37 CFR §1.720(f) And An Identification Of The Date Of The Last Day On Which The Application Could Be Submitted

This application is being submitted within the permitted sixty (60) day period, the last day of which is April 28, 2008.

6. A Complete Identification Of The Patent For Which An Extension Is Being Sought By The Name Of The Inventor, The Patent Number, The Date Of Issue, And The Date Of Expiration

The complete identification of the patent for which extension is sought is:

Inventors: Anthony F. Hadfield
Syed M. Shah
Michael W. Winkley
Karen W. Sutherland
James A. Provost
Aeri Park
Rex A. Shiplett
Brenton W. Russell
Beat T. Weber

Patent Number: 6,673,838

Issue Date: January 6, 2004

Expiration Date: February 11, 2022 (without extension under 35 U.S.C. §156)

7. A Copy Of The Patent For Which An Extension Is Being Sought, Including The Entire Specification (Including Claims) And Drawings

A complete copy of U.S. Patent No. 6,673,838 is annexed as **Exhibit C**.

8. A Copy Of Any Disclaimer, Certificate of Correction, Receipt Of Maintenance Fee Payment, Or Reexamination Certificate Issued In The Patent

The patent for which extension is being sought has not been the subject of any disclaimer, certificate of correction, or reexamination certificate. The first maintenance fee was duly paid on June 21, 2007 by Applicant, and no additional maintenance fees are due at this time. A copy of the maintenance fee statement evidencing this status is annexed as **Exhibit D**.

9. A Statement That The Patent Claims The Approved Product Or A Method Of Using Or Manufacturing The Approved Product, And A Showing Which Lists Each Applicable Patent Claim And Demonstrates The Manner In Which At Least One Such Patent Claim Reads On The Approved Product Or Method Of Using Or Manufacturing The Approved Product

U.S. Patent No. 6,673,838 claims the approved product, PRISTIQ™. More specifically, claims 1-7 and 22 read on the approved product and claim the active ingredient of the final approved product desvenlafaxine succinate, claims 23, 25-34, and 46 read on the approved product and claim pharmaceutical compositions comprising desvenlafaxine succinate, and claims 35 and 45 read on a methods that comprise using desvenlafaxine succinate for treatment. Claim 1 is compared to the approved product in the table below.

Patent Claim	Approved Product
1. A compound which is O-desmethyl venlafaxine succinate.	The active ingredient of the approved product is desvenlafaxine succinate, which is also known as and is identical to O-desmethyl venlafaxine succinate.

10. A Statement, Beginning On A New Page, Of The Relevant Dates And Information Pursuant To 35 U.S.C. § 156(g) In Order To Enable The Secretary Of Agriculture, As Appropriate, To Determine The Applicable Regulatory Review Period As Follows (i): For A Patent Claiming A Human Drug Product, Antibiotic, Or Human Biological Product, The Effective Date Of The Investigational New Drug (IND) Application And The IND Number; The Date On Which A New Drug Application (NDA) Or A Product License Application (PLA) Was Initially Submitted And The NDA Or PLA Number And The Date On Which The NDA Was Approved Or The Product License Issued

Wyeth was notified via teleconference with the FDA on May 9, 2002 that that the IND (IND 64,552) for desvenlafaxine succinate was in effect, and received a letter from the FDA confirming the IND became effective on June 11, 2002. For purposes of this application for patent term extension, the Applicant is entitled to an IND date of at least as early as June 11, 2002. The NDA (NDA 21-966) for PRISTIQ™ was initially submitted to the Food and Drug Administration on December 22, 2005 and was approved on February 29, 2008.

11. A Brief Description Beginning On A New Page OF The Significant Activities Undertaken By The Marketing Applicant During The Applicable Regulatory Review Period With Respect To The Approved Product And The Significant Dates Applicable To Such Activities

A brief description of significant activities undertaken by the marketing applicant during the regulatory review period with respect to the approved product in annexed as **Exhibit E**. This exhibit provides a chronology of the major communications between the marketing applicant and the Food and Drug Administration, including a brief summary of the subject matter and date of these communications.

Applicant reserves the right to supplement the chronology of **Exhibit E** with materials from which it was derived or other evidence related to Applicant's conduct in obtaining the approval of PRISTIQ™. *See, e.g.*, 21 CFR § 60.32.

12. A Statement Beginning On A New Page That In The Opinion Of The Applicant The Patent Is Eligible For The Extension And A Statement As To The Length Of The Extension Claimed, Including How The Length Of Extension Was Determined

Applicant is of the opinion that U.S. Patent No. 6,673,838 is eligible for extension under 35 U.S.C. § 156, because it satisfies all of the requirements for such extension as follows:

a. 35 U.S.C. §156(a); 37 CFR §1.720(a)

U.S. Patent No. 6,673,838 claims a product, and a method of using a product.

b. 35 U.S.C. §156(a)(1); 37 CFR §1.720(g)

The term of U.S. Patent No. 6,673,838 has not expired before submission of this application.

c. 35 U.S.C. §156(a)(2); 37 CFR §1.720(b)

The term of U.S. Patent No. 6,673,838 has never previously been extended under 35 U.S.C. §156.

d. 35 U.S.C. §156(a)(3); 37 CFR §1.730

This application for extension is submitted by the authorized agent or the owner of record in accordance with the requirement of 35 U.S.C. §156(d) and the rules of the U.S. Patent and Trademark Office.

e. 35 U.S.C. §156(a)(4); 37 CFR §1.720(d)

The product PRISTIQTTM has been subject to a regulatory review period as defined in 35 U.S.C. §156(g) before its commercial marketing or use.

- f. 35 U.S.C. §156(a)(5)(A); 37 CFR §1.720(e)(i)

The commercial marketing or use of the product PRISTIQ™ after the regulatory review period is the first permitted commercial marketing or use of the product under the provision of the Federal Food, Drug, and Cosmetics Act (21 U.S.C. §360) under which such regulatory review period occurred.

- g. 35 U.S.C. §156(c)(4); 37 CFR §1.720(h)

No other patent has been extended for the same regulatory review period for the product PRISTIQ™.

- h. 35 U.S.C. §156(d)(1); 37 CFR §1.720(f)

This application is submitted within the permitted 60 day period beginning on the date the product first received permission for commercial marketing or use.

Applicant is of the opinion that U.S. Patent No. 6,673,838 is eligible for extension under 35 U.S.C. § 156 for 17 days, as determined pursuant to 37 CFR §1.775 as follows:

Patent Information:

Patent Issue Date	January 6, 2004
Earliest non-provisional priority date	February 11, 2002
Days Extension under 35 U.S.C. 154(b)	0

FDA Information:

Latest Date IND Becomes Effective	June 11, 2002
Date NDA Submitted to the FDA	December 22, 2005
Date NDA Approved by the FDA	February 29, 2008

IND Period:

Latest Start Date of Regulatory Review Period	June 11, 2002
IND Review Period (days)	1290
½ IND Review Period (days)	645

Regulatory Review Period Allowed:

NDA Review Period (days)	800
Regulatory Review Period (days)	2090
Reg. Rev. Period less ½ IND period (days)	1445

Statutory Limitations:

Patent Expiration Date (20 year term)	February 11, 2022
Expiration under 5 year extension limitation (Date 1)	February 11, 2027
Expiration under 14 from NDA approval limitation (Date 2)	February 28, 2022
Expiration based upon full review period (Date 3)	January 26, 2026
Final Expiration Date (Earliest of Date 1, Date 2, or Date 3)	February 28, 2022
<u>Maximum Extension in Days:</u>	17

13. A Statement That Applicant Acknowledges A Duty To Disclose To The Commissioner Of Patents And Trademarks And The Secretary Of Health And Human Services Any Information Which Is Material To The Determination Of Entitlement To The Extension Sought

Applicant acknowledges a duty to disclose to the Commissioner of Patents and Trademarks and the Secretary of Health and Human Services any information which is material to any determinations of entitlement to the extension sought in the Application.

14. The Prescribed Fee For Receiving And Acting Upon The Application For Extension

The prescribed fee pursuant to 37 CFR §1.20(j) for receiving and acting upon this application is to be charged to the Deposit Account of Applicant's undersigned attorney as authorized in the attached letter, which is submitted in triplicate.

15. The Name, Address, And Telephone Number Of The Person To Whom Inquiries And Correspondence Relating To The Application For Patent Term Extension Are To Be Directed

Please address all correspondence to:

Kevin G. Shaw
Hogan & Hartson, LLP
555 Thirteenth St., NW
Washington, DC 20004

16. A Duplicate Of The Application Papers, Certified As Such

Applicant hereby certifies that this application for extension is being filed in triplicate.

17. An Oath Or Declaration

Applicant, through its undersigned patent attorney authorized to practice before the Patent and Trademark Office and who has general authority from the agent or owner to act on behalf of the agent or owner in patent matters, being duly warned that willful false statements are punishable by fine or imprisonment or both under section 1001 of Title 18, United States Code and that willful false statements and the like may jeopardize the validity of this application and the patent to which it relates, states and declares that the following statements made based on his own knowledge are true and that all statements made on information and belief are believed to be true:

- (1) The undersigned is registered to practice before the Patent and Trademark Office and is making this declaration as a patent attorney who has general authority to act on behalf of the applicant in patent matters.
- (2) The undersigned has reviewed and understands the contents of the application being submitted pursuant to this section;
- (3) The undersigned believes the patent is subject to an extension pursuant to 37 C.F.R. § 1.710 in the event of NDA approval and, in the interim, is subject to an extension pursuant to 37 C.F.R. § 1.790;

- (4) The undersigned believes an extension of the length claimed is justified under 35 U.S.C. 156 and the applicable regulations; and
- (5) The undersigned believes the patent for which extension is being sought meets the conditions for extension of the term of a patent as set forth in 37 C.F.R. § 1.720 in the event of NDA approval, and meets the requirements for an interim extension of a patent set forth in 37 C.F.R. § 1.790.


If this application for extension of patent term is held to be informal, applicant may seek to have that holding reviewed by filing a petition with the required fee, as necessary, pursuant to 37 C.F.R. §§ 1.181, 1.182 or 1.183, as appropriate, within such time as may be set in any notice that the application has been held to be informal, or if no time is set, within one month of the date on which the application was held informal.

Respectfully submitted,

Dated: April 25, 2008

HOGAN & HARTSON LLP

555 13th Street, N.W.
Washington, D.C. 20004
Telephone: 202-637-5600
Facsimile: 202-637-5910
Email: kgshaw@hhlaw.com
Customer No.: 24633

By: 
Kevin G. Shaw
Registration No. 43,110

U.S. Patent No. 6,673,838
Application for Extension of Patent Term

Exhibit A



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: U.S. Patent No. 6,673,838
Inventors: HADFIELD, Anthony F. et al.
Issue Date: January 6, 2007
For: SUCCINATE SALT OF O-DESMETHYL-VENLAFAXINE
Assignee: Wyeth

POWER OF ATTORNEY FOR PATENT TERM EXTENSION APPLICATION

Wyeth, a corporation organized and existing under the laws of Delaware, and having a principal place of business at 5 Giralda Farms, Madison, NJ 07490, is the sole owner of the entire interest in and to U.S. Patent No. 6,673,838 as reflected in the various assignment documents recorded by the U.S. Patent and Trademark Office on August 27, 2001 at Reel 012126, Frame 0893, on August 27, 2001 at Reel 012127, Frame 0102, on April 12, 2002 at Reel 012828, Frame 0928, on July 30, 2002 at Reel 013121, Frame 0837, on July 30, 2002 at Reel 013121, Frame 0855, on July 31, 2002 at Reel 013127, Frame 0287, on July 31, 2002 at Reel 013127, Frame 0306, on August 1, 2002 at Reel 013130, Frame 0479, and on August 21, 2002 at Reel 013229, Frame 0864.

Wyeth hereby revokes all previous powers of attorney and appoints Kevin G. Shaw and the registered practitioners of Hogan & Hartson, L.L.P. included in the Customer Number provided below to prosecute this patent term extension application and to transact all business in the Patent and Trademark Office connected therewith, and further directs that all correspondence be addressed to Kevin G. Shaw at that Customer Number.


U.S. Patent No. 6,673,838
Power of Attorney

The undersigned, acting in the official capacity stated below, has authority to does hereby execute this document on behalf of Wyeth.

Customer Number: 24633

Please direct all inquiries to:

Kevin G. Shaw
Telephone: (202) 637-6466
Facsimile: (202) 637-5910



William King
Assistant Secretary
Wyeth
5 Giralda Farms
Madison, NJ 07490

24 April 2008
Date

U.S. Patent No. 6,673,838
Application for Extension of Patent Term

Exhibit B



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857



NDA 21-992

NDA APPROVAL

Wyeth Pharmaceuticals, Inc.
Attention: Kenneth Bonk
Director II, Global Regulatory Affairs
P.O. Box 8299
Philadelphia, PA 19101-9822

Dear Mr. Bonk:

Please refer to your new drug application (NDA) dated and received on December 22, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Pristiq (desvenlafaxine succinate) 50mg, and 100mg extended release tablets.

We acknowledge receipt of your submissions dated:

April 4, 2007	December 14, 2007	February 14, 2008
May 11, 2007	December 19, 2007	February 15, 2008
June 1, 2007	December 20, 2007	February 20, 2008
June 27, 2007	January 14, 2008	February 21, 2008
August 23, 2007	February 4, 2008	February 22, 2008
August 29, 2007	February 11, 2008	

The August 29, 2007 submission constituted a complete response to our January 22, 2007 action letter.

This new drug application provides for the use of Pristiq (desvenlafaxine succinate) tablets for the treatment of major depressive disorder.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at <http://www.fda.gov/oc/datacouncil/spl.html> that is identical to the enclosed labeling (text for the package insert and Medication Guide). Upon receipt, we will transmit that version to the

National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, "SPL for approved NDA 21-992."

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and container labels that are identical to the submitted carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (October 2005)*.

Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission "**Final Printed Carton and Container Labels for approved NDA 21-992.**" Approval of this submission by FDA is not required before the labeling is used.

Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

PEDIATRIC RESEARCH EQUITY ACT (PREA)

All applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable. We are waiving the pediatric study requirement for ages 0-6 years because the necessary studies are impossible or highly impracticable because there are not enough patients in that age group with the disease to study. We are deferring submission of your pediatric studies for ages 7-17 years because the drug is ready for approval for use in adults and the pediatric studies have not been completed.

Your deferred pediatric studies required under section 2 of the Pediatric Research Equity Act (PREA) are considered required postmarketing study commitments. The status of these postmarketing studies shall be reported annually according to 21 CFR 314.81. These commitments are listed below.

POSTMARKETING COMMITMENTS

We remind you of your following postmarketing study commitments agreed upon in your submission dated February 19, 2008. These commitments are listed below.

1. Deferred Pediatric Studies Under PREA

You have agreed to conduct studies to assess the safety and effectiveness of desvenlafaxine succinate as a treatment for Major Depressive Disorder in pediatric patients ages 7 to 17 (children and adolescents). Both children (ages 7 to 11 years) and adolescents (ages 12 to 17 years) will be equally represented in the samples, and there will be a reasonable distribution of both sexes in these age strata. You have agreed to submit the results of these studies no later than 4.5 years after the date of approval for this NDA.

Final Report Submission: 4.5 years from the date of approval

Submit final study reports to this NDA. For administrative purposes, all submissions related to this/these pediatric postmarketing study commitment(s) must be clearly designated “**Required Pediatric Study Commitments**”.

2. Exploration of Dose Response for Effectiveness

Your NDA for desvenlafaxine succinate (DVS) demonstrates the effectiveness of doses as low as 50 mg as a treatment for Major Depressive Disorder (MDD), however, the available data for effectiveness for this drug in MDD suggests a flat dose response curve for efficacy between 50 and 400 mg/day. On the other hand, there is a clear dose response for adverse events as the dose increases from 50 to 400 mg/day. Therefore, there is a need to better understand the lower end of the dose response curve to determine if efficacy might be achieved at doses even lower than 50 mg/day. You have agreed to conduct and submit the results of a randomized controlled study including placebo and DVS doses of 10, 25, and 50 mg/day as a Postmarketing commitment. This study will assess efficacy in this dose range and will also include a validated and reliable outcome measure to assess for sexual dysfunction. You have agreed to submit the results of this trial no later than 3 years after the date of the approval for this NDA.

Final Report Submission: 3 years from the date of approval

3. Long-Term Efficacy Studies

Although your NDA for desvenlafaxine succinate demonstrates effectiveness of recommended doses (50-100 mg/day) as a treatment for Major Depressive Disorder over an interval of 8 weeks, it does not provide information about the duration and conditions of treatment with desvenlafaxine that are necessary to sustain its antidepressant effects over the full duration (likely 6 months to a year or longer) of an acute major depressive episode at these same recommended doses. While it is widely assumed that continued treatment of symptomatically remitted patients reduces their risk of relapse, [REDACTED] we have no evidence that desvenlafaxine at these lower doses has efficacy after 8 weeks. Once you have established the lower end of the dose-response curve for efficacy, you have agreed to conduct and submit the results of a randomized withdrawal study to address longer-term efficacy for your drug at appropriate doses. If the lower dose study establishes that 50 mg/day is the lowest effective dose, this study will evaluate doses of 50 and 100 mg/day. You have agreed to submit the results of this trial no later than 3 years after the date of initiation, or approximately 5.5 years from the date of approval for this NDA..

Final Report Submission: 5.5 years from the date of approval

4. Sexual Dysfunction

While it is clear that desvenlafaxine has a qualitatively negative effect on sexual function from the adverse events collected during your earlier trials, we do not have quantified sexual dysfunction data. You have agreed to assess sexual dysfunction in your planned lower dose study. If the lower dose study establishes that 50 mg/day is the lowest effective dose, you have

agreed to conduct another acute, randomized controlled trial with placebo, 50, and 100 mg/day, and employ a validated and reliable outcome measure to assess for sexual dysfunction. This study could be conducted in parallel with the longer-term efficacy trial, and the results could be submitted approximately 5.5 years from the date of approval for this NDA.

Final Report Submission: 5.5 years from the date of approval

5. Pharmacology/Toxicology

Your combined fertility and embryo-fetal toxicity study in rats did not adequately assess desvenlafaxine's potential for embryo-fetal toxicity, including teratogenicity, due to decreased number of fetuses available for analysis at the high dose of 300 mg/kg. This appeared to result from effects of desvenlafaxine on fertility and pre-implantation loss and would not be factors if dosing were only done during the period of organogenesis. Consequently, you have agreed to conduct a standard embryo-fetal toxicity study in rats, and submit the results no later than 3 years after the date of the approval for this NDA.

Final Report Submission: 3 years from the date of approval

Submit clinical protocols to your IND for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all study final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii), you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies, number of patients entered into each study. All submissions, including supplements, relating to these postmarketing study commitments should be prominently labeled "Postmarketing Study Commitment Protocol", "Postmarketing Study Commitment Final Report", or "Postmarketing Study Commitment Correspondence."

DISSOLUTION METHOD AND SPECIFICATION

Method:

Apparatus:	USP Apparatus 1 (baskets)
Speed:	100 rpm
Medium:	900 mL 0.9% NaCl in water
Temperature:	37°C ± 0.5°C

Specification:

Time	Criteria (% LC Released)
2 hours	<div style="border: 1px solid black; width: 80px; height: 150px; margin: 0 auto;"></div>
4 hours	
8 hours	
12 hours	
24 hours	

EXPIRY DATE

An expiration of 24 months has been granted.

ADVISORY COMMITTEE

NDA 21-992 was not referred to an advisory committee for review because there are several previously approved agents in the antidepressant class of drugs, evaluation of the safety data did not reveal particular safety issues that were unexpected for this class, and the design and results of the efficacy trials did not pose particular concerns.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see www.fda.gov/cder/ddmac.

LETTERS TO HEALTH CARE PROFESSIONALS

If you issue a letter communicating important safety related information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch
Food and Drug Administration
HFD-001, Suite 5100
5515 Security Lane
Rockville, MD 20852

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

MEDWATCH-TO-MANUFACTURER PROGRAM

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at www.fda.gov/medwatch/report/mmp.htm.

If you have any questions, call Renmeet Grewal, Pharm.D., Regulatory Project Manager, at (301) 796-1080.

Sincerely,

{See appended electronic signature page}

Robert Temple, M.D.
Director
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure: Label & Medguide

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Robert Temple
2/29/2008 03:15:15 PM

U.S. Patent No. 6,673,838
Application for Extension of Patent Term

Exhibit C

U.S. Patent No. 6,673,838
Application for Extension of Patent Term

Exhibit D



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Customer No 25291

ISTMT

DATE PRINTED
04/23/2008

WYETH
PATENT LAW GROUP
5 GIRALDA FARMS
MADISON NJ 07940

MAINTENANCE FEE STATEMENT

According to the records of the U.S. Patent and Trademark Office (USPTO), the maintenance fee and any necessary surcharge have been timely paid for the patent listed below. The "PYMT DATE" column indicates the payment date (i.e., the date the payment was filed).

The payment shown below is subject to actual collection. If the payment is refused or charged back by a financial institution, the payment will be void and the maintenance fee and any necessary surcharge unpaid.

Direct any questions about this statement to: Mail Stop M Correspondence, Director of the USPTO, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT NUMBER	FEE AMT	SUR CHARGE	PYMT DATE	U.S. APPLICATION NUMBER	PATENT ISSUE DATE	APPL. FILING DATE	PAYMENT YEAR	SMALL ENTITY?	ATTY DKT NUMBER
6,673,838	\$900.00	\$0.00	06/21/07	10/073,743	01/06/04	02/11/02	04	NO	AM-100463

U.S. Patent No. 6,673,838
Application for Extension of Patent Term

Exhibit E

Exhibit E

A brief description of significant activities undertaken by Wyeth during the regulatory review period for PRISTIQ™, together with applicable dates, follows below. A more detailed description of activities undertaken by Wyeth, including those listed below, is set forth in the IND Activities and NDA Activities tables produced on the pages following part 4 of this Exhibit.

1. Between June 11, 2002 and December 22, 2005, Wyeth conducted multiple clinical studies of PRISTIQ™. There were seven randomized, double-blind, placebo-controlled, fixed- and flexible-dose studies, one relapse prevention study, and three open-label, long-term safety studies. Wyeth also conducted at least 15 pharmacokinetic and pharmacodynamic studies.

2. Key Regulatory Dates

April 12, 2002	IND 64,552 submitted to FDA
May 9, 2002	FDA notification (via telephone) that IND is in effect
June 11, 2002	FDA letter confirming IND is in effect
February 4, 2003	Pre-Phase III meeting with FDA
April 10, 2003	End-of-Phase II/CMC meeting with FDA
November 6, 2003	Type C Meeting with FDA re: IVIVC
June 15, 2005	Meeting with FDA re: CMC Quality by Design (QbD)
September 20, 2005	Type C Meeting with FDA: CMC Pilot Program
September 8, 2005	Pre-NDA meeting with FDA
October 27, 2005	Pre-NDA meeting with FDA re: CMC Issues
December 22, 2005	NDA 21-992 submitted to FDA
January 22, 2007	FDA action letter ("approvable")
August 29, 2007	Complete response to FDA action letter
February 29, 2008	FDA approval

3. Summary of Phase III Clinical Studies

There were seven randomized, double-blind, placebo-controlled, fixed- and flexible-dose studies, one relapse prevention study, and three open-label, long-term safety studies.

Start	Stop	Study (n=patients randomized)
September 2002	March 2003	Fixed-Dose Efficacy (n=227)
June 2003	August 2005	Relapse Prevention (n=603)
June 2003	May 2004	Flexible-Dose Efficacy (n=247)
August 2003	March 2006	Open-Label Flexible-Dose Safety (n=1408)
November 2003	November 2004	Fixed-Dose Efficacy (n=480)
November 2003	September 2004	Fixed-Dose Efficacy (n=375)
January 2004	May 2005	Open-Label Flexible-Dose Safety (n=108)
March 2004	May 2005	Flexible-Dose Efficacy (n=369)
April 2004	March 2005	Flexible-Dose Efficacy (n=369)
July 2004	May 2005	Flexible-Dose Efficacy (n=244)
October 2004	October 2005	Open-Label Flexible-Dose Safety (n=52)

4. Following the initial submission of the NDA on December 22, 2005, Wyeth submitted additional information to FDA on the following dates:

February 1, 2006	September 14, 2006	December 13, 2007
February 14, 2006	September 22, 2006	December 14, 2007
February 16, 2006	September 26, 2006	December 19, 2007
March 7, 2006	October 10, 2006	December 20, 2007
March 16, 2006	October 12, 2006	January 14, 2008
April 21, 2006	October 26, 2006	February 4, 2008
April 28, 2006	November 1, 2006	February 11, 2008
May 10, 2006	December 8, 2006	February 14, 2008
June 7, 2006	January 25, 2007	February 15, 2008
June 9, 2006	February 2, 2007	February 20, 2008
June 26, 2006	April 4, 2007	February 21, 2008
July 3, 2006	May 11, 2007	February 22, 2008
July 13, 2006	June 1, 2007	February 29, 2008
July 31, 2006	June 27, 2007	
August 31, 2006	August 23, 2007	
September 5, 2006	August 29, 2007	

IND Activities

Orin Doc ID	App. Country	Doc. Date	Referral on #	Doc. Type	Sub1 Type	Sub2 Type	Sub3 Type	Chronology Description	Reg. Link Date	Email Protocol	Import Country	To	From	App. #	App. Description	App. Region	Corporate Tradename Address.
106612	UNITED STATES	12-Apr-02	0	IDA-Initial							060003-171-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ US
105132	UNITED STATES	25-Apr-02	1	1A Correspondence	Response to	Information Request		Current Specifications & Test Methods of Venlafaxine HCL				FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ US
105166	UNITED STATES	26-Apr-02	2	1A Correspondence	Response to	Information Request						FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ US
105166	UNITED STATES	26-Apr-02	2	1A Correspondence	CMC Issues	Info Request-Response						FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ US
105353	UNITED STATES	1-May-02	3	1A Correspondence	Response to	Information Request						FDA	W-LAR	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ US
105458	UNITED STATES	6-May-02	4	1A Correspondence	Response to	Information Request						FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ US
105518	UNITED STATES	6-May-02	5	1A Correspondence	Response to	Information Request						FDA	W-LAR	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ US
106838	UNITED STATES	5-Jun-02	6	1A Correspondence	Prot Amend	Change in Prot					060003-171-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ US
107202	UNITED STATES	17-Jun-02	7	1A Correspondence	Prot Amend	Change in Prot		Toxicology and Drug Metabolism Support for Phase 3 Clinical Studies			060003-171-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ US
107460	UNITED STATES	20-Jun-02	8	1A Correspondence	Request	Review/Comment						FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ US
107789	UNITED STATES	25-Jun-02	9	1A Correspondence	Info Amend-PharmTox							FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ US
108208	UNITED STATES	1-Jul-02	10	1A Correspondence	Info Amend-CMC							FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ US
108210	UNITED STATES	1-Jul-02	11	1A Correspondence	Prot Amend	New Protocol		New Protocol - Protocol No 060003-186-US - DVS-233 SR - IND No 64.552			060003-186-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ US
108212	UNITED STATES	1-Jul-02	12	1A Correspondence	Prot Amend	New Protocol		DVS-233 SR - IND No 64.552 - New Protocol #060003-223-US			060003-223-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ US
108213	UNITED STATES	1-Jul-02	13	1A Correspondence	Prot Amend	New Protocol		New Protocol - DVS-233 SR - IND No 64.552 - New Protocol #060003-223-US			060003-223-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ US
108683	UNITED STATES	16-Jul-02	14	1A Correspondence	Prot Amend	Change in Prot					060003-223-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ US
110383	UNITED STATES	13-Aug-02	15	1A Correspondence	Prot Amend	Change in Prot					060003-223-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ US
110543	UNITED STATES	15-Aug-02	16	1A Correspondence	Prot Amend	Change in Prot					060003-223-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ US
110575	UNITED STATES	16-Aug-02	17	1A Correspondence	Prot Amend	Audit Invest		S I C N S F D A D V - 233 SR IND 64.552 doc			060003-223-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ US
110575	UNITED STATES	16-Aug-02	17	1A Correspondence	Prot Amend	Del Subinvest		S I C N S F D A D V - 233 SR IND 64.552 doc			060003-223-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S	PRISTIQ US

IND Activities

110573 UNITED STATES	16-Aug-02	17 IA Correspondence	Prot Amend	Del Subinvest	S\CONSFDA\Ds-233 SRIND\017.doc	060003-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
110818 UNITED STATES	26-Aug-02	18 IA Correspondence	Prot Amend	Add Invest	S\CONSFDA\Ds-233 SRIND\018.doc	060003-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
111000 UNITED STATES	30-Aug-02	19 IA Correspondence	Prot Amend	Add Invest	S\CONSFDA\Ds-233 SRIND\020.doc	060003-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
111274 UNITED STATES	9-Sep-02	20 IA Correspondence	Info Amend-Pharm/Tor				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
111311 UNITED STATES	11-Sep-02	21 IA Correspondence	Info Amend-Pharm/Tor		S\CONSFDA\Ds-233 SRIND\022.doc		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
112048 UNITED STATES	26-Sep-02	22 IA Correspondence	Info Amend-Pharm/Tor				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
112178 UNITED STATES	2-Oct-02	23 IA Correspondence	Prot Amend	New Protocol		060003-172-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
112230 UNITED STATES	3-Oct-02	24 IA Correspondence	Prot Amend	Change in Prot		060003-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
113017 UNITED STATES	21-Oct-02	25 IA Correspondence	Info Amend-Clin	IRB - Add	DVS-233 / Protocol Amendment Change of Investigator, Addition/Deletion of Subinvestigators; Information Amendment	060003-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
113017 UNITED STATES	21-Oct-02	25 IA Correspondence	Prot Amend	Add Subinvest	DVS-233 / Protocol Amendment Change of Investigator, Addition/Deletion of Subinvestigators; Information Amendment	060003-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
113017 UNITED STATES	21-Oct-02	25 IA Correspondence	Info Amend-Clin	IRB - Delete	DVS-233 / Protocol Amendment Change of Investigator, Addition/Deletion of Subinvestigators; Information Amendment	060003-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
113017 UNITED STATES	21-Oct-02	25 IA Correspondence	Prot Amend	Del Subinvest	DVS-233 / Protocol Amendment Change of Investigator, Addition/Deletion of Subinvestigators; Information Amendment	060003-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
113017 UNITED STATES	21-Oct-02	25 IA Correspondence	Prot Amend	Add Invest		060003-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
113447 UNITED STATES	1-Nov-02	26 IA Correspondence	Prot Amend	Change in Prot		060003-223-PL	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
113474 UNITED STATES	1-Nov-02	27 IA Correspondence	Safety Rpt. Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
113860 UNITED STATES	14-Nov-02	28 IA Correspondence	Prot Amend	Add Subinvest	Desvenlafaxine Succinate (DVS-233) Protocol No. 060003-223-US	060003-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
113860 UNITED STATES	14-Nov-02	28 IA Correspondence	Prot Amend	Del Subinvest	Desvenlafaxine Succinate (DVS-233) Protocol No. 060003-223-US	060003-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
113860 UNITED STATES	14-Nov-02	28 IA Correspondence	Prot Amend	Name Change	Desvenlafaxine Succinate (DVS-233) Protocol No. 060003-223-US	060003-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

IND Activities

114110 UNITED STATES	15-Nov-02	29 IA Correspondence	Prot Amend	New Protocol		060003-175-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
114111 UNITED STATES	19-Nov-02	30 IA Correspondence	Meeting/Telecon	Meeting-Request	Request for Pre-Phase 3 Mtg		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
114227 UNITED STATES	21-Nov-02	31 IA Correspondence	Prot Amend	Add Invest		060003-223-PL	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
114227 UNITED STATES	21-Nov-02	31 IA Correspondence	Prot Amend	Add Subinvest		060003-223-PL	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
114334 UNITED STATES	26-Nov-02	32 IA Correspondence	Info Amend-Pharm/Tax				FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
114571 UNITED STATES	6-Dec-02	33 IA Correspondence	Safety Rpt Clin	Follow-up			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
114894 UNITED STATES	20-Dec-02	34 IA Correspondence	Prot Amend	Change in Prot		060003-175-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
115025 UNITED STATES	20-Dec-02	35 IA Correspondence	Non-Clinical Issues	Other			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
115028 UNITED STATES	23-Dec-02	36 IA Correspondence	Meeting/Telecon	Background Pkg-Submm	re: Pre-Phase 3 Meeting		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
115605 UNITED STATES	6-Jan-03	37 IA Correspondence	Safety Rpt Clin	Initial Written			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
115607 UNITED STATES	13-Jan-03	38 IA Correspondence	Info Amend-Clin	Name Change	FDA Submission - DVS-233 SR - SR071A0ADA1AISHAREDIC NSFDA0vs-233 SRIND/S040 doc FDA Submission - DVS-233 SR - SR071A0ADA1AISHAREDIC NSFDA0vs-233 SRIND/S040 doc	060003-223-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
115607 UNITED STATES	13-Jan-03	38 IA Correspondence	Prot Amend	Del Subinvest		060003-223-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
115607 UNITED STATES	13-Jan-03	38 IA Correspondence	Prot Amend	Add Subinvest		060003-223-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
115846 UNITED STATES	18-Jan-03	39 IA Correspondence	Safety Rpt Clin	Follow-up			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
116114 UNITED STATES	26-Jan-03	40 IA Correspondence	Safety Rpt Clin	Initial Written			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
116131 UNITED STATES	29-Jan-03	41 IA Correspondence	Response to	Information Request			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
116239 UNITED STATES	31-Jan-03	42 IA Correspondence	Response to	Information Request			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
116323 UNITED STATES	14-Feb-03	43 IA Correspondence	Info Amend-Pharm/Tax				FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
116323 UNITED STATES	14-Feb-03	43 IA Correspondence	Request	Review/Comment			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

IND Activities

116368	UNITED STATES	19-Feb-03	44 1A Correspondence	Info Amend-PharmTox		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
116368	UNITED STATES	19-Feb-03	44 1A Correspondence	Request	Review/Comment	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
116805	UNITED STATES	21-Feb-03	45 1A Correspondence	Info Amend-PharmTox		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
116837	UNITED STATES	21-Feb-03	46 1A Correspondence	Safety Rpt. Clin	Init Wt/Follow-up	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
116859	UNITED STATES	24-Feb-03	47 1A Correspondence	Meeting/Telecon	Meeting-Request	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
116878	UNITED STATES	24-Feb-03	48 1A Correspondence	Info Amend-Clin	IRB - Add	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
116878	UNITED STATES	24-Feb-03	48 1A Correspondence	Prot Amend	Del Subinvest	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
116878	UNITED STATES	24-Feb-03	48 1A Correspondence	Info Amend-Clin	IRB - Delete	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
116878	UNITED STATES	24-Feb-03	48 1A Correspondence	Prot Amend	Add Subinvest	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
117012	UNITED STATES	27-Feb-03	49 1A Correspondence	Meeting/Telecon	Minutes	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
117028	UNITED STATES	3-Mar-03	50 1A Correspondence	Prot Amend	New Protocol	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
117649	UNITED STATES	13-Mar-03	51 1A Correspondence	Meeting/Telecon	Background Pig-Submm	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
117847	UNITED STATES	13-Mar-03	52 1A Correspondence	Meeting/Telecon	Background Pig-Submm	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
117847	UNITED STATES	13-Mar-03	52 1A Correspondence	Meeting/Telecon	Request-Response	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
118061	UNITED STATES	20-Mar-03	53 1A Correspondence	Meeting/Telecon	Background Pig-Submm	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
118064	UNITED STATES	20-Mar-03	54 1A Correspondence	Meeting/Telecon	Info	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
118064	UNITED STATES	20-Mar-03	54 1A Correspondence	Meeting/Telecon	Request-Response	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
118532	UNITED STATES	1-Apr-03	55 1A Correspondence	Info Amend-PharmTox		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
118870	UNITED STATES	8-Apr-03	56 1A Correspondence	Annual Report/IDA	Subm	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
119248	UNITED STATES	8-Apr-03	57 1A Correspondence	Prot Amend	Add Subinvest	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

IND Activities

119249	UNITED STATES	8-Apr-03	57	IA Correspondence	Prot Amend	Del Subinvest	S:\CN\SFDA\DC-233 SRIND\5064.doc	060003-223-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
118759	UNITED STATES	21-Apr-03	58	IA Correspondence	Meeting/Telecon	Minutes	EDP2 April 10 CMC Meeting Minutes		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
119951	UNITED STATES	24-Apr-03	59	IA Correspondence	Info Amend-CMC		Addition of Guayama PR and firm coat		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
119954	UNITED STATES	24-Apr-03	60	IA Correspondence	Prot Amend	New Protocol		3151A1-304-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
119962	UNITED STATES	25-Apr-03	61	IA Correspondence	Prot Amend	New Protocol		3151A1-306-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
119977	UNITED STATES	28-Apr-03	62	IA Correspondence	Prot Amend	New Protocol		3151A1-308-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
120488	UNITED STATES	1-May-03	63	IA Correspondence	Info Amend-PharmTox				FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
121145	UNITED STATES	9-May-03	64	IA Correspondence	Safety Rpt. Clin	Follow-up			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
121217	UNITED STATES	14-May-03	65	IA Correspondence	Info Amend-PharmTox				FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
121486	UNITED STATES	16-May-03	66	IA Correspondence	Prot Amend	New Protocol		3151A1-302-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
121488	UNITED STATES	16-May-03	67	IA Correspondence	Prot Amend	New Protocol		3151A1-302-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
121503	UNITED STATES	16-May-03	68	IA Correspondence	Prot Amend	Change in Prot		060003-223-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
122331	UNITED STATES	29-May-03	69	IA Correspondence	Request	Review/Comment	Response to FDA Comments Rec'd during Feb 04 2003 Pre- Phase 3 Mtg		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
122425	UNITED STATES	4-Jun-03	70	IA Correspondence	Prot Amend	Change in Prot		060003-223-PL	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
123068	UNITED STATES	18-Jun-03	71	IA Correspondence	Info Amend-Clin	Research Facilit-Del		3151A1-304-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
123068	UNITED STATES	18-Jun-03	71	IA Correspondence	Info Amend-Clin	IRB - Add		3151A1-304-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
123068	UNITED STATES	18-Jun-03	71	IA Correspondence	Prot Amend	Add Invest		3151A1-304-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
123068	UNITED STATES	18-Jun-03	71	IA Correspondence	Info Amend-Clin	IRB - Delete		3151A1-304-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
123068	UNITED STATES	18-Jun-03	72	IA Correspondence	Info Amend-PharmTox				FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
123297	UNITED STATES	23-Jun-03	73	IA Correspondence	Info Amend-Clin	Research Facilit - Add		3151A1-302-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

IND Activities

123287	UNITED STATES	23-Jun-03	73 1A Correspondence	Prot Amend	Del Subinvest	S:\CN\SFDA\Dvs-233 SRIND\5068.doc	3151A1-302-MW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
123287	UNITED STATES	23-Jun-03	73 1A Correspondence	Prot Amend	Add Invest	S:\CN\SFDA\Dvs-233 SRIND\5068.doc	3151A1-302-MW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
123291	UNITED STATES	26-Jun-03	74 1A Correspondence	Info Amend-Pharm/Tax				FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
123292	UNITED STATES	23-Jul-03	75 1A Correspondence	Info Amend-Pharm/Tax		Submission provides for additional deletion of subinvestigators for Protocol No. 0600D3-223-US Additional material for additional deletion of subinvestigators for Protocol No. 0600D3-223-US		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
123577	UNITED STATES	29-Jul-03	76 1A Correspondence	Prot Amend	Add Subinvest		0600D3-223-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
123577	UNITED STATES	29-Jul-03	76 1A Correspondence	Prot Amend	Del Subinvest		0600D3-223-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
125817	UNITED STATES	29-Jul-03	77 1A Correspondence	Gen Corr		Rationale Designation Starting Material		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
125832	UNITED STATES	1-Aug-03	78 1A Correspondence	Info Amend-Clin	Address Change		3151A1-306-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
125832	UNITED STATES	1-Aug-03	78 1A Correspondence	Prot Amend	Add Invest		3151A1-306-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
126374	UNITED STATES	11-Aug-03	79 1A Correspondence	Prot Amend	Add Subinvest	S:\CN\SFDA\Dvs-233 SRIND\5077.doc	3151A1-306-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
126374	UNITED STATES	11-Aug-03	79 1A Correspondence	Prot Amend	Del Subinvest		3151A1-306-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
126598	UNITED STATES	14-Aug-03	80 1A Correspondence	Prot Amend	Change in Prot		3151A1-304-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
126875	UNITED STATES	21-Aug-03	81 1A Correspondence	Info Amend-Clin	Name Change	S:\CN\SFDA\Dvs-233 SRIND\5078.doc	3151A1-303-MW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
126875	UNITED STATES	21-Aug-03	81 1A Correspondence	Prot Amend	Add Invest		3151A1-303-MW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
126950	UNITED STATES	25-Aug-03	82 1A Correspondence	Info Amend-CMC				FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
126968	UNITED STATES	26-Aug-03	83 1A Correspondence	Info Amend-Pharm/Tax				FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
126967	UNITED STATES	27-Aug-03	84 1A Correspondence	Prot Amend	New Protocol		3151A1-174-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
127331	UNITED STATES	3-Sep-03	85 1A Correspondence	Prot Amend	Change in Prot		3151A1-302-MW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
127331	UNITED STATES	3-Sep-03	85 1A Correspondence	Response to	Other			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
127433	UNITED STATES	4-Sep-03	86 1A Correspondence	Prot Amend	Add Invest	S:\CN\SFDA\Dvs-233 SRIND\5084.doc	3151A1-303-MW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

IND Activities

127433 UNITED STATES	4-Sep-03	86 1A Correspondence	Prot Amend	Add Subinvest	S\KNSF\DA\Dvs-233 SRIND\G084.doc	3151A1-303-MW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
127548 UNITED STATES	5-Sep-03	87 1A Correspondence	Prot Amend	Change in Prot		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
127550 UNITED STATES	5-Sep-03	88 1A Correspondence	Prot Amend	Change in Prot		3151A1-308-MW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
127801 UNITED STATES	8-Sep-03	88 1A Correspondence	Prot Amend	Change in Prot		3151A1-303-MW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
127820 UNITED STATES	8-Sep-03	90 1A Correspondence	Prot Amend	Add Subinvest	S\KNSF\DA\Dvs-233 SRIND\G087.doc	060003-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
127820 UNITED STATES	9-Sep-03	90 1A Correspondence	Prot Amend	Del Subinvest	S\KNSF\DA\US 233 SRIND\G087.doc	060003-223-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
127838 UNITED STATES	9-Sep-03	91 1A Correspondence	Prot Amend	Add Invest	S\KNSF\DA\Dvs-233 SRIND\G088.doc	3151A1-302-MW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
127839 UNITED STATES	9-Sep-03	91 1A Correspondence	Prot Amend	Del Invest	S\KNSF\DA\Dvs-233 SRIND\G088.doc	3151A1-302-MW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
127704 UNITED STATES	11-Sep-03	92 1A Correspondence	Meeting/Telecon	Meeting-Request	Requesting a Type C Meeting with Agency		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
127712 UNITED STATES	11-Sep-03	93 1A Correspondence	Prot Amend	Add Subinvest	S\KNSF\DA\Dvs-233 SRIND\G090.doc	3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
127712 UNITED STATES	11-Sep-03	93 1A Correspondence	Prot Amend	Del Subinvest	S\KNSF\DA\Dvs-233 SRIND\G090.doc Submission provides for a new investigator and the addition/deletion of subinvestigators.	3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
127714 UNITED STATES	11-Sep-03	94 1A Correspondence	Prot Amend	Add Invest	S\KNSF\DA\US 233 SRIND\G089.doc Submission provides for a new investigator and the addition/deletion of subinvestigators.	3151A1-303-MW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
127714 UNITED STATES	11-Sep-03	94 1A Correspondence	Prot Amend	Del Subinvest	S\KNSF\DA\Dvs-233 SRIND\G089.doc Submission provides for a new investigator and the addition/deletion of subinvestigators.	3151A1-303-MW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
127714 UNITED STATES	11-Sep-03	94 1A Correspondence	Prot Amend	Add Subinvest		3151A1-303-MW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
127847 UNITED STATES	18-Sep-03	95 1A Correspondence	Safety Rpt. Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
128143 UNITED STATES	23-Sep-03	96 1A Correspondence	Info Amend-Pharm/Tox				FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
128391 UNITED STATES	28-Sep-03	97 1A Correspondence	Prot Amend	Add Subinvest		3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
128410 UNITED STATES	29-Sep-03	98 1A Correspondence	Response to	Information Request			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
128413 UNITED STATES	24-Oct-03	98 1A Correspondence	Prot Amend	Add Invest		3151A1-308-MW	FDA	W-AR	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

IND Activities

129556	UNITED STATES	28-Oct-03	100 1A Correspondence	Prot Amend	Add Invest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
129556	UNITED STATES	28-Oct-03	100 1A Correspondence	Prot Amend	Add Invest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
129556	UNITED STATES	28-Oct-03	100 1A Correspondence	Prot Amend	Del Invest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
129556	UNITED STATES	28-Oct-03	100 1A Correspondence	Prot Amend	Del Invest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
129560	UNITED STATES	28-Oct-03	101 1A Correspondence	Prot Amend	Add Invest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
129560	UNITED STATES	28-Oct-03	101 1A Correspondence	Prot Amend	Add Invest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
12870	UNITED STATES	31-Oct-03	102 1A Correspondence	Info Amend-Clin	Address Change		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
12870	UNITED STATES	31-Oct-03	102 1A Correspondence	Prot Amend	Add Subinvest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
12870	UNITED STATES	31-Oct-03	102 1A Correspondence	Prot Amend	Del Subinvest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
12870	UNITED STATES	31-Oct-03	102 1A Correspondence	Info Amend-Clin	Name Change		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
130393	UNITED STATES	14-Nov-03	103 1A Correspondence	CMC Issues	Other	Wyeth Meeting Minutes of 11-6-03 FDA/ Wyeth	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
130393	UNITED STATES	14-Nov-03	103 1A Correspondence	Meeting/Telecon	Minutes	Wyeth Meeting Minutes of 11-6-03 FDA/ Wyeth	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
130928	UNITED STATES	25-Nov-03	104 1A Correspondence	Clinical Issues	Info Request-Respon	Response to Reproductive-Related Comments	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
131177	UNITED STATES	3-Dec-03	105 1A Correspondence	Prot Amend	Add Invest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
131177	UNITED STATES	3-Dec-03	105 1A Correspondence	Prot Amend	Add Subinvest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
131177	UNITED STATES	3-Dec-03	105 1A Correspondence	Prot Amend	Del Subinvest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
131185	UNITED STATES	3-Dec-03	106 1A Correspondence	Prot Amend	Del Invest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
131185	UNITED STATES	3-Dec-03	106 1A Correspondence	Prot Amend	Del Subinvest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
131185	UNITED STATES	3-Dec-03	106 1A Correspondence	Prot Amend	Add Subinvest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
131850	UNITED STATES	15-Dec-03	107 1A Correspondence	Response to	Review/Comment Req		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

IND Activities

131660	UNITED STATES	22-Dec-03	108 1A Correspondence	Prot Amend	New Protocol		3151A1-318-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
131660	UNITED STATES	22-Dec-03	108 1A Correspondence	Prot Amend	Add Invest			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
131660	UNITED STATES	22-Dec-03	108 1A Correspondence	Prot Amend	Add Invest		3151A1-318-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
132814	UNITED STATES	15-Jan-04	109 1A Correspondence	Info Amend-CMC		IVVC/Comparator Info		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
132848	UNITED STATES	15-Jan-04	110 1A Correspondence	Prot Amend	New Protocol		3151A1-177-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
133048	UNITED STATES	21-Jan-04	111 1A Correspondence	Prot Amend	New Protocol		3151A1-317-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
133084	UNITED STATES	21-Jan-04	112 1A Correspondence	Prot Amend	Add Subinvest	Fulfillment of Pre-Phase 3 Meeting Request (Impenitension and Tachycardia)	3151A1-306-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
133245	UNITED STATES	27-Jan-04	113 1A Correspondence	Gen Corr				FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
133609	UNITED STATES	31-Mar-04	113 1A Correspondence	Response to	Information Request	FDA will not need any more detailed information	#####	Wyeth	FDA	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
133539	UNITED STATES	4-Feb-04	114 1A Correspondence	Safety Rpt. Clin	Initial Written	3151A1-303 Request for Feedback on Mouse Carc Study Dose Adjustment		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
133974	UNITED STATES	13-Feb-04	115 1A Correspondence	Request	Expedited Review			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
134155	UNITED STATES	18-Feb-04	116 1A Correspondence	Safety Rpt. Clin	Follow-up	3151A1-303		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
134201	UNITED STATES	19-Feb-04	117 1A Correspondence	Prot Amend	Add Subinvest		3151A1-303-MW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
134201	UNITED STATES	18-Feb-04	117 1A Correspondence	Prot Amend	Del Subinvest		3151A1-303-MW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
134247	UNITED STATES	20-Feb-04	118 1A Correspondence	Prot Amend	Add Subinvest		3151A1-306-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
134247	UNITED STATES	20-Feb-04	118 1A Correspondence	Prot Amend	Del Subinvest		3151A1-306-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
134356	UNITED STATES	23-Feb-04	119 1A Correspondence	Safety Rpt. Clin	Follow-up	3151A1-303		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
134815	UNITED STATES	3-Mar-04	121 1A Correspondence	Prot Amend	Add Invest		3151A1-318-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
134815	UNITED STATES	3-Mar-04	121 1A Correspondence	Prot Amend	Add Subinvest		3151A1-318-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
134815	UNITED STATES	3-Mar-04	121 1A Correspondence	Prot Amend	Del Subinvest		3151A1-318-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

135628	UNITED STATES	22-Mar-04	122 1A Correspondence	Prot Amend	New Protocol	3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
135668	UNITED STATES	24-Mar-04	123 1A Correspondence	Prot Amend	Add Invest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
135668	UNITED STATES	24-Mar-04	123 1A Correspondence	Prot Amend	Del Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
135668	UNITED STATES	24-Mar-04	123 1A Correspondence	Prot Amend	Add Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
135668	UNITED STATES	30-Mar-04	124 1A Correspondence	Prot Amend	Add Subinvest	3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
135668	UNITED STATES	30-Mar-04	124 1A Correspondence	Prot Amend	Other	3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
135668	UNITED STATES	30-Mar-04	124 1A Correspondence	Prot Amend	Del Subinvest	3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
135722	UNITED STATES	31-Mar-04	125 1A Correspondence	Prot Amend	Add Subinvest	3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
135722	UNITED STATES	31-Mar-04	125 1A Correspondence	Prot Amend	Del Subinvest	3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
135725	UNITED STATES	31-Mar-04	126 1A Correspondence	Info Amend-Clin	Address Change	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
135725	UNITED STATES	31-Mar-04	126 1A Correspondence	Prot Amend	Add Subinvest	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
135725	UNITED STATES	31-Mar-04	126 1A Correspondence	Prot Amend	Other	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
135727	UNITED STATES	31-Mar-04	127 1A Correspondence	Prot Amend	Change in Prot	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
135919	UNITED STATES	7-Apr-04	128 1A Correspondence	Prot Amend	Add Invest	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
136035	UNITED STATES	8-Apr-04	129 1A Correspondence	Info Amend-Pharm/Tox			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
136084	UNITED STATES	9-Apr-04	130 1A Correspondence	Prot Amend	Del Subinvest	3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
136122	UNITED STATES	12-Apr-04	131 1A Correspondence	Safety Rpt. Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
136478	UNITED STATES	21-Apr-04	132 1A Correspondence	Annual Report/DA	Subm		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
136516	UNITED STATES	22-Apr-04	133 1A Correspondence	Prot Amend	Add Invest	3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
136702	UNITED STATES	27-Apr-04	134 1A Correspondence	Safety Rpt. Clin	Initial Written		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

IND Activities

136800	UNITED STATES	30-Apr-04	135 1A Correspondence	Prot Amend	Add Invest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
136800	UNITED STATES	30-Apr-04	135 1A Correspondence	Prot Amend	Other		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
136800	UNITED STATES	30-Apr-04	135 1A Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
136800	UNITED STATES	30-Apr-04	135 1A Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
137193	UNITED STATES	10-May-04	136 1A Correspondence	Info Amend-CMC		RPT Update		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
137270	UNITED STATES	13-May-04	137 1A Correspondence	Prot Amend	Add Subinvest	Addition of a subinvestigator	3151A1-304-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
137272	UNITED STATES	13-May-04	138 1A Correspondence	Prot Amend	Add Subinvest		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
137272	UNITED STATES	13-May-04	138 1A Correspondence	Prot Amend	Del Subinvest		3151A1-306-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
137382	UNITED STATES	14-May-04	139 1A Correspondence	Prot Amend	Add Invest		3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
137382	UNITED STATES	14-May-04	139 1A Correspondence	Prot Amend	Del Subinvest		3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
137382	UNITED STATES	14-May-04	139 1A Correspondence	Prot Amend	Add Subinvest		3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
137487	UNITED STATES	18-May-04	140 1A Correspondence	Prot Amend	New Protocol		3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
137487	UNITED STATES	18-May-04	140 1A Correspondence	Prot Amend	Add Invest		3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
137475	UNITED STATES	18-May-04	141 1A Correspondence	Prot Amend	Add Subinvest		3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
137475	UNITED STATES	18-May-04	141 1A Correspondence	Prot Amend	Del Subinvest		3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
137842	UNITED STATES	26-May-04	142 1A Correspondence	Safety Rpt Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
137859	UNITED STATES	26-May-04	143 1A Correspondence	Safety Rpt Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
137939	UNITED STATES	28-May-04	144 1A Correspondence	Request	Review/Comment			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
137939	UNITED STATES	28-May-04	144 1A Correspondence	Protocol-Clinical	Other			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138060	UNITED STATES	2-Jun-04	144 1A Correspondence	Protocol-Clinical	Other	Copy of submission sent on 5/28 (SN 144).		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

IND Activities

137898	UNITED STATES	2-Jun-04	145 1A Correspondence	Safety Rpt. Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138020	UNITED STATES	2-Jun-04	146 1A Correspondence	Non-Clinical Issues	Info Resp-Response		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138068	UNITED STATES	3-Jun-04	147 1A Correspondence	Safety Rpt. Clin	Initial Written		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138080	UNITED STATES	3-Jun-04	148 1A Correspondence	Info Amend-Clin	Research Fac'd - Add		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138090	UNITED STATES	3-Jun-04	148 1A Correspondence	Prot Amend	Add Invest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138090	UNITED STATES	3-Jun-04	148 1A Correspondence	Prot Amend	Add Subinvest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138090	UNITED STATES	3-Jun-04	148 1A Correspondence	Info Amend-Clin	Address Change		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138090	UNITED STATES	3-Jun-04	148 1A Correspondence	Prot Amend	Del Subinvest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138100	UNITED STATES	4-Jun-04	149 1A Correspondence	Safety Rpt. Clin	Initial Written		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138123	UNITED STATES	7-Jun-04	150 1A Correspondence	Prot Amend	Add Invest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138421	UNITED STATES	14-Jun-04	151 1A Correspondence	Prot Amend	Add Subinvest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138421	UNITED STATES	14-Jun-04	151 1A Correspondence	Prot Amend	Del Subinvest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138423	UNITED STATES	14-Jun-04	152 1A Correspondence	Info Amend-Clin	Address Change		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138423	UNITED STATES	14-Jun-04	152 1A Correspondence	Prot Amend	Del Subinvest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138425	UNITED STATES	14-Jun-04	153 1A Correspondence	Prot Amend	Add Subinvest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138443	UNITED STATES	14-Jun-04	154 1A Correspondence	Prot Amend	New Protocol		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138472	UNITED STATES	15-Jun-04	155 1A Correspondence	Safety Rpt. Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138567	UNITED STATES	17-Jun-04	157 1A Correspondence	Request	Review/Comment		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138578	UNITED STATES	17-Jun-04	158 1A Correspondence	Safety Rpt. Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138601	UNITED STATES	18-Jun-04	159 1A Correspondence	Safety Rpt. Clin	Initial Written		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

9 month Toxicity Study in Dogs

Request FDA feedback regarding the proposed protocol specific analysis of the DESS data

IND Activities

138647	UNITED STATES	21-Jun-04	160 1A Correspondence	Prot Amend	Change in Prot		FDA	Wyeth	IND 64.552	3151A1-304-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138717	UNITED STATES	24-Jun-04	161 1A Correspondence	Prot Amend	New Protocol		FDA	Wyeth	IND 64.552	3151A1-161-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138787	UNITED STATES	24-Jun-04	162 1A Correspondence	Prot Amend	Change in Prot		FDA	Wyeth	IND 64.552	3151A1-308-WW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138868	UNITED STATES	28-Jun-04	163 1A Correspondence	Safety Rpt. Clin	Int. WHF follow-up		FDA	Wyeth	IND 64.552	3151A1-303-WW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138907	UNITED STATES	30-Jun-04	164 1A Correspondence	Prot Amend	Add Invest		FDA	Wyeth	IND 64.552	3151A1-303-WW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138997	UNITED STATES	30-Jun-04	164 1A Correspondence	Prot Amend	Del Subinvest		FDA	Wyeth	IND 64.552	3151A1-303-WW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138997	UNITED STATES	30-Jun-04	164 1A Correspondence	Prot Amend	Add Subinvest		FDA	Wyeth	IND 64.552	3151A1-303-WW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138969	UNITED STATES	30-Jun-04	165 1A Correspondence	Info Amend-CMC			FDA	Wyeth	IND 64.552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
139028	UNITED STATES	1-Jul-04	166 1A Correspondence	Prot Amend	Add Subinvest		FDA	Wyeth	IND 64.552	3151A1-306-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
139028	UNITED STATES	1-Jul-04	166 1A Correspondence	Prot Amend	Del Subinvest		FDA	Wyeth	IND 64.552	3151A1-306-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
139032	UNITED STATES	2-Jul-04	167 1A Correspondence	Info Amend-Clin	Address Change		FDA	Wyeth	IND 64.552	3151A1-304-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
139052	UNITED STATES	2-Jul-04	167 1A Correspondence	Prot Amend	Add Subinvest		FDA	Wyeth	IND 64.552	3151A1-304-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
139062	UNITED STATES	2-Jul-04	167 1A Correspondence	Prot Amend	Del Subinvest		FDA	Wyeth	IND 64.552	3151A1-304-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
139527	UNITED STATES	20-Jul-04	168 1A Correspondence	Safety Rpt. Clin	Follow-up		FDA	Wyeth	IND 64.552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
139569	UNITED STATES	21-Jul-04	169 1A Correspondence	Prot Amend	Change in Prot		FDA	Wyeth	IND 64.552	3151A1-304-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
139569	UNITED STATES	21-Jul-04	169 1A Correspondence	Response to	Information Request		FDA	Wyeth	IND 64.552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
139841	UNITED STATES	30-Jul-04	170 1A Correspondence	Prot Amend	Add Invest		FDA	Wyeth	IND 64.552	3151A1-320-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
139841	UNITED STATES	30-Jul-04	170 1A Correspondence	Prot Amend	Add Subinvest		FDA	Wyeth	IND 64.552	3151A1-320-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
139853	UNITED STATES	2-Aug-04	171 1A Correspondence	Prot Amend	Add Invest		FDA	Wyeth	IND 64.552	3151A1-309-EU	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
139890	UNITED STATES	2-Aug-04	172 1A Correspondence	Prot Amend	Add Subinvest		FDA	Wyeth	IND 64.552	3151A1-303-WW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

Update to DP & DS, HPLC analytical method for DS purity, stability data for DP & DS

IND Activities

139890	UNITED STATES	2-Aug-04	172 IA Correspondence	Prot Amend	Other	3151A1-303-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
139890	UNITED STATES	2-Aug-04	172 IA Correspondence	Prot Amend	Del Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
139897	UNITED STATES	4-Aug-04	173 IA Correspondence	Prot Amend	Add Subinvest	3151A1-317-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
139899	UNITED STATES	4-Aug-04	174 IA Correspondence	Prot Amend	Add Subinvest	3151A1-306-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
139900	UNITED STATES	4-Aug-04	174 IA Correspondence	Prot Amend	Del Subinvest	3151A1-306-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
140263	UNITED STATES	10-Aug-04	175 IA Correspondence	Prot Amend	New Protocol		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
140263	UNITED STATES	10-Aug-04	175 IA Correspondence	Prot Amend	New Protocol	3151A1-307-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
140847	UNITED STATES	20-Aug-04	176 IA Correspondence	Safety Rpt Clin	Initial Written		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
141187	UNITED STATES	31-Aug-04	177 IA Correspondence	Prot Amend	Add Subinvest	3151A1-320-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
141187	UNITED STATES	31-Aug-04	177 IA Correspondence	Prot Amend	Del Subinvest	3151A1-320-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
141188	UNITED STATES	31-Aug-04	178 IA Correspondence	Prot Amend	Add Invest	3151A1-308-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
141188	UNITED STATES	31-Aug-04	178 IA Correspondence	Prot Amend	Add Invest	3151A1-303-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
141188	UNITED STATES	31-Aug-04	178 IA Correspondence	Prot Amend	Del Invest	3151A1-303-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
141188	UNITED STATES	31-Aug-04	178 IA Correspondence	Prot Amend	Add Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
141238	UNITED STATES	1-Sep-04	179 IA Correspondence	Prot Amend	Add Subinvest	3151A1-306-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
141238	UNITED STATES	1-Sep-04	179 IA Correspondence	Prot Amend	Del Subinvest	3151A1-306-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
141243	UNITED STATES	1-Sep-04	180 IA Correspondence	Info Amend-Clin	Address Change	3151A1-303-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
141243	UNITED STATES	1-Sep-04	180 IA Correspondence	Prot Amend	Del Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
141243	UNITED STATES	1-Sep-04	180 IA Correspondence	Prot Amend	Add Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

141256	UNITED STATES	2-Sep-04	181 IA Correspondence	Prot Amend	Add Subinvest		3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
141256	UNITED STATES	2-Sep-04	181 IA Correspondence	Prot Amend	Del Subinvest		3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
141278	UNITED STATES	2-Sep-04	182 IA Correspondence	Safety Rpt Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
141330	UNITED STATES	3-Sep-04	183 IA Correspondence	Safety Rpt Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
141390	UNITED STATES	9-Sep-04	184 IA Correspondence	Info Amend-Clin	Address Change		3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
141390	UNITED STATES	9-Sep-04	184 IA Correspondence	Prot Amend	Add Invest		3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
141390	UNITED STATES	9-Sep-04	184 IA Correspondence	Prot Amend	Del Subinvest		3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
141390	UNITED STATES	9-Sep-04	184 IA Correspondence	Prot Amend	Add Subinvest		3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
141390	UNITED STATES	9-Sep-04	184 IA Correspondence	Info Amend-Clin	Name Change		3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
141390	UNITED STATES	16-Sep-04	185 IA Correspondence	Prot Amend	Change in Prot		3151A1-308-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
141897	UNITED STATES	17-Sep-04	188 IA Correspondence	Prot Amend	Add Invest		3151A1-308-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
141897	UNITED STATES	17-Sep-04	188 IA Correspondence	Prot Amend	Add Subinvest		3151A1-308-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
142118	UNITED STATES	22-Sep-04	187 IA Correspondence	Safety Rpt Clin	Initial Written			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
142334	UNITED STATES	27-Sep-04	189 IA Correspondence	Prot Amend	Add Invest		3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
142509	UNITED STATES	29-Sep-04	189 IA Correspondence	Prot Amend	Add Invest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
142509	UNITED STATES	29-Sep-04	189 IA Correspondence	Prot Amend	Del Subinvest		3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
142509	UNITED STATES	29-Sep-04	189 IA Correspondence	Prot Amend	Add IRB		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
142509	UNITED STATES	29-Sep-04	189 IA Correspondence	Prot Amend	Add Research Facil		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
142509	UNITED STATES	29-Sep-04	189 IA Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
142509	UNITED STATES	29-Sep-04	189 IA Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

142508	UNITED STATES	28-Sep-04	189 1A Correspondence	Prot Amend	Add Subinvest	3151A1-318-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
142570	UNITED STATES	30-Sep-04	190 1A Correspondence	Safety Rpt Clin	Follow-up		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
142606	UNITED STATES	6-Oct-04	191 1A Correspondence	Prot Amend	Add Invest	3151A1-320-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
142608	UNITED STATES	6-Oct-04	191 1A Correspondence	Prot Amend	Del Subinvest	3151A1-320-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
142609	UNITED STATES	6-Oct-04	191 1A Correspondence	Prot Amend	Add IRB	3151A1-320-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
142608	UNITED STATES	6-Oct-04	191 1A Correspondence	Prot Amend	Add Research Facil	3151A1-320-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
142608	UNITED STATES	6-Oct-04	191 1A Correspondence	Prot Amend	Del Subinvest	3151A1-306-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
142608	UNITED STATES	6-Oct-04	191 1A Correspondence	Prot Amend	Add Subinvest	3151A1-306-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
142608	UNITED STATES	6-Oct-04	191 1A Correspondence	Prot Amend	Add Subinvest	3151A1-320-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
143140	UNITED STATES	12-Oct-04	192 1A Correspondence	Safety Rpt Clin	Follow-up		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
143433	UNITED STATES	16-Oct-04	193 1A Correspondence	Safety Rpt Clin	Initial Written		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
143543	UNITED STATES	20-Oct-04	194 1A Correspondence	Prot Amend	Add Invest	3151A1-307-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
143543	UNITED STATES	20-Oct-04	194 1A Correspondence	Prot Amend	Add Subinvest	3151A1-307-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
143543	UNITED STATES	20-Oct-04	194 1A Correspondence	Prot Amend	Add Research Facil	3151A1-307-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
143543	UNITED STATES	20-Oct-04	194 1A Correspondence	Prot Amend	Del Subinvest	3151A1-318-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
143543	UNITED STATES	20-Oct-04	194 1A Correspondence	Prot Amend	Del Subinvest	3151A1-303-MW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
143543	UNITED STATES	20-Oct-04	194 1A Correspondence	Prot Amend	Add IRB	3151A1-307-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
143543	UNITED STATES	20-Oct-04	194 1A Correspondence	Prot Amend	Add Subinvest	3151A1-303-MW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
143543	UNITED STATES	20-Oct-04	194 1A Correspondence	Prot Amend	Address Change	3151A1-303-MW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
143543	UNITED STATES	20-Oct-04	194 1A Correspondence	Prot Amend	Add Subinvest	3151A1-318-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

IND Activities

145273	UNITED STATES	20-Oct-04	195 IA Correspondence	Safety Rpt. Clin	Follow-up	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
144940	UNITED STATES	28-Oct-04	196 IA Correspondence	Safety Rpt. Clin	Follow-up	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
144241	UNITED STATES	10-Nov-04	197 IA Correspondence	Meeting/Telecon	Meeting-Request	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
144253	UNITED STATES	2-Nov-04	198 IA Correspondence	Safety Rpt. Clin	Initial Written	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
144652	UNITED STATES	9-Nov-04	199 IA Correspondence	Info Amend-PharmTox		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
144722	UNITED STATES	10-Nov-04	200 IA Correspondence	Safety Rpt. Clin	Initial Written	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
144736	UNITED STATES	10-Nov-04	201 IA Correspondence	Prot Amend	Change in Prot	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
144846	UNITED STATES	11-Nov-04	202 IA Correspondence	Info Amend-CMC		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
144848	UNITED STATES	15-Nov-04	203 IA Correspondence	Safety Rpt. Clin	Follow-up	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
145272	UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Add Invest	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
145272	UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Add Subinvest	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
145272	UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Add Invest	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
145272	UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Add Subinvest	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
145272	UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Add Subinvest	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
145272	UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Del Subinvest	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
145272	UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Del Subinvest	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
145272	UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Name Change	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
145272	UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Add IRB	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
145272	UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Add IRB	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
145272	UNITED STATES	19-Nov-04	204 IA Correspondence	Prot Amend	Add Research Feas	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

Type A meeting request for 150 mg

CMC information to support manufacturing equipment change. Avelox as a positive control

145272	UNITED STATES	19-Nov-04	204 1A Correspondence	Prot Amend	Add Research Facil	3151A1-303-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
145272	UNITED STATES	19-Nov-04	204 1A Correspondence	Prot Amend	Address Change	3151A1-306-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
145272	UNITED STATES	19-Nov-04	204 1A Correspondence	Prot Amend	Del Subinvest	3151A1-318-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
145272	UNITED STATES	19-Nov-04	204 1A Correspondence	Prot Amend	Del Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
145272	UNITED STATES	19-Nov-04	204 1A Correspondence	Prot Amend	Add Subinvest	3151A1-307-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
145274	UNITED STATES	19-Nov-04	205 1A Correspondence	Safety Rpt Clin	Follow-up		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
145325	UNITED STATES	22-Nov-04	206 1A Correspondence	Safety Rpt Clin	Init WritF follow-up		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
145346	UNITED STATES	22-Nov-04	207 1A Correspondence	Info Amend-Pharm/Tox			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
145426	UNITED STATES	23-Nov-04	208 1A Correspondence	Response to	Information Request		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
145713	UNITED STATES	1-Dec-04	209 1A Correspondence	Safety Rpt Clin	Follow-up		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
146010	UNITED STATES	6-Dec-04	210 1A Correspondence	Safety Rpt Clin	Init WritF follow-up		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
146888	UNITED STATES	26-Dec-04	211 1A Correspondence	Safety Rpt Clin	Follow-up		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
146924	UNITED STATES	26-Dec-04	212 1A Correspondence	Prot Amend	Add Invest	3151A1-309-EU	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
146924	UNITED STATES	26-Dec-04	212 1A Correspondence	Prot Amend	Add IRB	3151A1-309-EU	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
146924	UNITED STATES	26-Dec-04	212 1A Correspondence	Prot Amend	Add Research Facil		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
146924	UNITED STATES	26-Dec-04	212 1A Correspondence	Prot Amend	Name Change	3151A1-318-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
146924	UNITED STATES	26-Dec-04	212 1A Correspondence	Prot Amend	Address Change	3151A1-303-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
146924	UNITED STATES	26-Dec-04	212 1A Correspondence	Prot Amend	Add Subinvest	3151A1-309-EU	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
146924	UNITED STATES	26-Dec-04	212 1A Correspondence	Prot Amend	Del Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
146924	UNITED STATES	26-Dec-04	212 1A Correspondence	Prot Amend	Add Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

146924	UNITED STATES	20-Dec-04	212 1A Correspondence	Prot Amend	Del Subinvest	3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
147028	UNITED STATES	22-Dec-04	213 1A Correspondence	Safety Rpt Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
147168	UNITED STATES	23-Dec-04	214 1A Correspondence	Safety Rpt Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
147291	UNITED STATES	29-Dec-04	215 1A Correspondence	Safety Rpt Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
147707	UNITED STATES	7-Jan-05	216 1A Correspondence	Prot Amend	New Protocol		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
147707	UNITED STATES	7-Jan-05	216 1A Correspondence	Prot Amend	New Protocol	3151A1-193-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
147797	UNITED STATES	11-Jan-05	217 1A Correspondence	Prot Amend	New Protocol		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
147797	UNITED STATES	11-Jan-05	217 1A Correspondence	Prot Amend	New Protocol	3151A1-183-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
147844	UNITED STATES	11-Jan-05	218 1A Correspondence	Prot Amend	Change in Prot		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148017	UNITED STATES	14-Jan-05	219 1A Correspondence	Prot Amend	New Protocol		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148017	UNITED STATES	14-Jan-05	219 1A Correspondence	Prot Amend	New Protocol	3151A1-184-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148104	UNITED STATES	17-Jan-05	220 1A Correspondence	Prot Amend	Change in Prot		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148217	UNITED STATES	19-Jan-05	221 1A Correspondence	Prot Amend	Change in Prot		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148262	UNITED STATES	19-Jan-05	222 1A Correspondence	Prot Amend	Add Invest	3151A1-302-MW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148262	UNITED STATES	19-Jan-05	222 1A Correspondence	Prot Amend	Add Subinvest	3151A1-303-MW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148262	UNITED STATES	19-Jan-05	222 1A Correspondence	Prot Amend	Add Subinvest	3151A1-320-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148262	UNITED STATES	19-Jan-05	222 1A Correspondence	Prot Amend	Del Subinvest	3151A1-303-MW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148262	UNITED STATES	19-Jan-05	222 1A Correspondence	Prot Amend	Name Change	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148262	UNITED STATES	19-Jan-05	222 1A Correspondence	Prot Amend	Name Change	3151A1-303-MW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148262	UNITED STATES	19-Jan-05	222 1A Correspondence	Prot Amend	Name Change	3151A1-302-MW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

148262	UNITED STATES	19-Jan-05	222 1A Correspondence	Prot Amend	Address Change		FDA	Wyeth	IND 64.552	3151A1-317-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148262	UNITED STATES	19-Jan-05	222 1A Correspondence	Prot Amend	Address Change		FDA	Wyeth	IND 64.552	3151A1-303-MW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148262	UNITED STATES	19-Jan-05	222 1A Correspondence	Prot Amend	Address Change		FDA	Wyeth	IND 64.552	3151A1-302-MW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148262	UNITED STATES	19-Jan-05	222 1A Correspondence	Prot Amend	Del Subinvest		FDA	Wyeth	IND 64.552	3151A1-320-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148262	UNITED STATES	19-Jan-05	222 1A Correspondence	Prot Amend	Del Subinvest		FDA	Wyeth	IND 64.552	3151A1-317-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148262	UNITED STATES	19-Jan-05	222 1A Correspondence	Prot Amend	Del Subinvest		FDA	Wyeth	IND 64.552	3151A1-306-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148262	UNITED STATES	19-Jan-05	222 1A Correspondence	Prot Amend	Add IRB		FDA	Wyeth	IND 64.552	3151A1-317-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148262	UNITED STATES	19-Jan-05	222 1A Correspondence	Prot Amend	Del Subinvest		FDA	Wyeth	IND 64.552	3151A1-302-MW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148262	UNITED STATES	19-Jan-05	222 1A Correspondence	Prot Amend	Add Subinvest		FDA	Wyeth	IND 64.552	3151A1-317-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148262	UNITED STATES	19-Jan-05	222 1A Correspondence	Prot Amend	Add Subinvest		FDA	Wyeth	IND 64.552	3151A1-302-MW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148302	UNITED STATES	20-Jan-05	223 1A Correspondence	Request	Other		FDA	Wyeth	IND 64.552	3151A1-303-MW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148413	UNITED STATES	24-Jan-05	224 1A Correspondence	Safety Rpt. Clin	Follow-up		FDA	Wyeth	IND 64.552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148696	UNITED STATES	28-Jan-05	225 1A Correspondence	Prot Amend	Change in Prot		FDA	Wyeth	IND 64.552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148801	UNITED STATES	1-Feb-05	226 1A Correspondence	Prot Amend	New Protocol		FDA	Wyeth	IND 64.552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148901	UNITED STATES	1-Feb-05	226 1A Correspondence	Prot Amend	New Protocol		FDA	Wyeth	IND 64.552	3151A1-195-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
149144	UNITED STATES	7-Feb-05	227 1A Correspondence	Safety Rpt. Clin	Int WtH Follow-up		FDA	Wyeth	IND 64.552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
149388	UNITED STATES	10-Feb-05	228 1A Correspondence	Prot Amend	New Protocol		FDA	Wyeth	IND 64.552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
149440	UNITED STATES	11-Feb-05	229 1A Correspondence	Safety Rpt. Clin	Follow-up		FDA	Wyeth	IND 64.552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
149811	UNITED STATES	15-Feb-05	230 1A Correspondence	Safety Rpt. Clin	Initial Written		FDA	Wyeth	IND 64.552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

149809	UNITED STATES	18-Feb-05	231 1A Correspondence	Prot Amend	Add Invest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
149809	UNITED STATES	18-Feb-05	231 1A Correspondence	Prot Amend	Del Invest	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
149809	UNITED STATES	18-Feb-05	231 1A Correspondence	Prot Amend	Address Change	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
149809	UNITED STATES	18-Feb-05	231 1A Correspondence	Prot Amend	Del Subinvest	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
149809	UNITED STATES	18-Feb-05	231 1A Correspondence	Prot Amend	Del Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
149809	UNITED STATES	18-Feb-05	231 1A Correspondence	Prot Amend	Del Subinvest	3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
149809	UNITED STATES	18-Feb-05	231 1A Correspondence	Prot Amend	Add Subinvest	3151A1-318-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
149809	UNITED STATES	18-Feb-05	231 1A Correspondence	Prot Amend	Add Subinvest	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
149809	UNITED STATES	18-Feb-05	231 1A Correspondence	Prot Amend	Add Subinvest	3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
149809	UNITED STATES	18-Feb-05	231 1A Correspondence	Prot Amend	Add IRB	3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
149809	UNITED STATES	18-Feb-05	231 1A Correspondence	Prot Amend	Add Research Fail	3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
149809	UNITED STATES	18-Feb-05	231 1A Correspondence	Prot Amend	Address Change	3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
149809	UNITED STATES	18-Feb-05	231 1A Correspondence	Prot Amend	Del Invest	3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
149809	UNITED STATES	18-Feb-05	231 1A Correspondence	Prot Amend	Add Invest	3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
149809	UNITED STATES	18-Feb-05	231 1A Correspondence	Prot Amend	Del Invest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
149809	UNITED STATES	18-Feb-05	231 1A Correspondence	Prot Amend	Add Invest	3151A1-317-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
149837	UNITED STATES	22-Feb-05	232 1A Correspondence	Safety Rpt. Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
150058	UNITED STATES	23-Feb-05	233 1A Correspondence	Safety Rpt. Clin	7-Day P/F & Initial		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

IND Activities

150187	UNITED STATES	23-Feb-05	233 1A Correspondence	Safety Rpt. Clin	7-Day P/F & Initial	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
150181	UNITED STATES	24-Feb-05	234 1A Correspondence	Safety Rpt. Clin	Follow-up	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
150237	UNITED STATES	25-Feb-05	235 1A Correspondence	Safety Rpt. Clin	Follow-up	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
150528	UNITED STATES	2-Mar-05	238 1A Correspondence	Safety Rpt. Clin	Follow-up	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
150555	UNITED STATES	3-Mar-05	237 1A Correspondence	Info Amend-CMC		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
151031	UNITED STATES	10-Mar-05	238 1A Correspondence	Safety Rpt. Clin	Follow-up	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
151509	UNITED STATES	18-Mar-05	239 1A Correspondence	Safety Rpt. Clin	Follow-up	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
151514	UNITED STATES	18-Mar-05	240 1A Correspondence	Prot Amend	Add Invest	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
151514	UNITED STATES	18-Mar-05	240 1A Correspondence	Prot Amend	Del Subinvest	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
151514	UNITED STATES	18-Mar-05	240 1A Correspondence	Prot Amend	Add Subinvest	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
151514	UNITED STATES	18-Mar-05	240 1A Correspondence	Prot Amend	Del Subinvest	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
151514	UNITED STATES	18-Mar-05	240 1A Correspondence	Prot Amend	Address Change	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
151514	UNITED STATES	18-Mar-05	240 1A Correspondence	Prot Amend	Address Change	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
151514	UNITED STATES	18-Mar-05	240 1A Correspondence	Prot Amend	Name Change	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
151514	UNITED STATES	18-Mar-05	240 1A Correspondence	Prot Amend	Add Research Facil	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
151514	UNITED STATES	18-Mar-05	240 1A Correspondence	Prot Amend	Add Subinvest	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
151514	UNITED STATES	18-Mar-05	240 1A Correspondence	Prot Amend	Add IRB	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
151514	UNITED STATES	18-Mar-05	240 1A Correspondence	Prot Amend	Add Research Facil	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
151514	UNITED STATES	18-Mar-05	240 1A Correspondence	Prot Amend	Add Research Facil	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
151514	UNITED STATES	18-Mar-05	240 1A Correspondence	Prot Amend	Name Change	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

FDA email correspondence regarding bioweaver

151514	UNITED STATES	18-Mar-05	240	IA Correspondence	Prot Amend	Address Change		3151A1-320-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
151514	UNITED STATES	18-Mar-05	240	IA Correspondence	Prot Amend	Address Change		3151A1-317-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
151514	UNITED STATES	18-Mar-05	240	IA Correspondence	Prot Amend	Del Subinvest		3151A1-320-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
151525	UNITED STATES	18-Mar-05	241	IA Correspondence	Prot Amend	Change in Prot		3151A1-308-EU	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
151553	UNITED STATES	21-Mar-05	242	IA Correspondence	Request	Review/Comment			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
151568	UNITED STATES	21-Mar-05	243	IA Correspondence	Info Amend-PharmTox				FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
151742	UNITED STATES	23-Mar-05	244	IA Correspondence	Safety Rpt Clin	Follow-up			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
152472	UNITED STATES	5-Apr-05	245	IA Correspondence	Info Amend-PharmTox				FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
152473	UNITED STATES	5-Apr-05	246	IA Correspondence	Safety Rpt Clin	Follow-up			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
152541	UNITED STATES	6-Apr-05	247	IA Correspondence	Safety Rpt Clin	Initial Written			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
153076	UNITED STATES	14-Apr-05	248	IA Correspondence	Response to	Information Request			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
153137	UNITED STATES	15-Apr-05	249	IA Correspondence	Safety Rpt Clin	Init Writ/Follow-up			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
153240	UNITED STATES	18-Apr-05	250	IA Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
153240	UNITED STATES	18-Apr-05	250	IA Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
153240	UNITED STATES	18-Apr-05	250	IA Correspondence	Prot Amend	Address Change			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
153240	UNITED STATES	18-Apr-05	250	IA Correspondence	Prot Amend	Del Subinvest		3151A1-317-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
153240	UNITED STATES	18-Apr-05	250	IA Correspondence	Prot Amend	Del Subinvest		3151A1-318-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
153240	UNITED STATES	18-Apr-05	250	IA Correspondence	Prot Amend	Add Subinvest		3151A1-304-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
153558	UNITED STATES	21-Apr-05	251	IA Correspondence	Safety Rpt Clin	Initial Written			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
154182	UNITED STATES	2-May-05	252	IA Correspondence	Safety Rpt Clin	Initial Written			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

[illegible]

IND Activities

155082	UNITED STATES	18-May-05	259	IA Correspondence	Prot Amend	Name Change	3151A1-318-US	FDA	Wyeth	IND 84.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
155082	UNITED STATES	18-May-05	259	IA Correspondence	Prot Amend	Address Change	3151A1-303-WW	FDA	Wyeth	IND 84.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
155082	UNITED STATES	18-May-05	259	IA Correspondence	Prot Amend	Add Subinvest	3151A1-302-WW	FDA	Wyeth	IND 84.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
155082	UNITED STATES	18-May-05	259	IA Correspondence	Prot Amend	Add Subinvest	3151A1-303-WW	FDA	Wyeth	IND 84.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
155082	UNITED STATES	18-May-05	259	IA Correspondence	Prot Amend	Add Subinvest	0600D3-223-PL	FDA	Wyeth	IND 84.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
155082	UNITED STATES	18-May-05	259	IA Correspondence	Prot Amend	Add Subinvest	3151A1-308-EU	FDA	Wyeth	IND 84.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
155180	UNITED STATES	19-May-05	260	IA Correspondence	Safety Rpt. Clin	Follow-up	FDA	FDA	Wyeth	IND 84.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
156114	UNITED STATES	27-May-05	261	IA Correspondence	Meeting/Telecon	Info	Meeting/Telecon 15-JUN-05						
156379	UNITED STATES	9-Jun-05	262	IA Correspondence	Safety Rpt. Clin	Initial Written	FDA	FDA	Wyeth	IND 84.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
156384	UNITED STATES	9-Jun-05	263	IA Correspondence	Safety Rpt. Clin	Initial Written	FDA	FDA	Wyeth	IND 84.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
156783	UNITED STATES	15-Jun-05	264	IA Correspondence	Safety Rpt. Clin	Follow-up	FDA	FDA	Wyeth	IND 84.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
156892	UNITED STATES	16-Jun-05	265	IA Correspondence	Prot Amend	Del Invest	3151A1-318-US	FDA	Wyeth	IND 84.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
156892	UNITED STATES	16-Jun-05	265	IA Correspondence	Prot Amend	Del Research Fail	3151A1-302-WW	FDA	Wyeth	IND 84.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
156892	UNITED STATES	16-Jun-05	265	IA Correspondence	Prot Amend	Address Change	3151A1-307-US	FDA	Wyeth	IND 84.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
156892	UNITED STATES	16-Jun-05	265	IA Correspondence	Prot Amend	Address Change	3151A1-303-WW	FDA	Wyeth	IND 84.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
156892	UNITED STATES	16-Jun-05	265	IA Correspondence	Prot Amend	Del Subinvest	3151A1-320-US	FDA	Wyeth	IND 84.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
156892	UNITED STATES	16-Jun-05	265	IA Correspondence	Prot Amend	Del Subinvest	3151A1-309-EU	FDA	Wyeth	IND 84.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
156892	UNITED STATES	16-Jun-05	265	IA Correspondence	Prot Amend	Del Subinvest	3151A1-307-US	FDA	Wyeth	IND 84.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
156892	UNITED STATES	16-Jun-05	265	IA Correspondence	Prot Amend	Del Subinvest	3151A1-303-WW	FDA	Wyeth	IND 84.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
156892	UNITED STATES	16-Jun-05	265	IA Correspondence	Prot Amend	Del Subinvest	3151A1-302-WW	FDA	Wyeth	IND 84.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

156892	UNITED STATES	16-Jun-05	265 IA Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED \$ PRSTIQ US
156892	UNITED STATES	16-Jun-05	265 IA Correspondence	Prot Amend	Add Subinvest		3151A1-307-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED \$ PRSTIQ US
156892	UNITED STATES	16-Jun-05	265 IA Correspondence	Prot Amend	Add Subinvest		3151A1-302-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED \$ PRSTIQ US
156892	UNITED STATES	16-Jun-05	265 IA Correspondence	Prot Amend	Add Subinvest		3151A1-320-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED \$ PRSTIQ US
157290	UNITED STATES	24-Jun-05	268 IA Correspondence	Prot Amend	Add Subinvest		3151A1-302-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED \$ PRSTIQ US
157290	UNITED STATES	24-Jun-05	268 IA Correspondence	Prot Amend	Del Subinvest	Name Change	3151A1-302-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED \$ PRSTIQ US
157290	UNITED STATES	24-Jun-05	268 IA Correspondence	Safety Rpt Clin	Follow-up		3151A1-302-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED \$ PRSTIQ US
158321	UNITED STATES	14-Jul-05	268 IA Correspondence	Meeting/Telcon	Background Pkg-Request		3151A1-302-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED \$ PRSTIQ US
158610	UNITED STATES	15-Jul-05	269 IA Correspondence	Prot Amend	Del Invest		3151A1-302-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED \$ PRSTIQ US
158610	UNITED STATES	15-Jul-05	269 IA Correspondence	Prot Amend	Add Subinvest		3151A1-302-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED \$ PRSTIQ US
158610	UNITED STATES	15-Jul-05	269 IA Correspondence	Prot Amend	Add Subinvest		3151A1-306-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED \$ PRSTIQ US
158610	UNITED STATES	15-Jul-05	269 IA Correspondence	Prot Amend	Del Subinvest		3151A1-302-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED \$ PRSTIQ US
158610	UNITED STATES	15-Jul-05	269 IA Correspondence	Prot Amend	Del Subinvest		3151A1-320-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED \$ PRSTIQ US
158610	UNITED STATES	15-Jul-05	269 IA Correspondence	Prot Amend	Del Subinvest		3151A1-317-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED \$ PRSTIQ US
159351	UNITED STATES	27-Jul-05	270 IA Correspondence	Prot Amend	Add Subinvest		3151A1-302-WW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED \$ PRSTIQ US
159351	UNITED STATES	27-Jul-05	270 IA Correspondence	Prot Amend	Change in Prot		3151A1-320-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED \$ PRSTIQ US
159648	UNITED STATES	2-Aug-05	271 IA Correspondence	Prot Amend	Change in Prot		3151A1-302-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED \$ PRSTIQ US
159681	UNITED STATES	2-Aug-05	272 IA Correspondence	Prot Amend	Change in Prot		3151A1-317-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED \$ PRSTIQ US

IND Activities

159712	UNITED STATES	3-Aug-05	273 IA Correspondence	Other		Protocol 306-EU statistical analysis plan	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
159713	UNITED STATES	4-Aug-05	274 IA Correspondence	Prot Amend	Change in Prot		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
160176	UNITED STATES	11-Aug-05	275 IA Correspondence	Safety Rpt Clin	Follow-up		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
160411	UNITED STATES	17-Aug-05	276 IA Correspondence	Prot Amend	Add Subinvest		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
160411	UNITED STATES	17-Aug-05	276 IA Correspondence	Prot Amend	Add Research Facil		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
160411	UNITED STATES	17-Aug-05	276 IA Correspondence	Prot Amend	Add Research Facil		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
160411	UNITED STATES	17-Aug-05	276 IA Correspondence	Prot Amend	Add Research Facil		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
160411	UNITED STATES	17-Aug-05	276 IA Correspondence	Prot Amend	Add Research Facil		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
160411	UNITED STATES	17-Aug-05	276 IA Correspondence	Prot Amend	Del Subinvest		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
160411	UNITED STATES	17-Aug-05	276 IA Correspondence	Prot Amend	Address Change		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
160411	UNITED STATES	17-Aug-05	276 IA Correspondence	Prot Amend	Del Subinvest		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
160411	UNITED STATES	17-Aug-05	276 IA Correspondence	Prot Amend	Address Change		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
161659	UNITED STATES	14-Sep-05	277 IA Correspondence	Annual Report-IDA	Subm		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
161797	UNITED STATES	15-Sep-05	278 IA Correspondence	Prot Amend	Add Invest		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
161797	UNITED STATES	15-Sep-05	278 IA Correspondence	Prot Amend	Add Subinvest		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
161797	UNITED STATES	15-Sep-05	278 IA Correspondence	Prot Amend	Add Subinvest		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
161797	UNITED STATES	15-Sep-05	278 IA Correspondence	Prot Amend	Del Subinvest		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
161797	UNITED STATES	15-Sep-05	278 IA Correspondence	Prot Amend	Address Change		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
161797	UNITED STATES	15-Sep-05	278 IA Correspondence	Prot Amend	Add IRB		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
161797	UNITED STATES	15-Sep-05	278 IA Correspondence	Prot Amend	Add Research Facil		FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

IND Activities

161797	UNITED STATES	15-Sep-05	278 1A Correspondence	Prot Amend	Address Change		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
161797	UNITED STATES	15-Sep-05	278 1A Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
162277	UNITED STATES	27-Sep-05	279 1A Correspondence	Meeting/Telecon	Minutes	pre-NDA meeting minutes		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
162369	UNITED STATES	3-Oct-05	280 1A Correspondence	Response to	Information Request	Response to FDA Request - Ven Mass Balance study		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
162969	UNITED STATES	7-Oct-05	281 1A Correspondence	Info Amend-CMC		Pre NDA-CMC meeting request/package		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
163351	UNITED STATES	13-Oct-05	282 1A Correspondence	Prot Amend	Add Invest		0600D3-175-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
163351	UNITED STATES	13-Oct-05	282 1A Correspondence	Prot Amend	Address Change		3151A1-309-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
163351	UNITED STATES	13-Oct-05	282 1A Correspondence	Prot Amend	Add IRB		0600D3-175-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
163351	UNITED STATES	13-Oct-05	282 1A Correspondence	Prot Amend	Add Research Facil		0600D3-175-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
163351	UNITED STATES	13-Oct-05	282 1A Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
163351	UNITED STATES	13-Oct-05	282 1A Correspondence	Prot Amend	Add Subinvest		0600D3-175-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
163351	UNITED STATES	13-Oct-05	282 1A Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
163392	UNITED STATES	14-Oct-05	283 1A Correspondence	Safety Rpt. Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
164361	UNITED STATES	2-Nov-05	284 1A Correspondence	Meeting/Telecon	Minutes	Pre-NDA CMC Type C Meeting		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
164910	UNITED STATES	11-Nov-05	285 1A Correspondence	Prot Amend	Add Invest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
164910	UNITED STATES	11-Nov-05	285 1A Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
164910	UNITED STATES	11-Nov-05	285 1A Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
166430	UNITED STATES	6-Dec-05	286 1A Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
166430	UNITED STATES	8-Dec-05	286 1A Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
166594	UNITED STATES	13-Dec-05	287 1A Correspondence	Info Amend-CMC		Updated DS specs & DP and using other compaction		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

IND Activities

187468	UNITED STATES	4-Jan-06	288 1A Correspondence	Prot Amend	Add Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
187468	UNITED STATES	4-Jan-06	288 1A Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
187891	UNITED STATES	11-Jan-06	289 1A Correspondence	Response to	Information Request			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
188172	UNITED STATES	24-Jan-06	290 1A Correspondence	Prot Amend	New Protocol		3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
188452	UNITED STATES	3-Feb-06	291 1A Correspondence	Prot Amend	Del Subinvest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
189563	UNITED STATES	21-Feb-06	292 1A Correspondence	Prot Amend	New Protocol		3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
170271	UNITED STATES	2-Mar-06	293 1A Correspondence	Prot Amend	Change in Prot		3151A1-302-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
170331	UNITED STATES	3-Mar-06	294 1A Correspondence	Prot Amend	Add Invest		3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
170331	UNITED STATES	3-Mar-06	294 1A Correspondence	Prot Amend	Add Invest		3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
170697	UNITED STATES	8-Mar-06	295 1A Correspondence	Safety Rpt. Clin	Follow-up			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
171652	UNITED STATES	15-Mar-06	296 1A Correspondence	Prot Amend	New Protocol		3151A1-900-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
171285	UNITED STATES	16-Mar-06	297 1A Correspondence	Prot Amend	New Protocol		3151A1-198-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
172348	UNITED STATES	30-Mar-06	298 1A Correspondence	Prot Amend	Add Invest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
172348	UNITED STATES	30-Mar-06	298 1A Correspondence	Prot Amend	Add Invest		3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
172348	UNITED STATES	30-Mar-06	298 1A Correspondence	Prot Amend	Add Invest		3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
172348	UNITED STATES	30-Mar-06	298 1A Correspondence	Prot Amend	Del Invest		3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
172348	UNITED STATES	30-Mar-06	298 1A Correspondence	Prot Amend	Add Subinvest		3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
173041	UNITED STATES	12-Apr-06	299 1A Correspondence	Annual Report-IDA	Subm			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
173324	UNITED STATES	18-Apr-06	300 1A Correspondence	Prot Amend	New Protocol		3151A1-901-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
173863	UNITED STATES	24-Apr-06	301 1A Correspondence	Request	Review/Comment			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

9-week Juvenile Rat Toxicity Study

IND Activities

173914	UNITED STATES	26-Apr-06	302 1A Correspondence	Prot Amend	Change in Prot	Change in Protocol Amendment 1 for 3151A1-332-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
173997	UNITED STATES	27-Apr-06	303 1A Correspondence	Prot Amend	Add Invest		3151A1-333-EU	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
174912	UNITED STATES	11-May-06	304 1A Correspondence	Safety Prot Clin	Follow-up			Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
175946	UNITED STATES	24-May-06	305 1A Correspondence	Prot Amend	Change in Prot		3151A1-900-US	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
175950	UNITED STATES	25-May-06	306 1A Correspondence	Prot Amend	Add Invest		3151A1-333-EU	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
175955	UNITED STATES	25-May-06	308 1A Correspondence	Prot Amend	Add IRB		3151A1-333-EU	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
175953	UNITED STATES	25-May-06	308 1A Correspondence	Prot Amend	Add Research Faci		3151A1-333-EU	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
175956	UNITED STATES	25-May-06	308 1A Correspondence	Prot Amend	Add Subinvest		3151A1-333-EU	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
176530	UNITED STATES	7-Jun-06	307 1A Correspondence	Prot Amend	Change in Prot		3151A1-901-US	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
176569	UNITED STATES	8-Jun-06	308 1A Correspondence	Prot Amend	Change in Prot			Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
176569	UNITED STATES	8-Jun-06	308 1A Correspondence	Prot Amend	Change in Prot		3151A1-900-US	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
176551	UNITED STATES	7-Jul-06	309 1A Correspondence	Prot Amend	Add Invest		3151A1-332-US	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
176551	UNITED STATES	7-Jul-06	309 1A Correspondence	Prot Amend	Add Subinvest		3151A1-333-EU	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
176551	UNITED STATES	7-Jul-06	309 1A Correspondence	Prot Amend	Del Subinvest		3151A1-333-EU	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
176551	UNITED STATES	7-Jul-06	309 1A Correspondence	Prot Amend	Del Subinvest		3151A1-332-US	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
176551	UNITED STATES	7-Jul-06	309 1A Correspondence	Prot Amend	Add Subinvest			Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
176669	UNITED STATES	11-Jul-06	310 1A Correspondence	Other		Submission of SAP for Study 303 (MDD)		W-A-R	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
176783	UNITED STATES	13-Jul-06	311 1A Correspondence	Response to	Review/Comment Req	Statistical criteria for Amendment 3		W-A-R	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
179350	UNITED STATES	21-Jul-06	312 1A Correspondence	Prot Amend	Add Research Faci		3151A1-333-EU	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
179350	UNITED STATES	21-Jul-06	312 1A Correspondence	Prot Amend	Add IRB		3151A1-333-EU	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

IND Activities

179350 UNITED STATES	21-Jul-06	312 1A Correspondence	Prot Amend	Add Invest		3151A1-333-EU	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
180655 UNITED STATES	9-Aug-06	313 1A Correspondence	Prot Amend	New Protocol		3151A1-401-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 1A Correspondence	Prot Amend	Add Invest		3151A1-303-MW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 1A Correspondence	Prot Amend	Del Invest		3151A1-333-EU	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 1A Correspondence	Prot Amend	Del IRB		3151A1-332-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 1A Correspondence	Prot Amend	Del IRB		3151A1-303-MW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 1A Correspondence	Prot Amend	Add IRB		3151A1-333-EU	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 1A Correspondence	Prot Amend	Add IRB		3151A1-332-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 1A Correspondence	Prot Amend	Add IRB		3151A1-303-MW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 1A Correspondence	Prot Amend	Add Research Facil		3151A1-333-EU	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 1A Correspondence	Prot Amend	Add Research Facil		3151A1-332-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 1A Correspondence	Prot Amend	Add Research Facil		3151A1-303-MW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 1A Correspondence	Prot Amend	Address Change		3151A1-333-EU	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 1A Correspondence	Prot Amend	Del IRB		3151A1-333-EU	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 1A Correspondence	Prot Amend	Address Change		3151A1-332-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 1A Correspondence	Prot Amend	Address Change		3151A1-303-MW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 1A Correspondence	Prot Amend	Del Subinvest		3151A1-333-EU	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 1A Correspondence	Prot Amend	Del Subinvest		3151A1-332-US	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 1A Correspondence	Prot Amend	Del Subinvest		3151A1-303-MW	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584 UNITED STATES	24-Aug-06	314 1A Correspondence	Prot Amend	Add Subinvest		3151A1-333-EU	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

181584	UNITED STATES	24-Aug-08	314 1A Correspondence	Prot Amend	Add Subinvest	3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584	UNITED STATES	24-Aug-08	314 1A Correspondence	Prot Amend	Add Subinvest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584	UNITED STATES	24-Aug-08	314 1A Correspondence	Prot Amend	Del Invest	3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584	UNITED STATES	24-Aug-08	314 1A Correspondence	Prot Amend	Add Invest	3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584	UNITED STATES	24-Aug-08	314 1A Correspondence	Prot Amend	Del Invest	3151A1-303-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181584	UNITED STATES	24-Aug-08	314 1A Correspondence	Prot Amend	Add Invest	3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
183473	UNITED STATES	8-Sep-08	315 1A Correspondence	Prot Amend	New Protocol	3151A1-403-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
183133	UNITED STATES	15-Sep-08	316 1A Correspondence	Info Amend-CMC						Submission of subunitine and a corresponding placebo as a comparator		
183475	UNITED STATES	21-Sep-08	317 1A Correspondence	Safety Rpt. Clin	Initial Written							
183515	UNITED STATES	22-Sep-08	318 1A Correspondence	Prot Amend	New Protocol	3151A1-335-US	FDA	W-AR	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
183784	UNITED STATES	27-Sep-08	319 1A Correspondence	Prot Amend	Change in Prot	3151A1-800-US	FDA	W-AR	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
183851	UNITED STATES	27-Sep-08	320 1A Correspondence	Prot Amend	Change in Prot	3151A1-332-US	FDA	W-AR	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
183931	UNITED STATES	28-Sep-08	321 1A Correspondence	Prot Amend	Change in Prot	3151A1-401-US	FDA	W-AR	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
185019	UNITED STATES	13-Oct-08	322 1A Correspondence	Prot Amend	Investigator Data	3151A1-332-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
185019	UNITED STATES	13-Oct-08	322 1A Correspondence	Prot Amend	Investigator Data	3151A1-335-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
185019	UNITED STATES	13-Oct-08	322 1A Correspondence	Prot Amend	Investigator Data	3151A1-403-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
185019	UNITED STATES	13-Oct-08	322 1A Correspondence	Prot Amend	Investigator Data	3151A1-333-EU	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
185817	UNITED STATES	24-Oct-08	323 1A Correspondence	Safety Rpt. Clin	Follow-up							
185982	UNITED STATES	25-Oct-08	324 1A Correspondence	Info Amend-CMC						Submission of comparator Lexapro		
186700	UNITED STATES	3-Nov-08	325 1A Correspondence	Prot Amend	New Protocol	3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

IND Activities

187070 UNITED STATES	9-Nov-06	326 1A Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64,552	315 1A1-333-EU	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
187070 UNITED STATES	9-Nov-06	326 1A Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64,552	315 1A1-403-WW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
188007 UNITED STATES	22-Nov-06	327 1A Correspondence	Prot Amend	Change in Prot		FDA	Wyeth	IND 64,552	315 1A1-335-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
188007 UNITED STATES	22-Nov-06	327 1A Correspondence	Request	Concurrence		FDA	Wyeth	IND 64,552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
188016 UNITED STATES	22-Nov-06	328 1A Correspondence	Safety Rpt Clin	Initial Written		FDA	Wyeth	IND 64,552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
188147 UNITED STATES	27-Nov-06	329 1A Correspondence	Safety Rpt Clin	Initial Written		FDA	Wyeth	IND 64,552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
188690 UNITED STATES	15-Dec-06	330 1A Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64,552	315 1A1-335-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
188690 UNITED STATES	15-Dec-06	330 1A Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64,552	315 1A1-403-WW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
188881 UNITED STATES	19-Dec-06	331 1A Correspondence	Safety Rpt Clin	Follow-up		FDA	Wyeth	IND 64,552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
188965 UNITED STATES	20-Dec-06	332 1A Correspondence	Prot Amend	New Protocol		FDA	Wyeth	IND 64,552	315 1A1-1203-EU	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
188971 UNITED STATES	20-Dec-06	333 1A Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64,552	315 1A1-332-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
188971 UNITED STATES	20-Dec-06	333 1A Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64,552	315 1A1-403-WW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
188971 UNITED STATES	20-Dec-06	333 1A Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64,552	315 1A1-335-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
188971 UNITED STATES	20-Dec-06	333 1A Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64,552	315 1A1-402-WW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
188971 UNITED STATES	20-Dec-06	333 1A Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64,552	315 1A1-333-EU	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
189995 UNITED STATES	21-Dec-06	334 1A Correspondence	Safety Rpt Clin	Follow-up		FDA	Wyeth	IND 64,552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
190068 UNITED STATES	22-Dec-06	335 1A Correspondence	Safety Rpt Clin	Initial Written		FDA	Wyeth	IND 64,552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
190984 UNITED STATES	15-Jan-07	336 1A Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64,552	315 1A1-335-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
190984 UNITED STATES	15-Jan-07	336 1A Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64,552	315 1A1-402-WW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
182403 UNITED STATES	6-Feb-07	337 1A Correspondence	Safety Rpt Clin	Follow-up		FDA	Wyeth	IND 64,552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

192568	UNITED STATES	8-Feb-07	338 IA Correspondence	Safety Rpt. Clin	Initial Written	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
192761	UNITED STATES	9-Feb-07	339 IA Correspondence	Safety Rpt. Clin	Follow-up	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
192850	UNITED STATES	12-Feb-07	340 IA Correspondence	Safety Rpt. Clin	Initial Written	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
192927	UNITED STATES	14-Feb-07	341 IA Correspondence	Safety Rpt. Clin	Initial Written	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
193158	UNITED STATES	16-Feb-07	342 IA Correspondence	Safety Rpt. Clin	Follow-up	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
193343	UNITED STATES	20-Feb-07	343 IA Correspondence	Safety Rpt. Clin	Follow-up	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
193528	UNITED STATES	1-Mar-07	344 IA Correspondence	Prot Amend	Investigator Data	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
193528	UNITED STATES	1-Mar-07	344 IA Correspondence	Prot Amend	Investigator Data	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
193528	UNITED STATES	1-Mar-07	344 IA Correspondence	Prot Amend	Investigator Data	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
193528	UNITED STATES	1-Mar-07	344 IA Correspondence	Prot Amend	Investigator Data	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
194271	UNITED STATES	7-Mar-07	345 IA Correspondence	Prot Amend	Change in Prot	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
194502	UNITED STATES	12-Mar-07	346 IA Correspondence	Prot Amend	Change in Prot	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
194502	UNITED STATES	12-Mar-07	346 IA Correspondence	Prot Amend	Change in Prot	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
194505	UNITED STATES	13-Mar-07	347 IA Correspondence	Info Amend-CMC		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
194745	UNITED STATES	15-Mar-07	348 IA Correspondence	Prot Amend	Investigator Data	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
194745	UNITED STATES	15-Mar-07	348 IA Correspondence	Prot Amend	Investigator Data	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
194745	UNITED STATES	15-Mar-07	348 IA Correspondence	Prot Amend	Investigator Data	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
194745	UNITED STATES	15-Mar-07	348 IA Correspondence	Prot Amend	Investigator Data	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
196008	UNITED STATES	2-Apr-07	349 IA Correspondence	Safety Rpt. Clin	Initial Written	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

Information on the blinded
comparator Paxlovid.

IND Activities

196586	UNITED STATES	6-Apr-07	350 IA Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64,552	3151A1-335-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
196588	UNITED STATES	6-Apr-07	350 IA Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64,552	3151A1-403-WW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
196589	UNITED STATES	6-Apr-07	350 IA Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64,552	3151A1-402-WW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
196595	UNITED STATES	10-Apr-07	351 IA Correspondence	Safety Rpt. Clin	Initial Written		FDA	Wyeth	IND 64,552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
197369	UNITED STATES	16-Apr-07	352 IA Correspondence	Safety Rpt. Clin	Follow-up		FDA	Wyeth	IND 64,552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
198111	UNITED STATES	26-Apr-07	353 IA Correspondence	Safety Rpt. Clin	Follow-up		FDA	Wyeth	IND 64,552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
198156	UNITED STATES	8-May-07	354 IA Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64,552	3151A1-335-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
198156	UNITED STATES	8-May-07	354 IA Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64,552	3151A1-402-WW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
198156	UNITED STATES	8-May-07	354 IA Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64,552	3151A1-403-WW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
198538	UNITED STATES	17-May-07	355 IA Correspondence	Prot Amend	New Protocol		FDA	Wyeth	IND 64,552	3151A1-336-AP	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
198597	UNITED STATES	17-May-07	356 IA Correspondence	Safety Rpt. Clin	Initial Written		FDA	Wyeth	IND 64,552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
200655	UNITED STATES	25-May-07	357 IA Correspondence	Safety Rpt. Clin	Initial Written		FDA	Wyeth	IND 64,552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
201023	UNITED STATES	31-May-07	358 IA Correspondence	Annual Report-IDA	Subm		FDA	Wyeth	IND 64,552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
201503	UNITED STATES	6-Jun-07	359 IA Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64,552	3151A1-332-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
201503	UNITED STATES	6-Jun-07	359 IA Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64,552	3151A1-402-WW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
201503	UNITED STATES	6-Jun-07	359 IA Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64,552	3151A1-403-WW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
201918	UNITED STATES	12-Jun-07	360 IA Correspondence	Safety Rpt. Clin	Follow-up		FDA	Wyeth	IND 64,552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
202107	UNITED STATES	14-Jun-07	361 IA Correspondence	Prot Amend	Change in Prot		FDA	Wyeth	IND 64,552	3151A1-402-WW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
202581	UNITED STATES	20-Jun-07	362 IA Correspondence	Safety Rpt. Clin	Follow-up		FDA	Wyeth	IND 64,552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
203068	UNITED STATES	27-Jun-07	363 IA Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64,552	3151A1-336-AP	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

IND Activities

203068	UNITED STATES	27-Jun-07	363 1A Correspondence	Prot Amend	Investigator Data	3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
205338	UNITED STATES	28-Jul-07	364 1A Correspondence	Prot Amend	Investigator Data	3151A1-335-US	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
205338	UNITED STATES	26-Jul-07	364 1A Correspondence	Prot Amend	Investigator Data	3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
205338	UNITED STATES	26-Jul-07	364 1A Correspondence	Prot Amend	Investigator Data	3151A1-403-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
205840	UNITED STATES	1-Aug-07	365 1A Correspondence	Safety Rpt. Clin	Initial Written		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
206045	UNITED STATES	2-Aug-07	368 1A Correspondence	Safety Rpt. Clin	Initial Written		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
207165	UNITED STATES	17-Aug-07	367 1A Correspondence	Safety Rpt. Clin	Initial Written		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
207861	UNITED STATES	23-Aug-07	368 1A Correspondence	Prot Amend	Investigator Data	3151A1-336-AP	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
207861	UNITED STATES	23-Aug-07	368 1A Correspondence	Prot Amend	Investigator Data	3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
208285	UNITED STATES	31-Aug-07	369 1A Correspondence	Safety Rpt. Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
209223	UNITED STATES	17-Sep-07	370 1A Correspondence	Prot Amend	Change in Prot	3151A1-336-AP	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
209849	UNITED STATES	19-Sep-07	371 1A Correspondence	Prot Amend	Add Invest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
209849	UNITED STATES	18-Sep-07	371 1A Correspondence	Prot Amend	Add Invest	3151A1-403-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
209849	UNITED STATES	19-Sep-07	371 1A Correspondence	Prot Amend	Add Invest		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
211301	UNITED STATES	2-Oct-07	372 1A Correspondence	Safety Rpt. Clin	Follow-up		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
212015	UNITED STATES	16-Oct-07	373 1A Correspondence	Safety Rpt. Clin	Initial Written		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
212918	UNITED STATES	17-Oct-07	374 1A Correspondence	Other			FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
213039	UNITED STATES	18-Oct-07	375 1A Correspondence	Prot Amend	Investigator Data	3151A1-336-AP	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
213039	UNITED STATES	18-Oct-07	375 1A Correspondence	Prot Amend	Investigator Data	3151A1-402-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
213039	UNITED STATES	18-Oct-07	375 1A Correspondence	Prot Amend	Investigator Data	3151A1-403-WW	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

Final Statistical Analysis Plan
for Study 335-US

IND Activities

213396	UNITED STATES	23-Oct-07	376 1A Correspondence	Safety Rpt. Clin	Follow-up	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
213647	UNITED STATES	25-Oct-07	377 1A Correspondence	Safety Rpt. Clin	Follow-up	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
215326	UNITED STATES	15-Nov-07	378 1A Correspondence	Prot Amend	Investigator Data	3151A1-402-WW	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
216773	UNITED STATES	6-Dec-07	379 1A Correspondence	Info Amend-CMC		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
217764	UNITED STATES	10-Dec-07	380 1A Correspondence	Safety Rpt. Clin	Follow-up	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
218016	UNITED STATES	11-Dec-07	381 1A Correspondence	Prot Amend	Investigator Data	3151A1-403-WW	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
218614	UNITED STATES	17-Dec-07	382 1A Correspondence	Prot Amend	Change in Prot	3151A1-336-AP	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
218615	UNITED STATES	17-Dec-07	383 1A Correspondence	Safety Rpt. Clin	7-Day P/F & Initial	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
218710	UNITED STATES	17-Dec-07	383 1A Correspondence	Safety Rpt. Clin	7-Day P/F & Initial	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
218697	UNITED STATES	18-Dec-07	384 1A Correspondence	Other		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
218721	UNITED STATES	19-Dec-07	385 1A Correspondence	Prot Amend	New Protocol	3151A6-2000-US	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
218777	UNITED STATES	19-Dec-07	386 1A Correspondence	Safety Rpt. Clin	Initial Written	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
219306	UNITED STATES	19-Dec-07	386 1A Correspondence	Safety Rpt. Clin	7-Day P/F & Initial	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
219657	UNITED STATES	20-Dec-07	387 1A Correspondence	Safety Rpt. Clin	Follow-up	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
219255	UNITED STATES	2-Jan-08	388 1A Correspondence	Safety Rpt. Clin	Follow-up	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
219304	UNITED STATES	3-Jan-08	389 1A Correspondence	Prot Amend	New Protocol	3151A6-2001-US	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
220802	UNITED STATES	15-Jan-08	390 1A Correspondence	Prot Amend	Investigator Data	3151A1-403-WW	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
220802	UNITED STATES	15-Jan-08	390 1A Correspondence	Prot Amend	Investigator Data	3151A1-403-WW	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
221239	UNITED STATES	16-Jan-08	391 1A Correspondence	Safety Rpt. Clin	Follow-up	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
221260	UNITED STATES	17-Jan-08	392 1A Correspondence	Prot Amend	Investigator Data	3151A6-2000-US	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

To submit 1025 mg CMC information

Pediatric Study Request

IND Activities

223906	UNITED STATES	15-Feb-08	393 1A Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64.552	3151A1-335-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
223906	UNITED STATES	15-Feb-08	393 1A Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64.552	3151A1-403-WW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
223906	UNITED STATES	15-Feb-08	393 1A Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64.552	3151A1-402-WW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
223906	UNITED STATES	15-Feb-08	393 1A Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64.552	3151A6-2000-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
225077	UNITED STATES	26-Feb-08	394 1A Correspondence	Safety Rpt. Clin	Initial Written		FDA	Wyeth	IND 64.552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
225801	UNITED STATES	11-Mar-08	395 1A Correspondence	Safety Rpt. Clin	Follow-up		FDA	Wyeth	IND 64.552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
225881	UNITED STATES	14-Mar-08	396 1A Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64.552	3151A1-336-AP	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
225881	UNITED STATES	14-Mar-08	396 1A Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64.552	3151A6-2001-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
225881	UNITED STATES	14-Mar-08	396 1A Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64.552	3151A1-402-WW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
225881	UNITED STATES	14-Mar-08	396 1A Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64.552	3151A6-2000-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
225881	UNITED STATES	14-Mar-08	396 1A Correspondence	Prot Amend	Investigator Data		FDA	Wyeth	IND 64.552	3151A1-403-WW	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
226429	UNITED STATES	20-Mar-08	397 1A Correspondence	Prot Amend	Change in Prot		FDA	Wyeth	IND 64.552	3151A6-2001-US	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
226523	UNITED STATES	21-Mar-08	398 1A Correspondence	Safety Rpt. Clin	Follow-up		FDA	Wyeth	IND 64.552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
105168	UNITED STATES	22-Apr-02	1A Correspondence	Request	Info		Wyeth	FDA	IND 64.552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
105167	UNITED STATES	19-Apr-02	1A Correspondence	Initial IDA	Other		FDA	Wyeth	IND 64.552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
105180	UNITED STATES	18-Apr-02	1A Correspondence	Initial IDA	Other		FDA	Wyeth	IND 64.552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
105633	UNITED STATES	2-May-02	1A Correspondence	CMC Issues	Info Request-Respon		FDA	Wyeth	IND 64.552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
129575	UNITED STATES	24-Oct-03	IDA-FDA Con Rpt	Phone	Clinical Issues		Wyeth	Wyeth	IND 64.552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
129561	UNITED STATES	23-Oct-03	IDA-FDA Con Rpt	Phone	Clinical Issues		Wyeth	Wyeth	IND 64.552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
129560	UNITED STATES	24-Oct-03	IDA-FDA Con Rpt	Phone	Clinical Issues		Wyeth	Wyeth	IND 64.552		DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

Additional Desk Copies of IND
- Cover Memo Only

Additional Copy of Initial IND

126162	UNITED STATES	14-Mar-03	IA Correspondence	Request	Info	#####	Wyeth	FDA	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
127320	UNITED STATES	25-Aug-03	IA Correspondence	Request	Info	#####	Wyeth	FDA	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
127319	UNITED STATES	2-Sep-03	IA Correspondence	Response to	Information Request	#####	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
127235	UNITED STATES	7-Aug-03	IDA-FDA Con Rpt	Phone	Meeting Sched/Issues	#####	Wyeth	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
126118	UNITED STATES	14-Feb-03	IA Correspondence	Request	Review/Comment	#####	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
126107	UNITED STATES	31-Jul-03	IA Correspondence	Response to	Review/Comment Req	#####	Wyeth	FDA	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
126020	UNITED STATES	28-Feb-03	IA-GRR Note to File	Mtg Min (No Doc)		NO DOC	Wyeth	FDA	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
125987	UNITED STATES	4-Feb-03	IA-GRR Note to File	Mtg Min (No Doc)		NO DOC	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
113475	UNITED STATES	30-Oct-02	IA Correspondence	Protocol-Clinical	Other	FDA Communications re New Prot Submission, 0600D3-172-US	Wyeth	FDA	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
112968	UNITED STATES	30-Sep-02	IA Correspondence	Clinical Issues	Other	Clinical Trials Data Bank Info	Wyeth	FDA	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
112598	UNITED STATES	6-May-02	IA Correspondence	Protocol-Clinical	Information-Request	re. 0600D3-170-EU study	Wyeth	FDA	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
112587	UNITED STATES	6-May-02	IA Correspondence	CMC Issues	Information-Request	#####	Wyeth	FDA	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
108455	UNITED STATES	8-May-02	IA Correspondence	CMC Issues	Info Request-Response	#####	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
181420	UNITED STATES	20-May-05	IA-GRR Note to File	Other		NO DOC	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
179393	UNITED STATES	20-Jul-06	IA Correspondence	Non-Clinical Issues	Other	Advice on dose selection.	Wyeth	FDA	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
178414	UNITED STATES	28-Jun-06	IA Correspondence	Prot Amend	New Protocol	Agency finds protocol #3151A1-800-US acceptable.	Wyeth	FDA	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
178705	UNITED STATES	9-Jun-06	IA Correspondence	Gen Con		Miscellaneous issues.	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
175428	UNITED STATES	27-Oct-05	IA-GRR Note to File	Mtg Min (No Doc)		NO DOC	Wyeth	FDA	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
175418	UNITED STATES	27-Oct-05	IA-GRR Note to File	Mtg Min (No Doc)		NO DOC	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
175379	UNITED STATES	8-Sep-05	IA-GRR Note to File	Mtg Min (No Doc)		NO DOC	Wyeth	FDA	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

IND Activities

175371 UNITED STATES	20-Sep-05	IA-GRR Note to File	Mtg Min (No Doc)		NO DOC	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
175237 UNITED STATES	15-Jun-05	IA-GRR Note to File	Mtg Min (No Doc)		NO DOC	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
175234 UNITED STATES	15-Jun-05	IA-GRR Note to File	Mtg Min (No Doc)		NO DOC	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
173593 UNITED STATES	20-Apr-06	IA Correspondence	Response to	Review/Comment Req	SIN 293 Review.	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
168478 UNITED STATES	27-Jan-06	IA Correspondence	Response to	Information Request	Answer to question on the Toxicology Amendment.	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
168123 UNITED STATES	23-Jan-06	IA Correspondence	Gen Corr		Interpretation of e-mail on Toxicology amendment.	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
168122 UNITED STATES	23-Jan-06	IA Correspondence	Response to	Information Request	Toxicology amendment	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
168113 UNITED STATES	20-Jan-06	IA Correspondence	Request	Info	Question on toxicology reports.	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
167818 UNITED STATES	26-Aug-05	IA Correspondence	Gen Corr		Acknowledged receipt of e-mail dated 18-AUG-05.	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
167518 UNITED STATES	19-Dec-05	IA Correspondence	Meeting/Telecon	Info	Include conversation with Dr. Oliver regarding the stability data.	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
167517 UNITED STATES	8-Dec-05	IA Correspondence	Meeting/Telecon	Minutes	27-OCT-2005 Teleconference	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
166938 UNITED STATES	25-Nov-05	IA Correspondence	Meeting/Telecon	Minutes	Discuss Pre-NDA CMC issues.	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
165927 UNITED STATES	23-Nov-05	IA Correspondence	CMC Issues	Other	Stability Data.	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
165904 UNITED STATES	26-Nov-05	IA Correspondence	Gen Corr		Acknowledged receipt of e-mail dated 28-NOV-2005 - statistical comments	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
165803 UNITED STATES	26-Nov-05	IA Correspondence	Gen Corr		Responding message dated 25-NOV-2005 - statistical comments.	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
165801 UNITED STATES	23-Nov-05	IDA-FDA Can Rpt	Phone	General	To obtain concurrence from the Agency.	Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
164758 UNITED STATES	28-Apr-03	IA Correspondence	Meeting/Telecon	Minutes	Minutes and overheads of 4-10-03.	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
164425 UNITED STATES	19-Oct-05	IA Correspondence	Meeting/Telecon	Confirm	Type C meeting to be held 27-OCT-2005.	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
164201 UNITED STATES	21-Oct-05	IDA-FDA Can Rpt	Phone	Meeting Sched/Issues	Teleconference scheduled for 27-OCT-2005	Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
164201 UNITED STATES	21-Oct-05	IDA-FDA Can Rpt	Phone	CMC Issues	Teleconference scheduled for 27-OCT-2005.	Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

IND Activities

184171 UNITED STATES	21-Oct-05	IA Correspondence	CMC Issues	Other	There will be no additional questions to include to the meeting package.	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
183301 UNITED STATES	20-Oct-05	IA Correspondence	Gen Corr		eCTD interactive demonstration.	#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
183770 UNITED STATES	19-Oct-05	IA Correspondence	Meeting/Telecon	Mtg Req-Response	Telecon granted 27-OCT-05.	#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
183836 UNITED STATES	28-Sep-05	IA Correspondence	Meeting/Telecon	Minutes	Minutes and Presentation of 20-SEP-05 CMC Pilot Program.	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
183543 UNITED STATES	11-Oct-05	IA Correspondence	Meeting/Telecon	Info	Date correction - 27-OCT-05.	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
183542 UNITED STATES	10-Oct-05	IA Correspondence	Meeting/Telecon	Info	Tentatively scheduled 20-OCT-05.	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
183539 UNITED STATES	13-Oct-05	IA Correspondence	Meeting/Telecon	Info	Teleconference information for 27-OCT-2005.	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
183408 UNITED STATES	11-Oct-05	IDA-FDA Con Rpt	Phone	CMC Issues	Confirmed receipt of the CMC meeting agenda and related information package.		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
183034 UNITED STATES	5-Oct-05	IA Correspondence	Meeting/Telecon	Info	CMC meeting package scheduled 27-OCT-05.	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
182806 UNITED STATES	30-Sep-05	IA Correspondence	Meeting/Telecon	Minutes	Minutes of 8-SEP-05.	#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
182487 UNITED STATES	29-Sep-05	IA Correspondence	Gen Corr		eCTD interactive demonstration.	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
182089 UNITED STATES	8-Sep-05	IA Correspondence	Meeting/Telecon	Confirm	Type C meeting scheduled for 20-SEP-05. Discuss CMC information.		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
182039 UNITED STATES	20-Sep-05	IA Correspondence	Meeting/Telecon	Info	Detailed feedback requested of the meeting held 8-SEP-05.	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
181881 UNITED STATES	1-Sep-05	IA Correspondence	CMC Issues	Info Request-Response	Accepted to the Pilot program.		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
181521 UNITED STATES	7-Sep-05	IA Correspondence	Meeting/Telecon	Info	Information regarding 8-SEP-05 meeting.	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
181513 UNITED STATES	6-Sep-05	IA Correspondence	Meeting/Telecon	Info		#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
181510 UNITED STATES	7-Sep-05	IA Correspondence	Meeting/Telecon	Info	Power Point Slide presentation for 8-SEP-05 meeting.	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
180523 UNITED STATES	25-Aug-05	IA Correspondence	Meeting/Telecon	Info	Additional questions.	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
180790 UNITED STATES	24-Aug-05	IA Correspondence	Gen Corr		Acknowledged e-mail receipt.	#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
180789 UNITED STATES	24-Aug-05	IA Correspondence	Response to	Information Request	Provide list of questions requested by the Agency.	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

IND Activities

160768	UNITED STATES	23-Aug-05	IA Correspondence	Gen Corr		Will provide information requested on 22-AUG-05. Please email questions with the 7-14-05 briefing document.	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
160767	UNITED STATES	22-Aug-05	IA Correspondence	Request	Info		#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
160520	UNITED STATES	18-Aug-05	IA Correspondence	Meeting/Telecon	Meeting-Request	FDA CMC pilot program		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
160428	UNITED STATES	11-Aug-05	IA Correspondence	CMC Issues	Other	Request to participate in the Agency's CMC pilot program.		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
160365	UNITED STATES	11-Aug-05	IDA-FDA Con Rpt	Phone	CMC Issues	FDA CMC pilot program. PDF copy of 11-AUG-05 formal written request to participate in FDA CMC pilot program.		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
160219	UNITED STATES	11-Aug-05	IA Correspondence	Meeting/Telecon	Info		#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
160061	UNITED STATES	4-Aug-05	IA Correspondence	Pediatric Exclus	Issues	Submission feedback letter received	#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
159819	UNITED STATES	3-Aug-05	IA Correspondence	Gen Corr		Submission feedback	#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
159193	UNITED STATES	25-Jul-05	IA Correspondence	Request	Info	Pediatric Waiver and Deferral SN 223	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
159143	UNITED STATES	14-Jul-05	IA Correspondence	Meeting/Telecon	Minutes	Meeting/Telecon held on 15-JUN-05		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
159132	UNITED STATES	22-Jul-05	IA Correspondence	Meeting/Telecon	Confirm	Type B meeting confirmed for 8-AUG-05	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
159097	UNITED STATES	20-Jul-05	IA Correspondence	Meeting/Telecon	Mtg Req-Response	Meeting granted 9-8-05		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
157528	UNITED STATES	20-Jun-05	IA Correspondence	Meeting/Telecon	Minutes	Quality by Design approach meeting 15-JUN-05	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
156908	UNITED STATES	14-Jun-05	IA Correspondence	Response to	Review/Comment Req	Drug interaction study development plan.	#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
156155	UNITED STATES	2-Jun-05	IA Correspondence	Gen Corr		Notification of the requested data on 217, 219 & 226	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
155909	UNITED STATES	27-May-05	IA Correspondence	Request	Other	Desk copies of 1/11, 1/14 and 2/1/2005 submissions. Inclusion of Executed Batch Records. Sustained versus Extended Release terminology.	#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
155760	UNITED STATES	27-May-05	IDA-FDA Con Rpt	Phone	CMC Issues			Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
154410	UNITED STATES	4-May-05	IA Correspondence	Gen Corr		Submission feedback.	#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
154274	UNITED STATES	22-Apr-05	IA Correspondence	Meeting/Telecon	Confirm	15-JUN-05 to discuss Quality by Design approach.		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
153804	UNITED STATES	22-Apr-05	IDA-FDA Con Rpt	Phone	Meeting Sched/Issues	Meeting scheduled for 15-JUN-05 to discuss Quality by Design approach and its applicability to upcoming NDA		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

IND Activities

153543	UNITED STATES	21-Apr-05	IA Correspondence	Request	Guidance	Feedback on submission SN 223 & 242.	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
152354	UNITED STATES	1-Apr-05	IA Correspondence	Meeting/Telecon	Meeting-Request	Meeting to discuss Wyeth's proposal for 'Quality by Design Approach'.		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
151769	UNITED STATES	21-Mar-05	IA Correspondence	Meeting/Telecon	Meeting-Request	Discuss CHQ Risk Based Approach.	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
149932	UNITED STATES	16-Feb-05	IA Correspondence	Gen Corr		FDA Feedback.		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
149707	UNITED STATES	15-Feb-05	IA Correspondence	Clinical Issues	Other	Requests and recommendations on submissions SN 151 & 161.	#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148959	UNITED STATES	28-Jan-05	IA Correspondence	Meeting/Telecon	Other	Meeting cancelled 31-JAN-05.	#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148748	UNITED STATES	11-Jan-05	IA Correspondence	Meeting/Telecon	Request - Other	Requesting 21-JAN-05 meeting attendees names	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148748	UNITED STATES	12-Jan-05	IA Correspondence	CMC Issues	Information-Request	Additional information requested 11-JAN-05 Teleconference.	#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148719	UNITED STATES	11-Jan-05	IA GRR Note to File	Mtg Min (No Doc)		NO DOC		FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148399	UNITED STATES	19-Jan-05	IA Correspondence	Gen Corr		e-mail received and able to view the document.	#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
148343	UNITED STATES	18-Jan-05	IA Correspondence	Response to	Information Request	12-JAN-05 info request	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
147992	UNITED STATES	11-Jan-05	IA Correspondence	Meeting/Telecon	Info	List of participants in the 11-JAN-05 telecon.	#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
147991	UNITED STATES	12-Jan-05	IA Correspondence	Response to	Information Request	Additional information requested on the 11-JAN-05 telecon.	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
147975	UNITED STATES	6-Jan-05	IA Correspondence	Meeting/Telecon	Meeting-Request	To clarify the submitted IVVC. Additional information in support of January 21 Type B meeting for Blower for 150 mg.	#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
147938	UNITED STATES	11-Jan-05	IDA-FDA Con Rpt	Phone	CMC Issues	Concur with the DRUDP's review.	#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
145060	UNITED STATES	15-Nov-04	IA Correspondence	Gen Corr		Seeking confirmation of designation of Methoxyacetate as starting material.	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
144821	UNITED STATES	8-Nov-04	IA Correspondence	CMC Issues	Information-Request	Confirmation of designation of Methoxyacetate as starting material.	#####	Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
144820	UNITED STATES	8-Nov-04	IDA-FDA Con Rpt	Phone	CMC Issues			Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
144618	UNITED STATES	5-Nov-04	Pre-IDA FDA Con Rpt	Other		Issues regarding SN 144.	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
144059	UNITED STATES	22-Oct-04	IA Correspondence	Request	Review/Comment	Feedback on submission dated 21-JUL-04 (SN 169).	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

IND Activities

143338	UNITED STATES	25-Oct-04	IA Correspondence	Clinical Issues	Info Request-Respon	Comments on the submission dated 21-JUL-04 and 16-SEP-04.	#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
143244	UNITED STATES	12-Oct-04	IDA-FDA Con Rpt	Phone	Pediatric Ex Issues	Requirements for a Pediatric development program.	#####	Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
143125	UNITED STATES	22-Sep-04	IA Correspondence	Request	Info	Question on the future product labeling.	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
143124	UNITED STATES	6-Aug-04	IA Correspondence	Request	Info	Status of FDA feedback on submissions SIN 146 and 157.	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
142939	UNITED STATES	21-Sep-04	IA Correspondence	Gen Corr		FDA cannot comment on how Wyeth discontinuation scale will impact labeling.	#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
142465	UNITED STATES	28-Sep-04	IA Correspondence	Response to	Information Request		#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
142068	UNITED STATES	21-Sep-04	IA Correspondence	Response to	Review/Comment Req	Feedback on the SIN 157 and 146.	#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
142068	UNITED STATES	21-Sep-04	IA Correspondence	Response to	Review/Comment Req	Response to status of submissions dated 02-JUN-04, 17-JUN-04 & 21-JUL-04.	#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
142003	UNITED STATES	20-Sep-04	IA Correspondence	Request	Review/Comment	Request for status of submissions dated 02-JUN-04, 17-JUN-04 & 21-JUL-04.	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
140239	UNITED STATES	6-Aug-04	IA Correspondence	Request	Info	Status of FDA feedback on submissions SIN 149 and 157.	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
139714	UNITED STATES	18-Jun-04	IA-GRR Note to File	Other		NO DOC FDA waiting for feedback from the Cardio consultants to respond to our request for feedback.	#####	Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
139385	UNITED STATES	12-Jul-04	IA Correspondence	Gen Corr			#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
139204	UNITED STATES	6-Jul-04	IA Correspondence	Request	Review/Comment	Requested feedback on our proposed QTc clinical study. Submission (1-27-04)	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138945	UNITED STATES	28-Jun-04	IA Correspondence	Gen Corr		comments from the Office of Biometrics	#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
134448	UNITED STATES	28-Jan-04	IA Correspondence	Pediatric Exclus	Issues	Question about pediatric written requests for MDD studies	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
138335	UNITED STATES	7-Jun-04	IDA-FDA Con Rpt	Phone	Other	Request for feedback on draft QT protocol	#####	Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
137428	UNITED STATES	12-May-04	IDA-FDA Con Rpt	Phone	Clinical Issues	Request for feedback on a draft QT protocol.	#####	Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
137248	UNITED STATES	23-Feb-04	IA Correspondence	Pediatric Exclus	Issues	Documents received	#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
136123	UNITED STATES	6-Nov-03	IA-GRR Note to File	Mtg Min (No Doc)		NO DOC	#####	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
135827	UNITED STATES	1-Apr-04	IA Correspondence	Request	Info		#####	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

IND Activities

126366	UNITED STATES	30-Jul-03	IA Correspondence	Protocol-Clinical	Other	FDA completed review of April 1, 2003 submission and have recommendations regarding development toxicity study in rats.		Wyeth	FDA	IND 64,552	DEIVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
126135	UNITED STATES	11-Jul-02	IA Correspondence	Response to	Review/Comment Req	response to Serial 008	#####	Wyeth	FDA	IND 64,552	DEIVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
189844	UNITED STATES	15-May-07	IA Correspondence	Clinical Issues	Info Request-Respon	Comments regarding Statistical plan.	#####	Wyeth	FDA	IND 64,552	DEIVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
108454	UNITED STATES	3-May-02	IA Correspondence	Response to	Information Request		#####	FDA	Wyeth	IND 64,552	DEIVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
108452	UNITED STATES	2-May-02	IA Correspondence	CMC Issues	Information-Request		#####	Wyeth	FDA	IND 64,552	DEIVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
108451	UNITED STATES	1-May-02	IA Correspondence	CMC Issues	Info Request-Respon		#####	FDA	Wyeth	IND 64,552	DEIVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
108448	UNITED STATES	29-Apr-02	IA Correspondence	CMC Issues	Information-Request		#####	Wyeth	FDA	IND 64,552	DEIVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
108441	UNITED STATES	25-Apr-02	IA Correspondence	CMC Issues	Info Request-Respon		#####	FDA	Wyeth	IND 64,552	DEIVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
108444	UNITED STATES	26-Apr-02	IA Correspondence	CMC Issues	Info Request-Respon		#####	FDA	Wyeth	IND 64,552	DEIVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
108440	UNITED STATES	23-Apr-02	IA Correspondence	CMC Issues	Other		#####	Wyeth	FDA	IND 64,552	DEIVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
107562	UNITED STATES	11-Jun-02	IA Correspondence	Perm to Proceed				Wyeth	FDA	IND 64,552	DEIVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
135485	UNITED STATES	22-Mar-04	IA Correspondence	Response to	Other	Missed Serial #120 - Should be no problem	#####	Wyeth	FDA	IND 64,552	DEIVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
135357	UNITED STATES	19-Mar-04	IA Correspondence	Gen Corr		Inform FDA that there will no serial #120	#####	FDA	Wyeth	IND 64,552	DEIVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
135048	UNITED STATES	8-Mar-04	IA Correspondence	Gen Corr		Clinical and PharmTox comments	#####	Wyeth	FDA	IND 64,552	DEIVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
134891	UNITED STATES	3-Mar-04	IA Correspondence	Prot Amend	Revised		#####	FDA	Wyeth	IND 64,552	DEIVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
134892	UNITED STATES	3-Mar-04	IA Correspondence	Response to	Information Request	Request clarification to 2725 e-mail	#####	FDA	Wyeth	IND 64,552	DEIVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
134892	UNITED STATES	3-Mar-04	IA Correspondence	Gen Corr		Request clarification to 2725 e-mail	#####	FDA	Wyeth	IND 64,552	DEIVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
134682	UNITED STATES	25-Feb-04	IA Correspondence	Safety Issues	Other	re: Safety Concern Issues, FDA Review of Prot - Perm to Proceed	#####	Wyeth	FDA	IND 64,552	DEIVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
134682	UNITED STATES	25-Feb-04	IA Correspondence	Perm to Proceed		re: Safety Concern Issues, FDA Review of Prot - Perm to Proceed	#####	Wyeth	FDA	IND 64,552	DEIVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
134524	UNITED STATES	6-Feb-04	IDA-FDA Con Rpt	Other		FDA waiting for a desk copy	#####	Wyeth	FDA	IND 64,552	DEIVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

IND Activities

134308	UNITED STATES	5-Feb-04	IA Correspondence	Gen Corr		Increase dose from 200mg to 400 mg	#####	Wyeth	FDA	IND 64-552	DESVENLAFAXINE SUCCLIMATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
134514	UNITED STATES	5-Feb-04	IA Correspondence	Gen Corr			#####	FDA	Wyeth	IND 64-552	DESVENLAFAXINE SUCCLIMATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
134409	UNITED STATES	13-Feb-04	IA Correspondence	Other		Dose adjustment	#####	FDA	Wyeth	IND 64-552	DESVENLAFAXINE SUCCLIMATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
134153	UNITED STATES	13-Feb-04	IA Correspondence	Gen Corr		Urgent Feedback sent to FDA	#####	FDA	Wyeth	IND 64-552	DESVENLAFAXINE SUCCLIMATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
132252	UNITED STATES	25-Nov-03	IA Correspondence	Meeting/Telecon	Minutes	New 8th mtg FDA's OCPB teams has completed their review of Wyeth's submission of 5/29/03 providing follow-up responses and have found Wyeth's plans reasonable regarding population pharmacokinetic analyses and plan to start Phase III PK using traditional PK methods.	#####	Wyeth	FDA	IND 64-552	DESVENLAFAXINE SUCCLIMATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
123586	UNITED STATES	24-Jun-03	IA Correspondence	Info Ahead-Pharm/Tra			#####	Wyeth	FDA	IND 64-552	DESVENLAFAXINE SUCCLIMATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
124566	UNITED STATES	10-Apr-03	IA-GRR Note to File	Mtg Min (No Doc)		NO DOC		FDA	Wyeth	IND 64-552	DESVENLAFAXINE SUCCLIMATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
124244	UNITED STATES	19-May-03	IA Correspondence	Protocol-Clinical	Info Request-Respon	permission to proceed	#####	Wyeth	FDA	IND 64-552	DESVENLAFAXINE SUCCLIMATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
123103	UNITED STATES	11-Jun-03	IDA-FDA Con Rpt	Phone	Clinical Issues			Wyeth	Wyeth	IND 64-552	DESVENLAFAXINE SUCCLIMATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
123016	UNITED STATES	9-Jun-03	IDA-FDA Con Rpt	Phone	Clinical Issues			Wyeth	Wyeth	IND 64-552	DESVENLAFAXINE SUCCLIMATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
126228	UNITED STATES	28-May-03	IA Correspondence	Request	Review/Comment	Wyeth seeks to speak to statistical reviewer regarding comment on multiplicity.	#####	FDA	Wyeth	IND 64-552	DESVENLAFAXINE SUCCLIMATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
122336	UNITED STATES	28-May-03	IA Correspondence	Other			#####	FDA	Wyeth	IND 64-552	DESVENLAFAXINE SUCCLIMATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
121328	UNITED STATES	17-Apr-03	IA Correspondence	Meeting/Telecon	Minutes		#####	FDA	Wyeth	IND 64-552	DESVENLAFAXINE SUCCLIMATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
133148	UNITED STATES	21-Jan-04	IA Correspondence	Pediatric Exclis	Written Request	Questions about Pediatric Written Requests for MDD Studies	#####	FDA	Wyeth	IND 64-552	DESVENLAFAXINE SUCCLIMATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
121327	UNITED STATES	4-Apr-03	IA Correspondence	Meeting/Telecon	Info	corrected background info., participants list and mtg questions	#####	FDA	Wyeth	IND 64-552	DESVENLAFAXINE SUCCLIMATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
120765	UNITED STATES	22-Apr-03	IA Correspondence	Meeting/Telecon	Minutes	Action Rpt - April 10, 2003 Mtg Minutes		Wyeth	FDA	IND 64-552	DESVENLAFAXINE SUCCLIMATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
117876	UNITED STATES	20-Feb-03	IA Correspondence	Request	Review/Comment		#####	FDA	Wyeth	IND 64-552	DESVENLAFAXINE SUCCLIMATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
117857	UNITED STATES	31-Jan-03	IA Correspondence	Response to	Information Request		#####	FDA	Wyeth	IND 64-552	DESVENLAFAXINE SUCCLIMATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US
117855	UNITED STATES	28-Jan-03	IA Correspondence	Response to	Information Request		#####	FDA	Wyeth	IND 64-552	DESVENLAFAXINE SUCCLIMATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S PRISTIQ	US

IND Activities

117854 UNITED STATES	3-Mar-03	IA Correspondence	Meeting/Telecon	Minutes	FDA Mtg Minutes - EOP2 02/04/03 Mtg	#####	Wyeth	FDA	IND 04.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
116920 UNITED STATES	29-Jan-03	IA Correspondence	Gen Corr		FDA sent e-mail confirming receipt of Wyeth's response to FDA Request for Pharma colonic data (serial no. 041)	#####	Wyeth	FDA	IND 04.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
115993 UNITED STATES	6-May-02	IA Correspondence	Gen Corr		request for clarification forwarded	#####	Wyeth	FDA	IND 04.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
131579 UNITED STATES	12-Nov-03	IA Correspondence	CMC Issues	Other	FDA comments on May 28th and Sept. 3rd, 5th and 8th submissions	#####	Wyeth	FDA	IND 04.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
130423 UNITED STATES	12-Nov-03	IA Correspondence	Response to	Review/Comment Req	re submission on May 29, Sep 3, 5, & 8	#####	Wyeth	FDA	IND 04.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
129384 UNITED STATES	23-Sep-03	IA Correspondence	Protocol-Clinical	Other	comments and recommendations regarding 3151A1-303-WWW for the SR	#####	Wyeth	FDA	IND 04.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
129372 UNITED STATES	23-Sep-03	IA Correspondence	Protocol-Clinical	Other	comments and recommendations regarding 3151A1-303-WWW for the SR	#####	Wyeth	FDA	IND 04.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
126997 UNITED STATES	9-Oct-03	IDA-FDA Con Rpt	Phone	CMC Issues			Wyeth	Wyeth	IND 04.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
128419 UNITED STATES	15-Apr-03	IA-GRR Note to File	Other		NO DOC		Wyeth	Wyeth	IND 04.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
128358 UNITED STATES	23-Sep-03	IA Correspondence	Request	Review/Comment	looking for feedback on Serial 069	#####	FDA	Wyeth	IND 04.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
128112 UNITED STATES	12-Sep-03	IA Correspondence	Response to	Information Request	response to clinical portion (serial no. 085) attached as pdf	#####	FDA	Wyeth	IND 04.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
128104 UNITED STATES	12-Sep-03	IA Correspondence	Response to	Information Request	response to when will we receive comments on serial 089?	#####	Wyeth	FDA	IND 04.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
127809 UNITED STATES	12-Sep-03	IDA-FDA Con Rpt	Phone	Clinical Issues			Wyeth	Wyeth	IND 04.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
122269 UNITED STATES	19-May-03	IA Correspondence	Protocol-Clinical	Info Request-Response	Permission to proceed with comments on 3 new protocols		Wyeth	FDA	IND 04.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
114726 UNITED STATES	6-Dec-02	IA Correspondence	Meeting/Telecon	Request-Response		#####	Wyeth	FDA	IND 04.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
114725 UNITED STATES	6-Dec-02	IA Correspondence	Meeting/Telecon	Response Req - Other		#####	FDA	Wyeth	IND 04.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
114517 UNITED STATES	2-Dec-02	IA Correspondence	Meeting/Telecon	Confirm		#####	Wyeth	FDA	IND 04.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
110596 UNITED STATES	13-Aug-02	IA Correspondence	Prot Amend	Change in Prot		#####	Wyeth	FDA	IND 04.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
109361 UNITED STATES	26-Apr-02	IA Correspondence	CMC Issues	Info Request-Response		#####	FDA	Wyeth	IND 04.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
109360 UNITED STATES	26-Apr-02	IA Correspondence	CMC Issues	Information-Request		#####	Wyeth	FDA	IND 04.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

IND Activities

105742	UNITED STATES	8-May-02	IA Correspondence	Response to	Information Request		#####	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
105951	UNITED STATES	24-Jun-02	IDA-FDA Con Rpt	Phone	Pediatric Ex Issues	Wyeth is seeking advice whether background information and proposed protocol are sufficient under one serial number for each protocol		Wyeth	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
116592	UNITED STATES	15-Jan-03	IA Correspondence	Protocol - Non-Clin	Other		#####	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
116598	UNITED STATES	23-Jan-03	IA Correspondence	Meeting/Telecon	Info		#####	Wyeth	FDA	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
116591	UNITED STATES	16-Jan-03	IA Correspondence	Response to	Guidance Request		#####	Wyeth	FDA	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
116434	UNITED STATES	30-Jan-03	IDA-FDA Con Rpt	Phone	Safety Issues	FDA has safety concerns regarding DVS-233 SR Tablets regarding proposed dose levels due to observations of tachycardia & hypertension. FDA requested pharmacokinetic steady-state profile of DVS-233 SR tablets & equivalent profiles for 100, 200 & 400 mg doses.		Wyeth	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
116197	UNITED STATES	28-Jan-03	IDA-FDA Con Rpt	Phone	Clinical Issues			Wyeth	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
116097	UNITED STATES	24-Jan-03	IDA-FDA Con Rpt	Phone	Meeting Sched/Issues			Wyeth	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
116080	UNITED STATES	22-Jan-03	IA Correspondence	Meeting/Telecon	Info		#####	FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
107582	UNITED STATES	11-Jun-02	IA Correspondence	Clinical Issues	Other			Wyeth	FDA	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
106640	UNITED STATES	4-Jun-02	IDA-FDA Con Rpt	Phone	Pediatric Ex Issues			Wyeth	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
106840	UNITED STATES	4-Jun-02	IDA-FDA Con Rpt	Phone	Clinical Issues			Wyeth	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
105903	UNITED STATES	10-May-02	IDA-FDA Con Rpt	Phone	General	IND in effect		Wyeth	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
105893	UNITED STATES	8-May-02	IDA-FDA Con Rpt	Phone	Clinical Issues			Wyeth	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
105891	UNITED STATES	8-May-02	IDA-FDA Con Rpt	Phone	Clinical Issues			Wyeth	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
105880	UNITED STATES	6-May-02	IA Correspondence	Response to	Information Request			Wyeth	FDA	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
105633	UNITED STATES	2-May-02	IA Correspondence	Response to	Information Request			FDA	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
107620	UNITED STATES	4-Jun-02	IA Correspondence	Clinical Issues	Other	re Clinical Trial Data Bank		Wyeth	FDA	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
107628	UNITED STATES	19-Jun-02	IDA-FDA Con Rpt	Phone	Clinical Issues			Wyeth	Wyeth	IND 64.552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

IND Activities

107502 UNITED STATES	11-Jun-02	IA Correspondence	Pediatric Excl	Waiver Req-Respon		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
105190 UNITED STATES	18-Apr-02	IA Correspondence	Response to	Information Request	Additional Copy of Initial IND	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
105414 UNITED STATES	22-Apr-02	IA Correspondence	CMC Issues	Other		Wyeth	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
105191 UNITED STATES	18-Apr-02	IA Correspondence	Initial IDA	Other	Requesting Additional Copies of IND	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
105191 UNITED STATES	18-Apr-02	IA Correspondence	Request	Info	Requesting Additional Copies of IND	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
105312 UNITED STATES	18-Apr-02	IA Correspondence	Initial IDA	Acknowledge Receipt		Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
105314 UNITED STATES	25-Apr-02	IA Correspondence	Initial IDA	Issues	re Incorrect receipt date	FDA	Wyeth	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US
105319 UNITED STATES	28-Apr-02	IA Correspondence	Initial IDA	Issues	re Incorrect Receipt Date	Wyeth	FDA	IND 64,552	DESVENLAFAXINE SUCCINATE (DVS-233) FOR THE TREATMENT OF DEPRESSION	UNITED S' PRISTIQ	US

NDA Activities

Grfts Doc ID	App. Country	Doc. Date #	Reference Doc. Type	Sub1 Type	Sub2 Type	Sub3 Type	Chronology Description	Email Date	To	From	App. #	App. Description	App. Region	Corporate Tradename	App. Country Abbrev.
162838	UNITED STATES	27-Sep-05	MA-FDA C Phone	General			NDA number assigned.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
163294	UNITED STATES	11-Oct-05	MA-Corres Request	Info			Feedback requested.	11-Oct-05	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
164424	UNITED STATES	1-Nov-05	MA-FDA C Phone	General			Outstanding NDA items.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
164844	UNITED STATES	9-Nov-05	MA-Corres Resp to Rt Info				Agency requests a literature search.	9-Nov-05	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
164931	UNITED STATES	9-Nov-05	MA-FDA C Phone	General			Literature search.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
170885	UNITED STATES	9-Nov-05	MA-User F Payment-Submission						FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
165026	UNITED STATES	12-Nov-05	MA-Corres General Corresp				Predclinical TOC and ECG tracings.	12-Nov-05	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US
167353	UNITED STATES	22-Dec-05	MA-Corres General Corresp				Delivery and Holiday week notification.	22-Dec-05	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S	PRISTIQ	US

NDA Activities

167099	UNITED STATES	22-Dec-05	MA-(Origin,Orig Full Subm	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
167350	UNITED STATES	28-Dec-05	MA-Corres Mtg/Teleco Request for Meeting	28-Dec-05	Wyeth	FDA	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
167351	UNITED STATES	29-Dec-05	MA-Corres Mtg/Teleco Info	29-Dec-05	Wyeth	FDA	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
167352	UNITED STATES	31-Dec-05	MA-Corres Mtg/Teleco Other	31-Dec-05	Wyeth	FDA	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
167696	UNITED STATES	11-Jan-06	MA-Corres Mtg/Teleco Request - Other	11-Jan-06	Wyeth	FDA	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
168112	UNITED STATES	20-Jan-06	MA-Corres Resp to Re Info	20-Jan-06	Wyeth	FDA	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
206335	UNITED STATES	20-Jan-06	MA-Corres General Corresp	20-Jan-06	Wyeth	FDA	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
168114	UNITED STATES	23-Jan-06	MA-Corres Request Other	23-Jan-06	Wyeth	FDA	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
168130	UNITED STATES	23-Jan-06	MA-Corres Mtg/Teleco Request for Meeting		Wyeth	FDA	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

168828	UNITED STATES	1-Feb-06	MA-FDA C-Phone	CMC Issues	Pilot Program.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
168794	UNITED STATES	1-Feb-06	MA-Corres/Mtg/Teleco	Request for Meeting	eCTD sequence No. 0001 - Pilot program.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
168849	UNITED STATES	3-Feb-06	MA-Corres/Mtg/Teleco	Other	Question and comments regarding the meeting logistics.	3-Feb-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
168939	UNITED STATES	3-Feb-06	MA-Corres/Resp to Re Info		8-FEB-2006 meeting.	3-Feb-06 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
168934	UNITED STATES	3-Feb-06	MA-FDA C-Phone	CMC Issues	Pilot Program meeting.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
168934	UNITED STATES	3-Feb-06	MA-FDA C-Phone	Meeting Sched/Issues	Pilot Program meeting.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
168940	UNITED STATES	6-Feb-06	MA-Corres/Request	Other	Permission to enter the conference room 10-15 minutes earlier.	6-Feb-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
169110	UNITED STATES	7-Feb-06	MA-Corres/Resp to Re Other		Room reservation made earlier than scheduled meeting time.	7-Feb-06 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
169303	UNITED STATES	9-Feb-06	MA-FDA C-Phone	CMC Issues	Coordinate submission package for the 8-MAR-2006 meeting.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

169719	UNITED STATES	10-Feb-06	MA-FDA C.Phone	CMC Issues	Agency's request for raw data sets.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
169666	UNITED STATES	14-Feb-06	MA-Corres Request	Other	Approval of Dual proprietary name.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
171268	UNITED STATES	16-Feb-06	MA-Corres Mtg/Teleco Confirm		8-MAR-2006.	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
169644	UNITED STATES	16-Feb-06	MA-Corres Mtg/Teleco Background Pkg		CMC Pilot Program meeting scheduled 8-MAR-06.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
169786	UNITED STATES	17-Feb-06	MA-FDA C.Phone	CMC Issues	Agency's request for raw data sets.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
169797	UNITED STATES	17-Feb-06	MA-FDA C.Phone	CMC Issues	Meeting to discuss Agency's questions.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
170047	UNITED STATES	23-Feb-06	MA-Corres Mtg/Teleco Confirm		8-MAR-2006 & 13-APR-2006.	23-Feb-06	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
170274	UNITED STATES	24-Feb-06	MA-FDA C.Phone	CMC Issues	Discuss Wyeth response to the Agency's questions.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
170290	UNITED STATES	24-Feb-06	MA-FDA C.Phone	CMC Issues	Agency's request for raw data sets.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

170679	UNITED STATES	24-Feb-06	MA-Corres Original Ap Other	Filing communication.	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
170098	UNITED STATES	27-Feb-06	MA-Corres Original Ap Acknowledge Receipt	27-Feb-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
170451	UNITED STATES	28-Feb-06	MA-FDA C-Phone CMC Issues	FDA CMC Pilot program meeting scheduled for 8-MAR- 2006.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
182003	UNITED STATES	28-Feb-06	MA-Corres Mtg/Teleco Info	List of attendees for 8- MAR-2006 meeting.	28-Feb-06	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
170473	UNITED STATES	3-Mar-06	MA-Corres Mtg/Teleco Info	List of attendees for meeting 8-MAR-2006.	3-Mar-06	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
170875	UNITED STATES	3-Mar-06	MA-FDA C-Phone CMC Issues	Environmental assessment section for NDA.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
170655	UNITED STATES	7-Mar-06	MA-Corres Amendmnr Other	Raw data sets used to develop the IVVC. eCTD sequence 0004.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
182015	UNITED STATES	7-Mar-06	MA-Corres Mtg/Teleco Info	Copies of the presentation.	7-Mar-06	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
171345	UNITED STATES	18-Mar-06	MA-Corres Amendmnr Other	Confidential and Non- Confidential Environmental Assessment.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

171423	UNITED STATES	16-Mar-06	MA-Corres Mtg/Teleco Minutes	Pilot program meeting 8-MAR-2006.	16-Mar-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
172309	UNITED STATES	24-Mar-06	MA-FDA C-Phone	Drug product samples for reviewer.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
172158	UNITED STATES	24-Mar-06	MA-Corres Mtg/Teleco Request - Other	Updated version of slides for meeting 8- Mar-2006. Also need samples of each strength.	24-Mar-06 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
172162	UNITED STATES	24-Mar-06	MA-Corres Mtg/Teleco Req Response- Other	Copy of slides presented at 8-Mar- 2006 meeting.	24-Mar-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
172825	UNITED STATES	7-Apr-06	MA-FDA C-Phone	Clinical Pharmacology Review.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
172826	UNITED STATES	7-Apr-06	MA-FDA C-Phone	Pilot program meeting 13-APR-2006. Meeting held 8-MAR- 2006 to discuss additional CMC information as part of the CMC pilot program.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
173287	UNITED STATES	7-Apr-06	MA-Corres Mtg/Teleco Minutes	Clinical site and sponsor inspections.	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
172986	UNITED STATES	10-Apr-06	MA-FDA C-Phone	Clinical Issues	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
173018	UNITED STATES	11-Apr-06	MA-Corres Request	Provide answers to aid in the review of the application.	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

173614	UNITED STATES	21-Apr-06	MA-Corres Safety Upd Other	Four Month update.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
173615	UNITED STATES	21-Apr-06	MA-Corres Resp to Re Info	Data from clinical investigators who participated in the study.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
173871	UNITED STATES	25-Apr-06	MA-Corres General Corresp	Acknowledged receipt of the 1572s.	25-Apr-06 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
173873	UNITED STATES	25-Apr-06	MA-Corres General Corresp	Recent submissions.	25-Apr-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
173895	UNITED STATES	25-Apr-06	MA-Corres Resp to Re Info	Recent submissions issues. 21-APR-2006 submission is not yet available.	25-Apr-06 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
173880	UNITED STATES	25-Apr-06	MA-Corres Resp to Re Info	Provide the 1572s requested by the Agency.	25-Apr-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
174224	UNITED STATES	27-Apr-06	MA-FDA C.Phone Other	QBR template questions.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
174176	UNITED STATES	28-Apr-06	MA-Corres Amendmer Other	Provide comparability protocol for the implementation of PAT.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
174798	UNITED STATES	5-May-06	MA-Corres Resp to Re Review/Comment		Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

174764	UNITED STATES	8-May-06	MA-User F. Information-Request	Official user fee action date.	8-May-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
208584	UNITED STATES	8-May-06	MA-Corres/Request Info	Copy of the IR letter.	8-May-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
174784	UNITED STATES	8-May-06	MA-Corres/Resp to Re Info	IR letter issued on 5-MAY-2006.	8-May-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
174861	UNITED STATES	9-May-06	MA-Corres/Resp to Re Info	User fee action date is 22-OCT-2006.	9-May-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
174879	UNITED STATES	10-May-06	MA-Corres/Amendmer Issues	Completed question based review template.		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
175432	UNITED STATES	16-May-06	MA-FDA C-Phone CMC Issues	Pilot program meeting 23-MAY-2006.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
175284	UNITED STATES	17-May-06	MA-Corres/General Corresp	Replacement of damaged media.		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
175343	UNITED STATES	18-May-06	MA-Corres/General Corresp	QBR template response.	18-May-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
175566	UNITED STATES	22-May-06	MA-Corres/Resp to Re Info	(5) compact disc review copies of the 10-MAY-2006 submission.		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

176104	UNITED STATES	22-May-06	MA-Corres General Corresp	Replacement of CD.	22-May-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
207881	UNITED STATES	22-May-06	MA-Corres Request	5 CD copies of the 10- MAY-2006 submission.	22-May-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
176455	UNITED STATES	6-Jun-06	MA-Corres Request	Requesting a copy of Data sets for 2-year carcinogenicity studies.	6-Jun-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
176593	UNITED STATES	7-Jun-06	MA-FDA C-Phone	Discuss questions on IVVC.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
176594	UNITED STATES	7-Jun-06	MA-Corres Request	Stat requestst.	7-Jun-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
176572	UNITED STATES	7-Jun-06	MA-Corres General Corresp	Tradename request: Elifore.		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
176706	UNITED STATES	9-Jun-06	MA-Corres General Corresp	Miscellaneous issues.	9-Jun-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
176701	UNITED STATES	9-Jun-06	MA-Corres Data	Mice and rats carcinogenicity Data Sets Req-Respor studies.		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
176946	UNITED STATES	12-Jun-06	MA-FDA C-Phone	Request for recalculation of IVVC data.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

177288	UNITED STATES	15-Jun-06	MA-Corres Request	Info	September's advisory committee.	15-Jun-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
177289	UNITED STATES	15-Jun-06	MA-Corres General Corresp		September's advisory committee.	15-Jun-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
177291	UNITED STATES	15-Jun-06	MA-Corres General Corresp			15-Jun-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
177487	UNITED STATES	16-Jun-06	MA-Corres Resp to Re Info		Questions regarding blood pressure.	16-Jun-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
177486	UNITED STATES	16-Jun-06	MA-Corres Request	Info	Advisory committee information.	16-Jun-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
177570	UNITED STATES	16-Jun-06	MA-Corres Report (No Other		Need to follow the guidance on page 61. 2- yr carcinogenicity studies.	21-Jun-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
177665	UNITED STATES	21-Jun-06	MA-Corres Request	Info	Carcinogenicity studies.	21-Jun-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
177753	UNITED STATES	22-Jun-06	MA-Corres Request	Info	September advisory committee meeting background information.		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
177852	UNITED STATES	26-Jun-06	MA-Corres Inspection Notice		Investigator files associated with study 306.	26-Jun-06	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

177862	UNITED STATES	26-Jun-06	MA-Corres/Amendmnr Other	Recalculated IVIVC Information.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
178420	UNITED STATES	26-Jun-06	MA-Corres/Resp to Re Info	Care Data Set questions and responses.	26-Jun-06 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
178415	UNITED STATES	27-Jun-06	MA-Corres/Request	Info	27-Jun-06 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
178458	UNITED STATES	28-Jun-06	MA-Corres/Request	Info	28-Jun-06 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
178397	UNITED STATES	3-Jul-06	MA-Corres/Resp to Re Info	Minor amendment CMC.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
178624	UNITED STATES	6-Jul-06	MA-Corres/Request	Info	6-Jul-06 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
178645	UNITED STATES	6-Jul-06	MA-Corres/Request	Guidance	6-Jul-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
178625	UNITED STATES	7-Jul-06	MA-Corres/Resp to Re Info	Information will be provided next week.	7-Jul-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
178649	UNITED STATES	7-Jul-06	MA-Corres/General Corresp	Inform the Agency eCTD has been loaded into the server.	7-Jul-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

178646	UNITED STATES	7-Jul-06	MA-Corres Request	Info	Carcinogenicity data sets.	7-Jul-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
178862	UNITED STATES	10-Jul-06	MA-Corres General Corresp		Re-confirmed NDA numbers.	10-Jul-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
178864	UNITED STATES	10-Jul-06	MA-Corres General Corresp		Clarification of NDA numbers.	10-Jul-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
178867	UNITED STATES	10-Jul-06	MA-Corres General Corresp		Correction - Typographical error.	10-Jul-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
178868	UNITED STATES	12-Jul-06	MA-Corres General Corresp		Revised version of the requests for info.	12-Jul-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
178869	UNITED STATES	13-Jul-06	MA-Corres Mtg/Teleco Request - Other		Reminder to send list of investigators/Briefing materials.	13-Jul-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
178910	UNITED STATES	13-Jul-06	MA (Pend) Clinical		Response to statistical queries.		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
179047	UNITED STATES	14-Jul-06	MA-Corres Resp to Re Other		Statistical queries.	14-Jul-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
179488	UNITED STATES	14-Jul-06	MA-Corres Fed Regist Other			14-Jul-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

179236	UNITED STATES	17-Jul-06	MA-Corres;Mtg/Teleco Minutes	Minutes of 23-MAY-2006.	17-Jul-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
179430	UNITED STATES	20-Jul-06	MA-Corres;Mtg/Teleco Info	Meeting date changed to 7-SEP-2006.	20-Jul-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
179827	UNITED STATES	27-Jul-06	MA-Corres;Request Info	Requesting Carcinogenicity Data sets.	27-Jul-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
179828	UNITED STATES	27-Jul-06	MA-Corres;Resp to Re Info	Expect to send the Carcinogenicity Data Sets Monday 31-JUL-2006.	27-Jul-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
179877	UNITED STATES	27-Jul-06	MA-Corres;Mtg/Teleco Other	Acknowledged receipt of date change.	27-Jul-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
179875	UNITED STATES	27-Jul-06	MA-Corres;Mtg/Teleco Info	Date for meeting has been changed to 7- SEPT-2006.	27-Jul-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
179953	UNITED STATES	31-Jul-06	MA-Corres;Amendmr Other	Re-submission of mouse and rat Carcinogenicity datasets.		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
180145	UNITED STATES	2-Aug-06	MA-Corres;General Corresp	CAC Data Sets.	2-Aug-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
180380	UNITED STATES	3-Aug-06	MA-Corres;Mtg/Teleco Background Pkg	7-SEP-2006 PDAC meeting.		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

180525	UNITED STATES	7-Aug-06	MA-Corres Clinical Iss: Other	Population PK analyses.	7-Aug-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
180526	UNITED STATES	7-Aug-06	MA-Corres Mtg/Teleco Info	Briefing book for 7-SEP-2006 Advisory Committee Meeting.	7-Aug-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
180571	UNITED STATES	7-Aug-06	MA-Corres General Corresp	Agency will confirm package arrival.	7-Aug-06 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
180572	UNITED STATES	7-Aug-06	MA-Corres Request Info	Resend and/or fax Investigator/Briefing materials.	7-Aug-06 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
180573	UNITED STATES	7-Aug-06	MA-Corres General Corresp		7-Aug-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
180574	UNITED STATES	7-Aug-06	MA-Corres General Corresp		7-Aug-06 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
180575	UNITED STATES	7-Aug-06	MA-Corres Clinical Iss: Other	Population PK feedback issues.	7-Aug-06 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
180576	UNITED STATES	7-Aug-06	MA-Corres Request Info	Statistical analyses of studies 309 and 320.	7-Aug-06 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
180816	UNITED STATES	9-Aug-06	MA-Corres General Corresp	Population PK feedback	9-Aug-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

181486	UNITED STATES	11-Aug-06	MA-Corres General Corresp	Message from Yanning.	11-Aug-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
181223	UNITED STATES	16-Aug-06	MA-Corres Mtg/Teleco Background Pkg-issue meeting.	7-SEP-2006 Drug Advisory Committee		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
181424	UNITED STATES	21-Aug-06	MA-Corres General Corresp	Assembly of data sets.	21-Aug-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
181479	UNITED STATES	21-Aug-06	MA-Corres Mtg/Teleco Info	Telephone information for the teleconference.	21-Aug-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
181476	UNITED STATES	21-Aug-06	MA-Corres Mtg/Teleco Info	List of attendees.	21-Aug-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
181848	UNITED STATES	25-Aug-06	MA-Corres General Corresp	Extension letter.	25-Aug-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
181949	UNITED STATES	28-Aug-06	MA-Corres General Corresp	Formatting issues. FDA request for raw data sets and electronic copy of presentation during the pre-approval inspection of Guyama.	28-Aug-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
181941	UNITED STATES	28-Aug-06	MA-FDA C-Phone	CMC Issues		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
182009	UNITED STATES	29-Aug-06	MA-Corres Data	Data Sets appear to be Req-Respor acceptable.	29-Aug-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

182046	UNITED STATES	29-Aug-06	MA-FDA C-Phone	Non-Clinical Issues		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
182142	UNITED STATES	30-Aug-06	MA-Corres General Corresp		Various issues.	30-Aug-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
182140	UNITED STATES	31-Aug-06	MA-Corres General Corresp		DPP has extended the UF date by 3 months.	31-Aug-06 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
182310	UNITED STATES	31-Aug-06	MA-Corres Amendmer Other		Response to request for statistical analyses.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
182347	UNITED STATES	1-Sep-06	MA-Corres Mtg/Teleco Info		Electronic copies of the pre-approval inspection in Guyana. PR.	1-Sep-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
182419	UNITED STATES	5-Sep-06	MA-Corres General Corresp		PAI introductory presentation - part 1.	5-Sep-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
182422	UNITED STATES	5-Sep-06	MA-Corres General Corresp		PAI introductory presentation - part 2.	5-Sep-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
182424	UNITED STATES	5-Sep-06	MA-Corres General Corresp		PAI introductory presentation - part 3.	5-Sep-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
182425	UNITED STATES	5-Sep-06	MA-Corres General Corresp		PAI introductory presentation - part 4.	5-Sep-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

182426	UNITED STATES	5-Sep-06	MA-Corres General Corresp	PAI introductory presentation - part 1a.	5-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
182427	UNITED STATES	5-Sep-06	MA-Corres General Corresp	PAI introductory presentation - part 4a.	5-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
182428	UNITED STATES	5-Sep-06	MA-Corres General Corresp	PAI introductory presentation - part 4b.	5-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
182441	UNITED STATES	5-Sep-06	MA-Corres Resp to Re Info	Nonmen Code and Data Sets.		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
183083	UNITED STATES	14-Sep-06	MA-Corres Resp to Re Info	Status of submissions.	14-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
183122	UNITED STATES	14-Sep-06	MA (Pend) Request-Response	Correction of population pharmacokinetics calculations.		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
183292	UNITED STATES	18-Sep-06	MA-Corres General Corresp	Withdraw request for dual tradename and proprietary name	18-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
183414	UNITED STATES	19-Sep-06	MA-Corres Request Info	Feedback on the dual trade name proposal.	19-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
183415	UNITED STATES	19-Sep-06	MA-Corres Resp to Re Info		19-Sep-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

183442	UNITED STATES	20-Sep-06	MA-Corres Original Ap Other	NDA review status.	20-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
183436	UNITED STATES	20-Sep-06	MA-FDA C.Phone CMC issues	Status of review.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
183744	UNITED STATES	21-Sep-06	MA-Corres Resp to Re Other	Dual trade names for VMS and MDD	21-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
183602	UNITED STATES	22-Sep-06	MA-Corres Resp to Re Info	Efficacy and Safety information and analyses.		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
183607	UNITED STATES	23-Sep-06	MA-Corres Request Info	Status and Carcinogenicity review.	23-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
183702	UNITED STATES	25-Sep-06	MA-Corres Resp to Re Info	Status and carcinogenicity review.	25-Sep-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
183802	UNITED STATES	26-Sep-06	MA (Pend). Other	Withdrawal of Eliflore as proposed trade name.		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
183884	UNITED STATES	27-Sep-06	MA-Corres General Corresp	Inform the Agency of the Carcinogenicity submission.	27-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
183885	UNITED STATES	27-Sep-06	MA-Corres General Corresp	Confirmed receipt of e. mail.	27-Sep-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

183886	UNITED STATES	27-Sep-06	MA-Corres Labeling	Other	Confirmed the last labeling submission dated 21-APR-2006.	27-Sep-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
184285	UNITED STATES	2-Oct-06	MA-Corres Resp to Re Info			Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US	
184284	UNITED STATES	2-Oct-06	MA-Corres Request	Info		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US	
184283	UNITED STATES	2-Oct-06	MA-Corres Request	Info		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US	
184312	UNITED STATES	3-Oct-06	MA-Corres Request	Info	Agency is looking for the open label exposure for the B group.	3-Oct-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
184313	UNITED STATES	3-Oct-06	MA-Corres Resp to Re Info			Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US	
184346	UNITED STATES	3-Oct-06	MA-Corres Request	Info	Need new carton and container for the new proposed name Pristiq.	3-Oct-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
184414	UNITED STATES	4-Oct-06	MA-Corres Resp to Re Info			4-Oct-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
184761	UNITED STATES	10-Oct-06	MA-Corres Resp to Re Info		Exposure information.	10-Oct-06	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

184779	UNITED STATES	10-Oct-06	MA (Pend) Clinical	Exposure year data for integrated safety groups B1, B2 and C.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
184981	UNITED STATES	12-Oct-06	MA (Pend) Labeling	Blister, bottle and carton labeling.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
185123	UNITED STATES	13-Oct-06	MA-Corres Labeling	Requested revised labels were submitted Thursday, 12-OCT-2006.	13-Oct-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
185124	UNITED STATES	16-Oct-06	MA-Corres General Corresp	Acknowledged receipt of revised labels.	16-Oct-06 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
185311	UNITED STATES	17-Oct-06	MA-Corres Request	P/T information.	17-Oct-06 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
185529	UNITED STATES	18-Oct-06	MA-Corres Resp to Re Other	Requested information will be provided to the Agency by 30-OCT-2006.	18-Oct-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
185998	UNITED STATES	25-Oct-06	MA-FDA C-Phone	Status of review of the CMC sections.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
186178	UNITED STATES	25-Oct-06	MA-Corres Resp to Re Info	Technical part of the response.	25-Oct-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
186179	UNITED STATES	26-Oct-06	MA-Corres Resp to Re Info	Historical Control Data.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

186605	UNITED STATES	1-Nov-06	MA (Pend) CMC	cGMP inspection update.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
186589	UNITED STATES	1-Nov-06	MA-Corres Inspection Issues	Guyama, PR manufacturing facility.	1-Nov-06 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
186994	UNITED STATES	6-Nov-06	MA-Corres Request	Info	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
187900	UNITED STATES	17-Nov-06	MA-FDA C-Phone	Meeting Sched/Issues	Request for CMC Pilot Program.	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
187885	UNITED STATES	17-Nov-06	MA-Corres General Corresp		Tradename for DVS.	17-Nov-06 Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
187955	UNITED STATES	20-Nov-06	MA-FDA C-Phone	Meeting Sched/Issues	CMC Pilot Program meeting scheduled for 30-NOV-2006.	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
188307	UNITED STATES	22-Nov-06	MA-FDA C-Phone	General	Tradename and review status.	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
188889	UNITED STATES	29-Nov-06	MA-Corres Request	Review/Comment	Request comments on proposed logo.	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
189178	UNITED STATES	8-Dec-06 A-	MA (Pend) Request-Response			FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

189612	UNITED STATES	12-Dec-06	MA-FDA C-Phone	General	Review status and trade name information.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
189548	UNITED STATES	12-Dec-06	MA-Corres;Request	Concurrence	Concurrence sought for FDA's Antidepressant Written Request Standard.	12-Dec-06	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
190354	UNITED STATES	15-Dec-06	MA-Corres;Resp to Re Info		Written request template not available at this time.	15-Dec-06	Wyeth	FDA	NDA 21-992	UNITED S' PRISTIQ	US
189786	UNITED STATES	18-Dec-06	MA-FDA C-Phone	CMC Issues		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
190380	UNITED STATES	19-Dec-06	MA-Corres;Pediatric E Issues		Written request template.	19-Dec-06	FDA	Wyeth	NDA 21-992	UNITED S' PRISTIQ	US
190241	UNITED STATES	19-Dec-06	MA-Corres;Mtg/Teleco Minutes		Minutes of 15-NOV-2006 and 30-NOV-2006.	3-Jan-07	FDA	Wyeth	NDA 21-992	UNITED S' PRISTIQ	US
190393	UNITED STATES	20-Dec-06	MA-Corres;Labeling	Issues		20-Dec-06	Wyeth	FDA	NDA 21-992	UNITED S' PRISTIQ	US
190328	UNITED STATES	21-Dec-06	MA-Corres;Promotion& Info Request-Respon	Tradename issues.		Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
190449	UNITED STATES	21-Dec-06	MA-Corres;Labeling	Trade Name Issues		Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

190411	UNITED STATES	22-Dec-06	MA-Corres Pediatric E. Issues		22-Dec-06	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
190759	UNITED STATES	9-Jan-07	MA-Corres Resp to Re Info	FDA will probably not act on this NDA until 22-JAN-2007.	9-Jan-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
191069	UNITED STATES	10-Jan-07	MA-FDA C-Phone CMC Issues	Clarification of action date and November 1 communication on cGMP inspection.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
191005	UNITED STATES	12-Jan-07	MA-Corres Mtg/Teleco Minutes	Minutes from the 11- JAN-2007.	12-Jan-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
191246	UNITED STATES	17-Jan-07	MA-Corres Resp to Re Info	Voice mail message.	17-Jan-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
191248	UNITED STATES	17-Jan-07	MA-Corres General Corresp		17-Jan-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
192069	UNITED STATES	22-Jan-07	MA-Corres Action Lettr Approvable-Orig App			Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
191506	UNITED STATES	22-Jan-07	MA-Corres General Corresp	Copy of action letter.	22-Jan-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
191727	UNITED STATES	25-Jan-07	MA-Corres Intent to Amend	Response to approvable letter.		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

191815	UNITED STATES	26-Jan-07	MA-FDA C-Phone	CMC Issues		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
191902	UNITED STATES	29-Jan-07	MA-Corres\General Corresp		Resubmission classification questions.	29-Jan-07	FDA	Wyeth	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
191962	UNITED STATES	29-Jan-07	MA-Corres\Resp to Re Info		Resubmission classification questions.	29-Jan-07	Wyeth	FDA	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
192112	UNITED STATES	30-Jan-07	MA-Corres\Labeling	Issues	Combined labeling for both indications MDD and VMS.	30-Jan-07	FDA	Wyeth	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
192208	UNITED STATES	30-Jan-07	MA-FDA C-Phone	CMC Issues			Wyeth	Wyeth	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
192339	UNITED STATES	2-Feb-07	MA-Corres\Resp to Re Info		Clarification to comment #5 under CMC section.		FDA	Wyeth	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
192374	UNITED STATES	5-Feb-07	MA-Corres\Resp to Re Info		Label alignment.	5-Feb-07	Wyeth	FDA	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
192589	UNITED STATES	5-Feb-07	MA-FDA C-Phone	CMC Issues			Wyeth	Wyeth	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
192593	UNITED STATES	7-Feb-07	MA-Corres\Labeling	Issues	Additional questions.	7-Feb-07	FDA	Wyeth	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

193202	UNITED STATES	9-Feb-07	MA-Corres Resp to Re Info	Labeling alignment and additional questions.	9-Feb-07 W-AL (Wye FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ US
193651	UNITED STATES	22-Feb-07	MA-Corres Request Info	Risk Management Plan Questions.	22-Feb-07 FDA Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ US
194059	UNITED STATES	27-Feb-07	MA-Corres CMC issues	Clarification on what the Reference Listed Drug Name would be.	Wyeth FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ US
194068	UNITED STATES	1-Mar-07	MA-Corres Request Info	Risk management plan questions.	1-Mar-07 FDA Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ US
194091	UNITED STATES	2-Mar-07	MA-Corres Clinical Iss Info-Request	Responses to Approvable Letter.	2-Mar-07 FDA Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ US
194215	UNITED STATES	5-Mar-07	MA-Corres Resp to Re Info	Responses to the approvable letter.	5-Mar-07 Wyeth FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ US
194353	UNITED STATES	7-Mar-07	MA-Corres General Corresp	Risk Management Plan Questions were forwarded to the reviewers.	7-Mar-07 Wyeth FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ US
194451	UNITED STATES	8-Mar-07	MA-Corres General Corresp	Risk Management Questions information.	8-Mar-07 Wyeth FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ US
196445	UNITED STATES	4-Apr-07	MA (Pend) Request-Response		FDA Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ US

NDA Activities

196925	UNITED STATES	10-Apr-07	MA-Corres Clinical Iss	Other	Partial response to the approvable letter.	10-Apr-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
198858	UNITED STATES	30-Apr-07	MA-Corres CMC Issues		No objections to proposal.	30-Apr-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
199293	UNITED STATES	3-May-07	MA-Corres Request	Info			Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
199338	UNITED STATES	8-May-07	MA-FDA C-Phone	CMC Issues	Pilot program meeting to discuss the IR letter.		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
199265	UNITED STATES	8-May-07	MA-Corres Mtg/Teleco	Info		8-May-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
201251	UNITED STATES	11-May-07	MA-Corres Request	Review/Comment	Pre-operational review of the PAT process in the CMC facility.		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
199725	UNITED STATES	15-May-07	MA-Corres Request	Info	Feedback on the embryo-fetal study.	15-May-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
200417	UNITED STATES	21-May-07	MA-Corres Mtg/Teleco	Info	List of attendees for CMC pilot program 22-MAY-2007.	21-May-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
201032	UNITED STATES	30-May-07	MA-Corres Resp to Re	Info	Postmarketing commitment issues.		Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

201254	UNITED STATES	1-Jun-07	MA-Corres Resp to Re Info	CMC information request letter dated 3-MAY-2007.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
201789	UNITED STATES	7-Jun-07	MA-Corres Mitg/Teleco Other	Requesting time change for teleconference scheduled 13-JUN-2007.	7-Jun-07 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
201791	UNITED STATES	7-Jun-07	MA-Corres Mitg/Teleco Other	Requested time changed granted to 2:30.	7-Jun-07 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
201902	UNITED STATES	8-Jun-07	MA-FDA C-Phone	Clinical Issues	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
202438	UNITED STATES	14-Jun-07	MA-FDA C-Phone	Clinical Issues	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
202516	UNITED STATES	18-Jun-07	MA-Corres Mitg/Teleco Minutes	22-MAY-2207.	18-Jun-07 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
203138	UNITED STATES	27-Jun-07	MA-Corres Action Lettr Response	Response to approvable letter dated 22-JAN-2007.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
203138	UNITED STATES	27-Jun-07	MA-Corres CMC Issues	Response to approvable letter dated 22-JAN-2007.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
203683	UNITED STATES	6-Jul-07	MA-Corres Mitg/Teleco Minutes	Minutes of 22-MAY-2007.	6-Jul-07 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

204455	UNITED STATES	16-Jul-07	MA-FDA C-Phone	CMC Issues	Follow-up regarding requests made during pre-operational visits.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
206120	UNITED STATES	30-Jul-07	MA-FDA C-Phone	CMC Issues	Response submission to CMC questions.	30-Jul-07	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
206579	UNITED STATES	7-Aug-07	MA-FDA C-Phone	CMC Issues	Pre-operational visit requested by FDA.	7-Aug-07	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
207799	UNITED STATES	23-Aug-07	MA (Pend) CMC		Response to the approvable letter dated 23-JUL-2007.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
208221	UNITED STATES	29-Aug-07	MA-Corres Resp to Re Info		Complete response to approvable letter dated 22-JAN-2007.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
208738	UNITED STATES	5-Sep-07	MA-Corres Resp to Re Info		Due date will 29-FEB-2008.	5-Sep-07	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
208741	UNITED STATES	5-Sep-07	MA-FDA C-Phone	Other	Response to approvable letter being sent via FDA Gateway.		Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
213860	UNITED STATES	11-Oct-07	MA-Corres Request	Info	Various issues.	11-Oct-07	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
213861	UNITED STATES	14-Oct-07	MA-Corres Resp to Re Info		Various issues.	14-Oct-07	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

213862	UNITED STATES	14-Oct-07	MA-Corres General Corresp		14-Oct-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
213013	UNITED STATES	15-Oct-07	MA-Corres General Corresp	Follow-up on the 29- AUG-2007.	15-Oct-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
213014	UNITED STATES	16-Oct-07	MA-Corres Resp to Re Info		16-Oct-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
214267	UNITED STATES	16-Oct-07	MA-Corres Action Lettr Approval - Orig App	User fee goal date 29- FEB-2008.		Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
215711	UNITED STATES	15-Nov-07	MA-Corres Request	Copy of the IR letter.	15-Nov-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
216018	UNITED STATES	20-Nov-07	MA-Corres Request	Proprietary name feedback.	20-Nov-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
216019	UNITED STATES	20-Nov-07	MA-Corres Resp to Re Info	Proprietary name feedback.	20-Nov-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
216020	UNITED STATES	20-Nov-07	MA-Corres Request	Proprietary name feedback.	20-Nov-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
216335	UNITED STATES	20-Nov-07	MA-Corres General Corresp	Proprietary name issues.	20-Nov-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

216835	UNITED STATES	27-Nov-07	MA-Corres/Mtg/Teleco Req	Response- Other	27-Nov-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
217021	UNITED STATES	29-Nov-07	MA-Corres/Request	Info	Proprietary name feedback request.	29-Nov-07	FDA	Wyeth	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
217310	UNITED STATES	30-Nov-07	MA-Corres/General Corresp		Proprietary name issues.	30-Nov-07	Wyeth	FDA	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
217450	UNITED STATES	4-Dec-07	MA-Corres/Request	Info	Proprietary name feedback issues.	4-Dec-07	FDA	Wyeth	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
219441	UNITED STATES	11-Dec-07	MA-Corres/Clinical Iss/Info-Request		Exposure data in patient-years for study 332 and 333.	11-Dec-07	Wyeth	FDA	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
219442	UNITED STATES	11-Dec-07	MA-Corres/Resp to Re Other			11-Dec-07	FDA	Wyeth	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
219445	UNITED STATES	12-Dec-07	MA-Corres/Mtg/Teleco Request for Meeting		To discuss study 302.	12-Dec-07	FDA	Wyeth	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
219576	UNITED STATES	13-Dec-07	MA-Corres/Mtg/Teleco Info		Meeting scheduled 17- JAN-2008.	13-Dec-07	FDA	Wyeth	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
218725	UNITED STATES	13-Dec-07	MA-Corres/Mtg/Teleco Minutes		CMC - Pilot program minutes of the 29- NOV-2007 meeting.		FDA	Wyeth	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

219578	UNITED STATES	14-Dec-07	MA-Corres Mtg/Teleco Info	List of Wyeth's attendees for the 17-JAN-2008 meeting.	14-Dec-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
219351	UNITED STATES	14-Dec-07	MA-Corres Resp to Re Info		14-Dec-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
218739	UNITED STATES	14-Dec-07	MA-Corres Clinical Iss Info Req-Response	Patient Exposure Year Data.		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
219585	UNITED STATES	17-Dec-07	MA-Corres Clinical Iss Info-Request		17-Dec-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
219628	UNITED STATES	17-Dec-07	MA-Corres Clinical Iss Info-Request	Confirm that Analyses and Datasets will not be classified as a major amendment.	17-Dec-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
219589	UNITED STATES	18-Dec-07	MA-Corres General Corresp		18-Dec-07	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
219590	UNITED STATES	18-Dec-07	MA-Corres General Corresp		18-Dec-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
219079	UNITED STATES	19-Dec-07	MA-Corres CMC Issue Request-Response	Amendment Response to CMC Information Request		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
219632	UNITED STATES	20-Dec-07	MA-Corres Request Info	Proprietary name issues.	20-Dec-07	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

219339	UNITED STATES	20-Dec-07	MA-Corres Clinical Iss Info Req-Response	Information regarding studies 332 and 333.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
219633	UNITED STATES	21-Dec-07	MA-Corres General Corresp		21-Dec-07	FDA	Wyeth	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
220173	UNITED STATES	4-Jan-08	MA-Corres General Corresp	Relapse Position Paper.	4-Jan-08	FDA	Wyeth	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
220162	UNITED STATES	7-Jan-08	MA-Corres Request Info	Proposed Tradename.	7-Jan-08	FDA	Wyeth	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
220378	UNITED STATES	8-Jan-08	MA-FDA C-Phone	Status of the Agency review of 19-DEC- 2007.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
220744	UNITED STATES	11-Jan-08	MA-Corres Resp to Re Info	Proprietary information issues.	11-Jan-08	Wyeth	FDA	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
220745	UNITED STATES	11-Jan-08	MA-Corres Request Info	Proprietary information issues.	11-Jan-08	FDA	Wyeth	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
220759	UNITED STATES	11-Jan-08	MA-Corres Resp to Re Info	Proprietary information.	11-Jan-08	Wyeth	FDA	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
220760	UNITED STATES	11-Jan-08	MA-Corres General Corresp		11-Jan-08	FDA	Wyeth	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

220903	UNITED STATES	14-Jan-08	MA (Pend) Other	Relapse Prevention Position Paper.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
221052	UNITED STATES	15-Jan-08	MA-Corres Mitg/Teleco Info	List of attendees for the 17-JAN-2008 meeting.	15-Jan-08 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
221493	UNITED STATES	17-Jan-08	MA-Corres Mitg/Teleco Info	List of attendees. DMETS review found name acceptable.	17-Jan-08 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
221493	UNITED STATES	17-Jan-08	MA-Corres Resp to Re Info	List of attendees. DMETS review found name acceptable.	17-Jan-08 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
221494	UNITED STATES	17-Jan-08	MA-Corres General Corresp	Tradename questions.	17-Jan-08 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
221555	UNITED STATES	17-Jan-08	MA-FDA C-Phone Meeting Sched/Issues Withdrawl Study.	Acceptability of the Randomized	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223096	UNITED STATES	25-Jan-08	MA-Corres Request Info	RiskMap plan.	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
222607	UNITED STATES	25-Jan-08	MA-Corres General Corresp	Copy of RiskMap letter.	25-Jan-08 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
222626	UNITED STATES	26-Jan-08	MA-Corres General Corresp	Confirm receipt of letter - RiskMap.	26-Jan-08 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

222630	UNITED STATES	29-Jan-08	MA-Corres General Corresp	Response to RiskMAP will probably be submitted this Friday or Monday.	29-Jan-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223123	UNITED STATES	1-Feb-08	MA-Corres Mtg/Teleco Info	Questions for teleconference 4-FEB-2008.	1-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223087	UNITED STATES	3-Feb-08	MA-Corres Mtg/Teleco Info	Dialing info for the teleconference on the 4-FEB-2008.	3-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223130	UNITED STATES	4-Feb-08	MA-Corres Request Info		4-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223132	UNITED STATES	4-Feb-08	MA-Corres Resp to Re Info		4-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
222864	UNITED STATES	4-Feb-08	MA (Pend) Request-Response	Questions concerning RiskMAPs.		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223266	UNITED STATES	5-Feb-08	MA-Corres Labeling Other		5-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223268	UNITED STATES	7-Feb-08	MA-Corres Mtg/Teleco Request - Other		7-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223565	UNITED STATES	7-Feb-08	MA-Corres Labeling Request			Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

223585	UNITED STATES	7-Feb-08	MA-Corres Phase IV C Information-Request		Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223665	UNITED STATES	8-Feb-08	MA-Corres Request Info	Various issues - Labeling and Phase 4 commitments.	8-Feb-08 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223666	UNITED STATES	8-Feb-08	MA-Corres General Corresp		8-Feb-08 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223687	UNITED STATES	8-Feb-08	MA-Corres Resp to Re Info	Clarification response.	8-Feb-08 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223694	UNITED STATES	8-Feb-08	MA-Corres Mtg/Teleco Info	List of attendees 4- FEB-2008.	8-Feb-08 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223607	UNITED STATES	8-Feb-08	MA-Corres Mtg/Teleco Info	CMC pilot program of the unofficial minutes of 4-FEB-2008 meeting.	8-Feb-08 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223646	UNITED STATES	11-Feb-08	MA-Corres Mtg/Teleco Minutes	Pilot Program meeting minutes 4-FEB-2008.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223787	UNITED STATES	12-Feb-08	MA-Corres Labeling Revision - Request		12-Feb-08 Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223788	UNITED STATES	12-Feb-08	MA-Corres General Corresp		12-Feb-08 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

223790	UNITED STATES	12-Feb-08	MA-Corres Phase IV C Other		12-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US	
223791	UNITED STATES	12-Feb-08	MA-Corres Labeling	Issues	Update on the labeling revisions.	12-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223826	UNITED STATES	12-Feb-08	MA-Corres Labeling	Issues		12-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223828	UNITED STATES	12-Feb-08	MA-Corres Mtg/Teleco	Info	List of attendees for the 15-FEB-2008 teleconference.	12-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223964	UNITED STATES	12-Feb-08	MA-FDA C-Phone	CMC Issues	Amendment to provide responses to FDA's 1-FEB-2008 e- mail.		Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US	
223832	UNITED STATES	13-Feb-08	MA-Corres Labeling	Request		13-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223833	UNITED STATES	13-Feb-08	MA-Corres Labeling	Request-Response		13-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223978	UNITED STATES	13-Feb-08	MA-Corres General	Corresp		13-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223979	UNITED STATES	13-Feb-08	MA-Corres Mtg/Teleco	Info		13-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

223981	UNITED STATES	13-Feb-08	MA-Corres Labeling	Other	13-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US	
223967	UNITED STATES	13-Feb-08	MA-Corres Labeling	Request-Response	13-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US	
223974	UNITED STATES	13-Feb-08	MA-Corres Labeling	Other	Additional information.	13-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223961	UNITED STATES	14-Feb-08	MA-Corres Clinical Iss	Other	Phase 4 Commitment comments.	14-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
223965	UNITED STATES	14-Feb-08	MA-Corres Request	Info	14-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US	
223966	UNITED STATES	14-Feb-08	MA-Corres Resp to Re Info		14-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US	
224091	UNITED STATES	14-Feb-08	MA-Corres Labeling	Rev Req - Response	E-mail dated 12-FEB- 2008.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US	
224131	UNITED STATES	15-Feb-08	MA-Corres Mtg/Teleco	Request - Other	List of attendees for today's meeting.	15-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224400	UNITED STATES	15-Feb-08	MA-Corres CMC Issues		15-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US	

NDA Activities

224558	UNITED STATES	15-Feb-08	MA-FDA C-Phone	CMC Issues		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224112	UNITED STATES	15-Feb-08	MA (Pend)-CMC			FDA		NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224375	UNITED STATES	15-Feb-08	MA-Corres Mtg Teleco Info		List of attendees for today's meeting.	15-Feb-08	Wyeth	FDA	NDA 21-992	UNITED S' PRISTIQ	US
224374	UNITED STATES	15-Feb-08	MA-Corres General Corresp		Updated adverse events table.	15-Feb-08	Wyeth	FDA	NDA 21-992	UNITED S' PRISTIQ	US
224373	UNITED STATES	15-Feb-08	MA-Corres Labeling	Rev Req - Response		15-Feb-08	FDA	Wyeth	NDA 21-992	UNITED S' PRISTIQ	US
224397	UNITED STATES	19-Feb-08	MA-Corres Request	Info		19-Feb-08	Wyeth	FDA	NDA 21-992	UNITED S' PRISTIQ	US
224398	UNITED STATES	19-Feb-08	MA-Corres Phase IV C Issues			19-Feb-08	FDA	Wyeth	NDA 21-992	UNITED S' PRISTIQ	US
224399	UNITED STATES	19-Feb-08	MA-Corres Phase IV C Issues			19-Feb-08	FDA	Wyeth	NDA 21-992	UNITED S' PRISTIQ	US
224388	UNITED STATES	19-Feb-08	MA-Corres Phase IV C Issues		Change - Studies conducted in 8 weeks not 6.	19-Feb-08	FDA	Wyeth	NDA 21-992	UNITED S' PRISTIQ	US

NDA Activities

224402	UNITED STATES	19-Feb-08	MA-Corres Request	Info	19-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224557	UNITED STATES	19-Feb-08	MA-FDA C-Phone	CMC Issues	FDA's request to remove Impurities test from NDA.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224381	UNITED STATES	19-Feb-08	MA-Corres Labeling	Other		19-Feb-08	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224383	UNITED STATES	19-Feb-08	MA-Corres Labeling	Issues	Updated labeling.	19-Feb-08	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224384	UNITED STATES	19-Feb-08	MA-Corres Phase IV C	Other		19-Feb-08	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224389	UNITED STATES	20-Feb-08	MA-Corres Labeling	Issues		20-Feb-08	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224546	UNITED STATES	20-Feb-08	MA-Corres Labeling	Request		20-Feb-08	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224548	UNITED STATES	20-Feb-08	MA-Corres Labeling	Issues		20-Feb-08	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224554	UNITED STATES	20-Feb-08	MA-Corres Labeling	Request-Response		20-Feb-08	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

224533	UNITED STATES	20-Feb-08	MA-Corres	CMC Issues	Follow-up to telecon. 20-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224536	UNITED STATES	20-Feb-08	MA-Corres	CMC Issues	Summary of teleconference 19-FEB-2008.	20-Feb-08	FDA	Wyeth	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224544	UNITED STATES	20-Feb-08	MA-FDA	C-Phone Labeling	Doc dated 2007 in error.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224544	UNITED STATES	20-Feb-08	MA-FDA	C-Phone Other	Doc dated 2007 in error.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224568	UNITED STATES	20-Feb-08	MA-Corres	Labeling Rev Req - Response		20-Feb-08	FDA	Wyeth	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224444	UNITED STATES	20-Feb-08	MA-Corres	Resp to Re Info	CMC correspondence dated 15-FEB-2008.	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224578	UNITED STATES	21-Feb-08	MA-Corres	Mitg/Teleco Request for Meeting	Day of approval logistics.	21-Feb-08	FDA	Wyeth	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224579	UNITED STATES	21-Feb-08	MA-FDA	C-Phone CMC Issues	Remove impurities tests from NDA.	Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224583	UNITED STATES	21-Feb-08	MA-Corres	Labeling Request		21-Feb-08	FDA	Wyeth	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

224585	UNITED STATES	21-Feb-08	MA-Corres General Corresp	Discuss good communication practices.	21-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224531	UNITED STATES	21-Feb-08	MA-Corres Labeling Draft			FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224587	UNITED STATES	22-Feb-08	MA-Corres Resp to Re Info		22-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224588	UNITED STATES	22-Feb-08	MA-Corres Labeling Issues	Minor error in the last paragraph of section 10.	22-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224589	UNITED STATES	22-Feb-08	MA-Corres General Corresp	Communication issues.	22-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224590	UNITED STATES	22-Feb-08	MA-Corres Labeling Issues	Minor label correction fixed.	22-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224594	UNITED STATES	22-Feb-08	MA (Pend) CMC			FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224594	UNITED STATES	22-Feb-08	MA (Pend) Request-Response			FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
224991	UNITED STATES	26-Feb-08	MA-Corres Labeling Issues		26-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

224992	UNITED STATES	27-Feb-08	MA-Corres General Corresp	Tradename question.	27-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
225165	UNITED STATES	27-Feb-08	MA-Corres Labeling	Issues	27-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
225042	UNITED STATES	27-Feb-08	MA-Corres Labeling	Request	Updated labeling version.	27-Feb-08	Wyeth	FDA	NDA 21-992	UNITED S' PRISTIQ	US
225177	UNITED STATES	28-Feb-08	MA-Corres Phase IV C Issues		28-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
225178	UNITED STATES	28-Feb-08	MA-Corres Phase IV C Other		28-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
225166	UNITED STATES	28-Feb-08	MA-FDA C/Phone	Labeling		Wyeth	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
225179	UNITED STATES	29-Feb-08	MA-Corres General Corresp	Request copy of Approval letter ASAP.	29-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
225180	UNITED STATES	29-Feb-08	MA-Corres Labeling	Issues	29-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
225219	UNITED STATES	29-Feb-08	MA-Corres General Corresp	Thank you note.	29-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

225220	UNITED STATES	29-Feb-08	MA-Corres General Corresp	Thank you note.	29-Feb-08	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
226310	UNITED STATES	29-Feb-08	MA-Corres Action Lettr Approval - Orig App			Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
225120	UNITED STATES	29-Feb-08	MA-Corres Labeling Draft			FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
225215	UNITED STATES	29-Feb-08	MA-Corres Action Lettr Approval - Orig App		29-Feb-08	Wyeth	FDA	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
225281	UNITED STATES	3-Mar-08	223002-01 MA-Promo Routine PPR			FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
226311	UNITED STATES	3-Mar-08	MA-Corres Promotion& Information-Request	Advisory comments.		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
225321	UNITED STATES	3-Mar-08	215956-01 MA-Promo Routine WWW			FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
225322	UNITED STATES	3-Mar-08	216156-01 MA-Promo Routine WWW			FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
225323	UNITED STATES	3-Mar-08	223151-01 MA-Promo Routine WWW			FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR) DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

NDA Activities

225324	UNITED STATES	3-Mar-08	224485-01	MA-Promo Routine	COT	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
225325	UNITED STATES	3-Mar-08	224715-01	MA-Promo Routine	POT	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
225298	UNITED STATES	4-Mar-08		MA-Corresp Promotion & Other		4-Mar-08 FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
226150	UNITED STATES	12-Mar-08		MA-Corresp Labeling	FPL	FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US
226281	UNITED STATES	13-Mar-08		MA-Corresp General Corresp		FDA	Wyeth	NDA 21-992	DESVENLAFAXI NE SUCCINATE (MAJOR DEPRESSIVE DISORDER)	UNITED S' PRISTIQ	US

Initial launch
campaign material
sent to DDMAC.

Provide a copy of the
submission to the
NDA in eCTD format.